3D SYSTEMS CORP, 10-K filed on 3/9/2026
Annual Report
v3.25.4
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2025
Mar. 02, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2025    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-34220    
Entity Registrant Name 3D SYSTEMS CORPORATION    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 95-4431352    
Entity Address, Address Line One 333 Three D Systems Circle    
Entity Address, City or Town Rock Hill    
Entity Address, State or Province SC    
Entity Address, Postal Zip Code 29730    
City Area Code 803    
Local Phone Number 326-3900    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol DDD    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 189,570,915
Entity Common Stock, Shares Outstanding   146,066,333  
Documents Incorporated by Reference Portions of the registrant's definitive proxy statement for its 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the registrant's fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.    
Amendment Flag false    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Entity Central Index Key 0000910638    
Auditor Firm ID 34    
v3.25.4
Audit Information
 12 Months Ended
Dec. 31, 2025
Audit Information [Abstract]  
Auditor Name Deloitte & Touche LLP
Auditor Location Charlotte, North Carolina
Auditor Firm ID 34
v3.25.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 95,635 $ 171,324
Accounts receivable, net of reserves — $3,608 and $2,433 83,806 101,471
Inventories 127,496 118,530
Prepaid expenses and other current assets 39,770 34,329
Assets held for sale 0 3,176
Total current assets 346,707 428,830
Property and equipment, net 49,249 51,044
Intangible assets, net 16,614 18,020
Goodwill 15,575 14,879
Operating lease right-of-use assets 45,364 50,715
Finance lease right-of-use assets 7,774 8,726
Long-term deferred income tax assets 2,787 2,063
Other assets 37,658 34,569
Total assets 521,728 608,846
Current liabilities:    
Current portion of long-term debt, net of deferred financing costs 3,944 0
Current operating lease liabilities 11,583 9,514
Accounts payable 41,017 41,833
Accrued and other liabilities 46,656 45,488
Customer deposits and deferred revenue 17,423 32,010
Liabilities held for sale 0 10,251
Total current liabilities 120,623 139,096
Long-term debt, net of deferred financing costs 86,394 211,995
Long-term operating lease liabilities 45,420 52,527
Long-term deferred income tax liabilities 2,740 2,076
Other liabilities 24,000 25,001
Total liabilities 279,177 430,695
Commitments and contingencies (Note 20)
Redeemable non-controlling interest 2,193 1,958
Stockholders’ equity:    
Preferred stock, 5,000 shares authorized; no par value; no shares issued and outstanding as of December 31, 2025 and 2024 0 0
Common stock, $0.001 par value, authorized 220,000 shares; shares issued 145,581 and 135,510 as of December 31, 2025 and 2024, respectively 146 136
Additional paid-in capital 1,620,399 1,593,366
Accumulated deficit (1,332,360) (1,362,243)
Accumulated other comprehensive loss (47,827) (55,066)
Total stockholders’ equity 240,358 176,193
Total liabilities, redeemable non-controlling interest and stockholders’ equity $ 521,728 $ 608,846
v3.25.4
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Accounts receivable, reserves $ 3,608 $ 2,433
Stockholders’ equity:    
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 220,000,000 220,000,000
Common stock, shares issued (in shares) 145,581,000 135,510,000
v3.25.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenue:      
Total revenue $ 386,902 $ 440,121 $ 488,069
Cost of sales:      
Total cost of sales 255,857 275,943 291,648
Gross profit 131,045 164,178 196,421
Operating expenses:      
Selling, general and administrative 161,331 210,132 210,172
Research and development 65,037 86,479 89,466
Asset impairment charges 760 144,967 302,787
Total operating expenses 227,128 441,578 602,425
Loss from operations (96,083) (277,400) (406,004)
Non-operating income (loss):      
Foreign exchange gain (loss), net 3,637 2,452 (4,825)
Interest income 3,956 7,302 19,511
Interest expense (5,162) (2,564) (3,301)
Gain on disposition 139,590 0 0
Other income, net 3,654 20,214 32,307
Total non-operating income 145,675 27,404 43,692
Net income (loss) before income taxes 49,592 (249,996) (362,312)
(Provision) benefit for income taxes (14,871) (2,193) 641
Loss on equity method investment, net of income taxes (4,838) (3,404) (1,282)
Net income (loss) before redeemable non-controlling interest 29,883 (255,593) (362,953)
Less: net loss attributable to redeemable non-controlling interest 0 0 (265)
Net income (loss) attributable to 3D Systems Corporation $ 29,883 $ (255,593) $ (362,688)
Net income (loss) per common share:      
Basic (in dollars per share) $ 0.23 $ (1.94) $ (2.79)
Diluted (in dollars per share) $ 0.19 $ (1.94) $ (2.79)
Weighted average shares outstanding:      
Basic (in shares) 129,159 131,861 129,944
Weighted average shares - Diluted (in shares) 175,514 131,861 129,944
Products      
Revenue:      
Total revenue $ 223,405 $ 279,178 $ 328,731
Cost of sales:      
Total cost of sales 151,145 175,859 203,258
Services      
Revenue:      
Total revenue 163,497 160,943 159,338
Cost of sales:      
Total cost of sales $ 104,712 $ 100,084 $ 88,390
v3.25.4
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Statement of Comprehensive Income [Abstract]      
Net income (loss) before redeemable non-controlling interest $ 29,883 $ (255,593) $ (362,953)
Other comprehensive income (loss), net of taxes:      
Pension plan adjustment 20 (163) (386)
Foreign currency translation 7,219 (10,653) 9,630
Unrealized gain on short-term investments 0 0 108
Amounts reclassified from accumulated other comprehensive income (loss) 0 0 220
Total other comprehensive income (loss), net of taxes: 7,239 (10,816) 9,572
Total comprehensive income (loss), net of taxes 37,122 (266,409) (353,381)
Less: comprehensive loss attributable to redeemable non-controlling interest 0 0 (265)
Comprehensive income (loss) attributable to 3D Systems Corporation $ 37,122 $ (266,409) $ (353,116)
v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
OPERATING ACTIVITIES      
Net income (loss) before redeemable non-controlling interest $ 29,883 $ (255,593) $ (362,953)
Adjustments to reconcile income (loss) to net cash used in operating activities:      
Depreciation and amortization 21,511 33,310 33,413
Accretion of debt discount 1,463 1,378 2,640
Stock-based compensation 9,525 18,457 23,504
Loss on short-term investments 0 0 6
Non-cash operating lease expense 9,974 9,871 9,267
Provision for inventory obsolescence and revaluation 8,201 12,360 6,350
Provision for bad debts 1,810 506 595
(Gain) loss on the disposition of businesses, property, equipment and other assets (138,569) 2,795 6
Gain on debt extinguishment (5,484) (21,518) (32,181)
Benefit for deferred income taxes and reserve adjustments (685) (952) (2,412)
Loss on equity method investment 4,838 3,404 1,282
Asset impairment charges 760 144,967 304,698
Changes in operating accounts:      
Accounts receivable 18,423 (6,376) (6,186)
Inventories (14,440) 15,766 (20,555)
Prepaid expenses and other current assets 698 7,049 (7,961)
Accounts payable (3,472) (5,812) (5,526)
Deferred revenue and customer deposits (8,421) 3,602 1,245
Accrued and other liabilities (4,518) (6,187) (12,933)
All other operating activities (19,325) (1,914) (12,994)
Net cash used in operating activities (87,828) (44,887) (80,695)
INVESTING ACTIVITIES      
Purchases of property and equipment (9,944) (16,121) (27,183)
Sales and maturities of short-term investments 0 0 180,925
Proceeds from sale of assets and businesses, net of cash sold 122,681 96 194
Acquisitions and other investments, net of cash acquired (3,933) (3,000) (29,152)
Other investing activities 186 0 0
Net cash provided by (used in) investing activities 108,990 (19,025) 124,784
FINANCING ACTIVITIES      
Proceeds from borrowings 92,030 0 0
Debt issuance and amendment costs (6,132) 0 0
Repayment of borrowings and long-term debt (169,987) (87,218) (100,614)
Stock repurchases (14,960) 0 0
Taxes paid related to net-share settlement of equity awards (1,025) (2,662) (5,211)
Other financing activities (1,593) (1,385) (644)
Net cash used in financing activities (101,667) (91,265) (106,469)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 4,724 (5,053) 3,516
Net decrease in cash, cash equivalents and restricted cash (75,781) (160,230) (58,864)
Cash, cash equivalents and restricted cash at the beginning of the year 172,881 333,111 391,975
Cash, cash equivalents and restricted cash at the end of the year 97,100 172,881 333,111
Balances per Consolidated Balance Sheets:      
Cash and cash equivalents 95,635 171,324 331,525
Restricted cash included in prepaid expenses and other current assets 126 123 119
Restricted cash included in other assets [1] 1,339 1,434 1,467
Total cash, cash equivalents and restricted cash 97,100 172,881 333,111
Supplemental cash flow information      
Lease assets obtained in exchange for new lease liabilities 3,483 6,678 38,037
Cash interest payments 3,538 1,017 478
Cash income tax payments, net 9,633 5,540 3,898
Transfer of equipment from inventory to property and equipment, net [2] 4,032 1,992 2,098
Exchange of NAMI trade receivables for loan receivable [3] 0 1,960 0
Exchange of assets for investment 1,016 0 0
Conversion of debt to equity 30,773 0 0
Shares issued as debt issuance costs $ 1,328 $ 0 $ 0
[1] Amounts included in restricted cash as of December 31, 2025, December 31, 2024 and December 31, 2023 includes guarantees in the form of a standby letter of credit as security for a long-term real estate lease.
[2] Inventory is transferred to property and equipment at cost when we require additional machines for training or demonstration or for placement into on demand manufacturing services locations.
[3] During the year ended December 31, 2024, the Company provided $2.0 million to the NAMI joint venture as a short-term loan to finance its working capital and capital expenditures requirements, which was used by the joint venture to pay outstanding trade receivables due to the Company. Refer to Note 9 for further information.
v3.25.4
Consolidated Statements of Cash Flows (Parenthetical)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Statement of Cash Flows [Abstract]  
Short-term, non-interest bearing loan agreement $ 2.0
v3.25.4
Consolidated statement of Stockholder's Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2022   131,207      
Beginning balance at Dec. 31, 2022 $ 749,944 $ 131 $ 1,547,597 $ (743,962) $ (53,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued, vested & expired under equity incentive plans (in shares)   3,033      
Shares issued, vested & expired under equity incentive plans 3 $ 3      
Shares withheld related to net-share settlement of equity awards (in shares)   (621)      
Shares withheld related to net-share settlement of equity awards (5,211)   (5,211)    
Stock-based compensation expense 35,612   35,612    
Net income (loss) attributable to 3D Systems Corporation (362,688)     (362,688)  
Pension plan adjustment (386)       (386)
Unrealized loss on short-term investments 328       328
Redeemable non-controlling interest redemption value below carrying value (479)   (479)    
Foreign currency translation adjustment 9,630       9,630
Ending balance (in shares) at Dec. 31, 2023   133,619      
Ending balance at Dec. 31, 2023 426,753 $ 134 1,577,519 (1,106,650) (44,250)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued, vested & expired under equity incentive plans (in shares)   2,511      
Shares issued, vested & expired under equity incentive plans 2 $ 2      
Shares withheld related to net-share settlement of equity awards (in shares)   (620)      
Shares withheld related to net-share settlement of equity awards (2,662)   (2,662)    
Stock-based compensation expense 18,448   18,448    
Net income (loss) attributable to 3D Systems Corporation (255,593)     (255,593)  
Pension plan adjustment (163)       (163)
Redeemable non-controlling interest redemption value below carrying value 61   61    
Foreign currency translation adjustment (10,653)       (10,653)
Ending balance (in shares) at Dec. 31, 2024   135,510      
Ending balance at Dec. 31, 2024 176,193 $ 136 1,593,366 (1,362,243) (55,066)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued, vested & expired under equity incentive plans (in shares)   1,184      
Shares withheld related to net-share settlement of equity awards (in shares)   (434)      
Shares withheld related to net-share settlement of equity awards (1,025)   (1,025)    
Stock-based compensation expense 10,078   10,078    
Net income (loss) attributable to 3D Systems Corporation 29,883     29,883  
Pension plan adjustment 20       20
Redeemable non-controlling interest redemption value below carrying value 0        
Foreign currency translation adjustment 7,087   (132)   7,219
Retirement of Treasury Shares (in shares)   (8,000)      
Retirement of Treasury Shares (14,960) $ (8) (14,952)    
Shares Issued for Convertible Debt (in shares)   17,321      
Shares Issued for Convertible Debt 33,082 $ 18 33,064    
Ending balance (in shares) at Dec. 31, 2025   145,581      
Ending balance at Dec. 31, 2025 $ 240,358 $ 146 $ 1,620,399 $ (1,332,360) $ (47,827)
v3.25.4
Consolidated statement of Stockholder's Equity (Parenthetical) - $ / shares
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]        
Common stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001 $ 0.001
v3.25.4
OVERVIEW AND BASIS OF PRESENTATION
 12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
OVERVIEW AND BASIS OF PRESENTATION
NOTE 1 - OVERVIEW AND BASIS OF PRESENTATION

Nature of Business
3D Systems Corporation ("3D Systems" or the "Company" or "we," "our" or "us") markets our products and services through subsidiaries in North America and South America ("Americas"), Europe and the Middle East ("EMEA") and Asia Pacific and Oceania ("APAC"). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. Our solutions support advanced applications in two key industry verticals: Healthcare Solutions (which includes dental, medical devices, personalized health services and regenerative medicine) and Industrial Solutions (which includes aerospace, defense, transportation and general manufacturing). We have over 35 years of experience and expertise, which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions that enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The consolidated financial statements include the accounts of the Company, including all majority and wholly-owned subsidiaries and entities in which a controlling interest is maintained. Intercompany accounts and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current year presentation.
A non-controlling interest in a subsidiary reflects an ownership interest in a majority-owned subsidiary that is not attributable to the Company. For the periods presented, the Company's financial statements include a redeemable non-controlling interest ("RNCI"), which has been reported in temporary equity in the consolidated balance sheets. The net loss attributable to the RNCI is presented as an adjustment to the Company's consolidated net income (loss) to arrive at net income (loss) attributable to 3D Systems Corporation in the consolidated statements of operations and consolidated statements of comprehensive loss. Furthermore, adjustments to record the RNCI at its redemption value are recorded to additional paid-in capital, and the excess redemption value is recognized as an increase or decrease to net income (loss) attributable to 3D Systems’ shareholders for purposes of reporting income (loss) per share. See Note 14 for a summary of the activity related to the reported RNCI balance during the periods presented.
Our annual reporting period is the calendar year.
v3.25.4
SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect (1) the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the balance sheet dates and (2) the reported amounts of revenues and expenses during the reporting periods. We base our estimates on historical experience, currently available information and various other assumptions that we believe are reasonable under the circumstances. Actual results could differ from these estimates.

Revenue Recognition
We account for revenue in accordance with Accounting Standards Codification ("ASC") Topic 606, "Revenue from Contracts with Customers," ("ASC 606"). Collaborative arrangement contracts, for which the collaboration partner meets the definition of a customer, are recorded in accordance with ASC 606; otherwise, the collaborative arrangements are recorded in accordance with ASC Topic 808, "Collaborative Arrangements." See Note 4 for further discussion.
Revenue recognition for arrangements within the scope of ASC 606 includes the following five steps: (i) identifying the contract(s) with a customer; (ii) identifying the performance obligations in the contract; (iii) determining the transaction price; (iv) allocating the transaction price to the performance obligations in the contract; and (v) recognizing revenue when (or as) a performance obligation is satisfied.
Revenue is recognized when control of the promised products or services is transferred to customers and in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and, accordingly, are accounted for as separate performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based upon its relative stand-alone selling price ("SSP"). Revenue is recognized net of allowances for returns and any taxes collected from customers that are subsequently remitted to governmental authorities.

A majority of our revenue is recognized at the point in time when products are shipped to or services are performed for customers. However, the Company also enters into service contracts and collaboration agreements with customers, for which the Company is typically required to recognize revenue over time.

Hardware and Materials

Revenue from hardware and material sales is recognized when control has been transferred to the customer, which generally occurs when the goods have been shipped or delivered to the customer, risk of loss has transferred to the customer, and the Company has a present right to payment. In limited circumstances, when printer or other hardware sales include substantive customer acceptance provisions, revenue is recognized either when customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the customer acceptance provisions have been satisfied.

Printers and certain other products include an assurance warranty for periods up to one year to ensure the product works as expected. These assurance warranties are not a separate performance obligation. For these initial product warranties, estimated costs are accrued at the time of the sale of the product. These cost estimates are established using historical information regarding the nature, frequency and average cost of claims for each type of printer or other product, as well as assumptions about future activity and events. Revisions to expense accruals are made as necessary based on changes in these historical and future factors.

Software

The Company also markets and sells software tools that enable our customers to capture and customize content using our printers, design optimization and simulation software, and reverse engineering and inspection software. Our software does not require significant modification or customization, and the license provides the customer with a right to use the software as it exists when made available. Revenue from these software licenses is recognized either upon delivery of the product or of a key code which allows the customer to download the software. Customers may purchase post-sale support. Generally, the first year of support is included, but subsequent years are optional. Post-sale support, including the first year of support and the optional, subsequent years, are considered a separate obligation from the software and revenue is deferred at the time of sale and subsequently recognized ratably over future periods.

Services

The Company offers training, installation and non-contract maintenance services for our products. Additionally, the Company offers maintenance contracts customers can purchase at their option. For maintenance contracts, revenue is deferred at the time of sale based on the stand-alone selling prices of these services. Deferred revenue is recognized ratably over the term of the maintenance period on a straight-line basis and costs are expensed as incurred. Revenue from training, installation and non-contract maintenance services is recognized at the time of performance of the service. The Company also sells software as a service, whereby the customer has the right to access the software. Revenue is recognized ratably over the related subscription period, as our performance obligation to provide access to the software is progressively fulfilled over the stated term of the contract. Healthcare Solutions service sales are included within services revenue, and revenue is recognized upon shipment or delivery of the parts or performance of the service, based on the terms of the arrangement.
Collaboration Agreements

The nature of the activities to be performed and the consideration exchanged under collaboration arrangements varies on a contract-by-contract basis. We evaluate collaboration arrangements to determine whether they meet the definition of a customer relationship for which revenue should be recorded and recognized. These contracts may contain multiple performance obligations and may contain fees for licensing, research and development services, contingent milestone payments upon the achievement of contractual developmental criteria and/or royalty fees based on the licensees’ product revenue. We determine the revenue to be recognized under these arrangements based upon an evaluation of the distinct performance obligations; the identification and evaluation of material rights; the estimation of the amount of variable consideration to be included in transaction price, as well as the timing for inclusion of such variable consideration; and the amount of transaction price assigned to and the pattern of transfer of control for each distinct performance obligation. This typically results in the recognition of revenue over time using a cost-to-cost percentage of completion model to measure the progress of the transfer of control.
We review and update our estimate of variable consideration on a regular basis. Any adjustments to estimated revenue are recognized under the cumulative catch-up method.
Currently, all of our collaboration arrangement revenue and related costs relate to R&D being performed under a single regenerative medicine contract.
Terms of Sale

Shipping and handling activities are treated as fulfillment costs rather than as an additional promised service. The Company accrues the costs of shipping and handling when the related revenue is recognized. The Company’s incurred costs associated with shipping and handling are included in product cost of sales. Creditworthiness is determined, and credit is extended, based upon an evaluation of each customer’s financial condition. New customers are generally required to complete a credit application and provide references and bank information to facilitate an analysis of creditworthiness. The Company’s terms of sale generally provide payment terms that are customary in the countries where the Company transacts business. To reduce credit risk in connection with certain sales, the Company may, depending upon the circumstances, require significant deposits or payment in full prior to shipment. For maintenance services, the Company either bills customers on a time-and-materials basis or sell maintenance contracts that provide for payment in advance on either an annual or other periodic basis.

Significant Judgments

Allocation of Transaction Price

The Company’s contracts with customers often include promises to transfer multiple products and services to a customer. For such arrangements, the Company allocates revenue to each performance obligation based on its relative SSP. Judgment is required to determine the SSP for each distinct performance obligation in a contract. The Company estimates SSP using historical transaction data of observable prices. The Company uses a range of amounts to estimate SSP when the Company sells each of the products and services separately and needs to determine whether there is a discount to be allocated based on the relative SSP of the various products and services. In other instances where SSP is not directly observable, such as when the product or service is not sold separately, the Company determines the SSP using information that may include market conditions, expected cost plus margin, and other observable inputs.

In some circumstances, the Company has more than one SSP for individual products and services due to the stratification of those products and services by customers, geographic region or other factors. In these instances, the Company may use information such as the size of the customer and geographic region in determining the SSP.

Variable Consideration

The Company must assess if and when it is appropriate to include variable consideration when determining transaction price. This assessment, which impacts the timing and the amount of revenue recognized under contracts accounted for in accordance with ASC 606, requires management to conclude that it is probable that a significant reversal of the amount of cumulative revenue recognized with respect to a contract will not occur when the uncertainty associated with the variable consideration is subsequently resolved.
The Company’s collaboration agreements include the Company’s most significant variable consideration and require judgment in the estimation of the amount of variable consideration to be included in the transaction price, as well as the timing for inclusion of such variable consideration. In addition, the nature of the Company’s sales may lead to consideration that is variable in the form of discounts based on volumes purchased, trade in allowances, rebates or other discounts; however, these have historically not been material. The Company estimates variable consideration based on the expected value approach, which requires judgment in the identification of possible outcomes and in assessing the probability of those outcomes, or the most likely amount approach, which requires judgment to identify the most likely amount in a range of amounts. After estimating the amount of variable consideration, the Company includes the estimated variable consideration in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company assesses both the likelihood of a future reversal of revenue and how significant the reversal is relative to the total consideration. The Company’s estimates are based on historical experience, contract terms and other factors. Ongoing assessments are performed to determine if updates are needed to the original estimates.

Contracts Recognized Over Time

The Company recognizes the revenue attributable to certain contracts over time using a cost-to-cost percentage of completion model to measure progress of the transfer of control to the customer as services are performed, for which management believes the use of costs incurred reliably depicts the measurement of progress achieved by the Company in satisfying the performance obligation because it best depicts the transfer of control to the customer as we incur costs on our contracts. The application of this accounting requires the Company to estimate total costs that will be required to satisfy the related performance obligations. These estimates could change over the term of a contract.

Contract Balances

The timing of revenue recognition, billings and cash collections results in the recognition of billed accounts receivable and contract assets (including unbilled receivables) and customer deposits and deferred revenue (contract liabilities) on our consolidated balance sheets. Timing of revenue recognition may differ from the timing of invoicing to customers. We record accounts receivable when we have an unconditional right to recognize revenue at the time of invoicing, and unbilled receivables when revenue is recognized prior to invoicing. For most of our contracts, customers are invoiced when products are shipped or when services are performed resulting in billed accounts receivables for the remainder of the owed contract price. Unbilled receivables generally result from circumstances in which items have been shipped, revenue has been recognized, but the customer has not been charged. We also recognize a contract asset upon the recognition of revenue related to certain performance milestones that are deemed probable of achievement, but for which billing has not occurred and receipt of payment is conditioned upon factors other than the passage of time. Some contracts require the customer to remit a large payment at or near contract inception as a deposit prior to production, which is recorded as a customer deposit liability, however, revenue is not recorded until the performance obligation is satisfied. We also typically bill in advance for installation, training and maintenance contracts, as well as for extended warranties, resulting in deferred revenue.

Practical Expedients and Exemptions

We generally expense sales commissions when incurred because the amortization period would be one year or less. These costs are recorded within selling, general and administrative expenses. Additionally, the Company has excluded performance obligations with an original expected duration of one year or less from our disclosure of remaining performance obligations.
Held for Sale
The Company classifies assets and liabilities to be sold ("disposal group") as held for sale in the period when all of the applicable criteria are met, including: (i) management, having the authority to approve the action, commits to a plan to sell, (ii) the disposal group is available to sell in its present condition, (iii) there is an active program to locate a buyer, (iv) the disposal group is being actively marketed at a reasonable price in relation to its fair value, (v) significant changes to the plan to sell are unlikely, and (vi) the sale of the disposal group is generally probable of being completed within one year. Management performs an assessment at least quarterly, or when events or changes in business circumstances indicate that a change in classification may be necessary. Assets and liabilities identified as held for sale are presented separately within the consolidated balance sheets, with adjustments made, if necessary, to measure the disposal group at the lower of its carrying value or fair value less costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Gains on the sale of a disposal group are not recognized until the date of sale. Depreciation of property, plant and equipment and amortization of intangible and right-of-use assets are not recorded while these assets are classified as held for sale. For each period that a disposal group remains classified as held for sale, its recoverability is reassessed and any necessary adjustments are made to its carrying value. Gains or losses recognized upon the sale of a disposal group that does not qualify as a discontinued operation are included in loss from operations in the consolidated statements of operations. Refer to Note 3 for further discussion.

Cash and Cash Equivalents
Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less when acquired. At times, cash and cash equivalents balances may be in excess of FDIC insurance limits.

Variable Interest Entities
Upon making an investment in an entity, we assess whether the entity is a variable interest entity ("VIE"). The determination of whether an entity in which we hold a direct or indirect variable interest is a VIE is based on several factors, including whether the entity’s total equity investment at risk at the time of our investment is sufficient to finance the entity’s activities without additional subordinated financial support. We make judgments regarding the sufficiency of the equity at risk based first on a qualitative analysis, and then a quantitative analysis, if necessary.
We analyze any investments in VIEs to determine whether we are the primary beneficiary. We perform this assessment at the time that we become involved with a VIE and continuously reassess whether circumstances indicate that there might be a change in our conclusion regarding whether we are the primary beneficiary. In evaluating whether we are the primary beneficiary, we consider both our direct and indirect economic interests in the entity. Determining which reporting entity, if any, is the primary beneficiary of a VIE is primarily a qualitative approach focused on identifying which reporting entity has both (1) the power to direct the activities of a VIE that most significantly impact such entity’s economic performance and (2) the obligation to absorb losses or the right to receive benefits from such entity that could potentially be significant to such entity. This analysis requires the exercise of judgment. We consider a variety of factors in identifying the entity that holds the power to direct matters that most significantly impact a VIE’s economic performance including, but not limited to, the ability to direct a VIE’s operating decisions and activities. In addition, we consider the rights of other investors to participate in those decisions.

Investments and Note Receivable

Investments in Equity Securities with a Readily Determinable Fair Value

We recognize investments in equity securities without a readily determinable fair value at cost, minus impairment. In addition, we are required to remeasure the carrying value of an investment in equity securities without a readily determinable fair value if we identify observable price changes that relate to orderly transactions for an identical or similar investment in the same issuer. The remeasurement of the carrying value of an investment due to an identified observable price change shall be based upon the investment's fair value as of the date that the observable transaction occurred. Remeasurements, whether the result of impairment or observable price changes attributable to orderly transactions, are recorded as an adjustment to our reported net income or net loss.
We assess our investments in equity securities without a readily determinable fair value for potential impairment upon the occurrence of an event or a change in circumstances that would indicate the carrying amount of an investment may be impaired. On a quarterly basis, we first perform a qualitative assessment for potential impairment to determine whether measurement of the fair value of an investment to further assess for impairment is required. Impairments of equity securities without a readily determinable fair value are recorded to other income (loss), net in our consolidated statements of operations in the period in which they become impaired.

Refer to Note 9 for additional details regarding the carrying value of the Company's investments in equity securities without a readily determinable fair value as of each balance sheet date.

Equity Method of Accounting

The Company accounts for its investments in the common stock of NAMI and Enhatch using the equity method of accounting because it does not have a controlling interest and is not the primary beneficiary of these VIEs; however, the Company has the ability to exert significant influence. The Company's investments in NAMI's common stock were initially recorded at cost; whereas, the Company's investment in Enhatch's common stock, which reflects the partial exercise of a warrant, was recorded at the fair value of the common stock that was received upon exercise of the warrant. Each of these investments is subsequently adjusted for the Company’s proportionate share of the net earnings or losses and the other comprehensive income or loss of the investee. Intra-entity profits or losses associated with each equity method investment are eliminated until realized by the investee or the Company in transactions with third parties. Income or loss from these equity method investments is recorded as a separate line item in the consolidated statements of operations on a three-month lag. We evaluate material events occurring during the three-month lag period to determine whether the effects of such events should be disclosed in our financial statements. The Company evaluates each investment for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. Refer to Note 9 for additional details regarding the Company's investments accounted for in accordance with the equity method of accounting.

Notes Receivable

Refer to Note 9 for additional details regarding the carrying value of the Company’s outstanding note receivable balance as of each balance sheet date.

Accounts Receivable and Allowance for Credit Losses

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. In evaluating the collectability of accounts receivable, we assess a number of factors, including specific customers’ ability to meet their financial obligations to us, the length of time receivables are past due, historical collection experience, current economic conditions, and reasonable and supportable forecasts. Based on these assessments, we record and adjust reserves for accounts receivable balances due from specific customers, as well as establish an allowance for expected credit losses related to our accounts receivable as a whole. If circumstances related to specific customers change or economic conditions deteriorate such that our past collection experience is no longer relevant, our estimate of the recoverability of accounts receivable could be further reduced from the levels provided for in the consolidated financial statements. As of December 31, 2025 and December 31, 2024, no single customer represented more than 10% of our consolidated accounts receivable balance.

The following presents the changes in the balance of our allowance for credit losses:
YearItemBalance at beginning of yearAdditions charged to expense
Other (a)
Balance at end of year
2025
Allowance for credit losses
$2,433 $1,810 $(635)3,608 
2024
Allowance for credit losses
3,389 506 (1,462)2,433 
2023
Allowance for credit losses
3,114 595 (320)3,389 
(a)Other includes the impact of write-offs, recoveries and foreign currency translation adjustments.

Inventories
Inventories are stated at the lower of cost or net realizable value, with cost reflecting standard cost, which approximates the first-in, first-out method. Capitalized inventory costs include materials, labor, and manufacturing overhead that relate to the acquisition of raw materials and production into finished goods. The Company regularly reviews inventory for excess and obsolescence and records a provision to write down inventory to its net realizable value when carrying value is in excess of such value.
Property and Equipment
Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the determination of net income or loss. Repairs and maintenance costs are expensed as incurred.
Depreciation expense has been computed principally by the straight-line method based on the estimated useful lives of the depreciable assets which are generally as follows:
Category
Useful Life (in years)
Machinery and equipment
2-5
Capitalized software
3-5
Office furniture and equipment
1-5
Leasehold improvements
Life of lease a
Construction in progressN/A
a. Leasehold improvements are amortized on a straight-line basis over the shorter of (i) their estimated useful life or (ii) the estimated or contractual life of the related lease.

Intangible Assets (Excluding Goodwill)
Intangible assets include patents, trade names, customer relationships, acquired technology, and in process research and development ("IPR&D"). Intangible assets with a finite life are (1) amortized on a straight-line basis, with estimated useful lives typically ranging from 2 to 20 years, and (2) assessed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable, consistent with the Company's accounting policy for other long-lived assets with a finite life. Amortization expense is generally recognized within selling, general and administrative expense on the consolidated statements of operations.
Acquired IPR&D represents the fair value assigned to those research and development ("R&D") projects that were acquired in a business combination for which the related products have not received regulatory approval or commercial viability and have no alternative future use. If the project is not completed or is terminated or abandoned, the Company may have to recognize an impairment related to the IPR&D, which is charged to expense. Refer to Note 7 for further discussion of intangible asset impairment charges for the years ended December 31, 2024 and 2023.

Goodwill

Goodwill is the excess of the cost of an acquired entity over the amounts assigned to the assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. Goodwill is tested for impairment annually on November 1st, and is tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level, with all goodwill assigned to a reporting unit.
The testing of goodwill for impairment requires the Company to make several estimates related to projected future cash flows to determine the fair value of the reporting units to which goodwill has been assigned. The Company determines whether each reporting unit's fair value exceeds its carrying amount, including goodwill, based upon projections of future revenues, expenses, and cash flows discounted to their present value, as well as the application of a market approach. Internal operational budgets and long-range strategic plans are used as a basis for the cash flow analysis. The Company also utilizes assumptions related to working capital, capital expenditures, and terminal growth rates. The discount rate applied to the cash flow analysis is based on the weighted average cost of capital ("WACC") for each reporting unit. These valuation approaches require the application of Level 3 valuation inputs (as defined in Note 23). An impairment is recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit. Refer to Note 8 for further discussions regarding goodwill impairment tests and charges for the years ended December 31, 2025, 2024 and 2023.
Long Lived Assets Impairment

We review long-lived assets, including property and equipment, right of use assets and intangible assets, ("asset groups") that are held and used for impairment whenever events or changes in circumstances indicate that the carrying value of an asset group may not be recoverable. The carrying value of an asset group that is held and used is not recoverable if it exceeds the sum of the undiscounted cash flows that are expected to result from the asset group's use and eventual disposition. If we determine that an asset group's carrying value is not recoverable, we must then compare the asset group's carrying value to its estimated fair value and record any excess carrying value over fair value as an impairment loss. Any impairment loss that is recognized is required to be allocated to the long-lived assets of an asset group on a pro rata basis, using the relative carrying amounts of the long-lived assets comprising the asset group, except that the loss allocated to an individual long-lived asset shall not reduce its carrying amount below its fair value whenever that fair value is determinable without undue cost and effort. Refer to Notes 6, 7, and 10 for further discussions regarding long-lived asset impairments for the years ended December 31, 2025, 2024, and 2023.

Common Stock

The holders of the common stock are entitled to one vote for each share held at all meetings of stockholders (and for written actions in lieu of meetings).
We do not currently pay, and have not paid, any dividends on our common stock, and we currently intend to retain any future earnings for use in our business. Any future determination as to the declaration of dividends on our common stock will be made at the discretion of the Board of Directors and will depend on our earnings, operating and financial condition, capital requirements, and other factors deemed relevant by the Board of Directors, including the applicable requirements of the Delaware General Corporation Law, which provides that dividends are payable only out of surplus or current net profits.
The payment of dividends on our common stock may be restricted by the provisions of credit agreements or other financing documents that we may enter into or the terms of securities that we may issue from time to time. Under the 2030 Notes indenture agreement, the Company may not declare and pay a cash dividend.

Contingencies

We follow the provisions of ASC 450, "Contingencies," which requires that an estimated loss from a loss contingency be accrued by a charge to income if (1) it is probable that an asset has been impaired or that a liability has been incurred and (2) the amount of the loss can be reasonably estimated. Legal costs related to the defense or settlement of a loss contingency are expensed when such costs are incurred and, accordingly, future legal costs expected to be incurred are not accrued as part of the liability recorded when a loss contingency has been deemed probable and estimable.

Foreign Currency Translation and Transactions

The local currency in which a subsidiary operates is generally considered its functional currency for those subsidiaries domiciled outside the United States ("foreign subsidiaries"). The functional currency financial statements of foreign subsidiaries are translated to U.S. dollars ("USD") in connection with the preparation of the Company's consolidated financial statements. Assets and liabilities of foreign subsidiaries are translated to USD at month-end exchange rates applicable to the reporting period. Income and expense items are translated to USD monthly using monthly average exchange rates. The effects of translating a foreign subsidiary's financial statements are recorded as currency translation adjustments and reported as a component of accumulated other comprehensive income (loss) in shareholders’ equity.
Foreign currency transactions are those transactions whose terms are denominated in a currency other than an entity's functional currency. Foreign currency transactions that remain unsettled as of the end of a reporting period must be remeasured into the entity's functional currency, resulting in the recognition of a gain or loss when a change in exchange rate has occurred subsequent to the date on which the transaction was originally recognized or was most recently remeasured. The Company recognizes foreign currency transaction gains and losses within foreign exchange gain (loss), net on its consolidated statements of operations.

Research and Development Costs

Research and development costs relate to the development of new products and services and consist primarily of employee compensation, operating supplies, facility costs and depreciation. These costs are expensed as incurred.
Earnings Per Share and Net Loss Per Share

Basic net income (loss) per share is calculated using the weighted-average number of common shares outstanding during each period. Diluted net income (loss) per share is calculated based upon the inclusion of additional dilutive and potentially dilutive shares, which include shares issuable upon exercise of outstanding stock options, upon vesting of employee restricted stock-based awards, upon the accrual of incentive compensation to be paid in shares (if any performance-based conditions have been satisfied as of the end of the reporting period), and to settle the portion of the convertible notes that may be settled in shares (where the conversion of such instruments would be dilutive). Refer to Note 17.

Advertising Costs

Advertising costs are expensed as incurred and recorded in selling, general and administrative expense. Advertising costs, including trade shows, were $4.0 million, $5.1 million and $7.1 million for the years ended December 31, 2025, 2024 and 2023, respectively.

Pension Costs

We sponsor a retirement benefit for one of our non-U.S. subsidiaries in the form of a defined benefit pension plan. Accounting standards require the cost of providing this pension benefit be measured on an actuarial basis. Actuarial gains and losses resulting from both normal year-to-year changes in valuation assumptions and differences between assumptions and actual experience are deferred and amortized. The application of these accounting standards require us to make assumptions and judgments that can significantly affect these measurements. Our critical assumptions in performing these actuarial valuations include the selection of the discount rate to determine the present value of the pension obligations, which affects the amount of pension expense recorded in any given period. Changes in the discount rate could have a material effect on our reported pension obligations and related pension expense. Refer to Note 13.

Equity Compensation Plans

We recognize compensation expense for our stock-based compensation programs, which provide for the issuance of stock options, restricted stock, and restricted stock units ("RSU") that can have service-based conditions and market-based conditions.

The fair value of service-based awards is estimated at the grant date and recognized as expense ratably over the requisite service period of the award.

The fair value of awards with market conditions ("market-based awards") is determined using a Monte Carlo valuation model and is expensed over an implicit or explicit service period regardless of whether the market condition is probable of achievement or not. Market-based awards that cliff vest are expensed ratably using the straight-line method; whereas, market-based awards with graded vesting features are expensed using the graded vesting method. Stock compensation expense is not reversed if the market condition is not met.
For all share-based payment awards, we recognize forfeitures when they occur.

Income Taxes

We and the majority of our domestic subsidiaries file a consolidated U.S. federal income tax return. Our non-U.S. subsidiaries file income tax returns in their respective jurisdictions.
Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax benefit carryforwards. Our deferred income tax assets and liabilities at the end of each period are determined using enacted tax rates.
We establish a valuation allowance for those jurisdictions in which the expiration date of tax benefit carryforwards or projected taxable earnings leads us to conclude that it is "more likely than not" that a deferred tax asset will not be realized. This evaluation process includes the consideration of all available evidence regarding historical results and future projections, including the estimated timing of reversals of existing taxable temporary differences and potential tax planning strategies. Once a valuation allowance is established, it is maintained until a change in factual circumstances gives rise to sufficient income of the appropriate character and timing that will allow a partial or full utilization of the deferred tax asset.
In accordance with ASC 740, "Income Taxes," the impact of an uncertain tax position on our income tax returns is recognized at the largest amount that is more likely than not to be required to be recognized upon audit by the relevant taxing authority.
We include interest and penalties accrued in the consolidated financial statements as a component of income tax expense. For the year ended December 31, 2024, interest and penalties reported in income tax expense totaled $1.0 million. These amounts were immaterial for the years ended December 31, 2025 and December 31, 2023.
Refer to Note 16 for further discussion.
Operating and Finance Leases

We determine if an arrangement contains a lease at inception. We record both operating leases and finance leases on our balance sheet and do not separate non-lease components from our real estate leases. We exclude leases with a term of one year or less from our consolidated balance sheets.
Some leases include the option to purchase the leased asset, terminate the lease or extend the lease for one or more years. These options are considered in the determination of the estimated lease term when it is reasonably certain that an option will be exercised. Our leases do not contain any material residual value guarantees or material restrictive covenants.
Most of our leases do not provide an implicit rate; therefore, we use our incremental borrowing rate based on information available at the lease commencement date to determine the present value of the future lease payments.
Certain of our leases include variable costs. Variable costs include non-lease components that are incurred based upon actual terms, rather than contractually fixed amounts. In addition, variable costs are incurred for lease payments that are indexed to a change in rate or index. Because the right-of-use ("ROU") assets recorded on the balance sheet are determined based upon factors considered at the lease commencement date, subsequent changes in the rate or index that were not contemplated in the ROU asset balances at lease commencement result in variable expenses being recorded when these expenses are incurred during the lease term. Refer to Note 10.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted
In September 2025, the FASB issued ASU No. 2025-06, "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software." The ASU revises the accounting and disclosure requirements for internally developed software, including moving website development guidance from ASC 350-50 to ASC 350-40, eliminating the use of development stages, and introducing new capitalization criteria based on (1) management’s authorization and funding commitment, and (2) the probability of project completion and intended functionality. It also includes guidance for assessing significant development uncertainty. This update is effective for annual periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effects of this ASU on our consolidated financial statements.

In July 2025, the FASB issued ASU No. 2025-05, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets." The ASU introduces a practical expedient that allows entities to assume that current conditions as of the balance sheet date will remain unchanged over the remaining life of eligible accounts receivable and contract assets. Under this expedient, entities are not required to forecast future changes in conditions for these assets; however, they must continue to consider customer-specific information and any known or expected deviations from current conditions. This update is effective for annual reporting periods beginning after December 15, 2025, including interim periods within those annual periods. Early adoption is permitted. The Company does not expect that the adoption of this standard will have a material impact on our Consolidated Financial Statements.

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The amendments in this ASU require public entities to provide disaggregated disclosure of expenses included within relevant income statement expense captions, as well as additional disclosures about selling expenses. This update is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effects of this ASU on our consolidated financial statements.
Recently Adopted Accounting Standards
In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. We adopted this ASU prospectively for the year ended December 31, 2025, and we have included the required disclosures in Note 16.
In November 2024, the FASB issued ASU No. 2024-04, "Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments," related to induced conversions of convertible debt instruments. The amendments in this ASU clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions rather than as debt extinguishments. The Company early adopted this ASU as of April 1, 2025 and applied the guidance on a prospective basis. Adoption did not have a material impact on our consolidated financial statements.
v3.25.4
DIVESTITURES
 12 Months Ended
Dec. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
DIVESTITURES
NOTE 3 - DIVESTITURES

Oqton and 3DXpert

In September 2025, the Company entered into a definitive agreement for the sale of its 3DXpert and Oqton businesses to Hubb Global Holdings, LLC. On October 31, 2025, the Company completed the sale of the 3DXpert and Oqton businesses for $3.3 million in cash, which reflected applicable purchase price adjustments, plus a revenue-based royalty receivable which had a present value of $7.1 million as of the divestiture date. The revenue-based royalty receivable, net is included within Other assets on the consolidated balance sheet and payment is expected to be received in installments between 2027 and 2031, with payment amounts varying based on revenue earned. The annual effective interest rate used to calculate the present value of the guaranteed royalty consideration is 6.0%. The gross and net carrying values of the revenue-based royalty receivable are summarized below.
(in thousands)December 31, 2025
Revenue-based royalty receivable, gross
$9,900 
Discount on revenue-based royalty receivable
(2,850)
Revenue-based royalty receivable, net
$7,050 

3DXpert and Oqton are included in our Industrial Solutions segment. The Company recorded a pre-tax gain of $13.9 million from the sale of 3DXpert and Oqton in the year ended December 31, 2025.

No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been classified as a discontinued operation in the accompanying consolidated financial statements, as the sale of 3DXpert and Oqton does not constitute a strategic shift that would have a major effect on the Company’s operations.
Geomagic

In December 2024, the Company entered into a definitive agreement with Hexagon AB for the sale of its Geomagic software business ("Geomagic"), which was included in our Industrial Solutions segment. On April 1, 2025, the Company completed the sale of Geomagic and received $119.4 million in cash, which reflected applicable purchase price adjustments. The Company recorded a pre-tax gain of $125.7 million from the sale of Geomagic in the year ended December 31, 2025.
No loss was recognized to measure the disposal group at the lower of its carrying value or fair value less costs to sell. The disposal group has not been presented as a discontinued operation in the accompanying consolidated financial statements because the sale of Geomagic does not represent a strategic shift that will have a major effect on the Company’s operations.
The Company determined that the associated assets and liabilities met the held for sale criteria in December 2024. The following table summarizes the assets and liabilities of Geomagic:

(in thousands)December 31, 2024
Assets
Accounts receivable, net$765 
Prepaid expenses and other current assets47 
Total current assets held for sale812 
Intangible assets, net917 
Other assets1,447 
Total assets held for sale$3,176 
Liabilities
Current operating lease liabilities
Accounts payable$491 
Accrued and other liabilities303 
Deferred revenue7,197 
Total current liabilities held for sale7,991 
Other liabilities2,260 
Total liabilities held for sale$10,251 
v3.25.4
REVENUES
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES
NOTE 4 - REVENUES

Remaining Performance Obligations
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account as defined in ASC 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
Remaining performance obligations represent the transaction price allocated to performance obligations which are unsatisfied as of the end of the period. The Company has excluded performance obligations with an original expected duration of one year or less. Remaining performance obligations as of December 31, 2025 were $6.5 million. We expect to recognize approximately 90% of the $6.5 million of remaining performance obligations as revenue within the next 2.0 years, and the remaining balance thereafter.

Contract Assets
In certain circumstances, contract assets are recorded to include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customers, and right to payment is subject to contractual performance obligations rather than subject only to the passage of time. Contract assets were $1.6 million and $0.3 million as of December 31, 2025 and 2024, respectively. Contract assets are included in Prepaid expenses and other current assets on the accompanying consolidated balance sheets.
Contract Liabilities
Our contract liabilities consist of deferred revenue generally related to maintenance and service contracts, post-sale support and extended warranty sales, where we generally receive up-front payment and recognize revenue over the service or support term. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. The non-current portion of deferred revenue is recorded within Other liabilities on our consolidated balance sheets.
During the year ended December 31, 2025, we recognized revenue of $32.6 million related to our contract liabilities at December 31, 2024. During the year ended December 31, 2024, we recognized revenue of $32.0 million related to our contract liabilities at December 31, 2023. The change in contract liabilities from December 31, 2025 to December 31, 2024 was primarily due to the timing of cash receipts and sales of extended service contracts.

Our contract liabilities consisted of the following:

December 31,
(in thousands)20252024
Deferred revenue, current and customer deposits17,423 32,010 
Deferred revenue, noncurrent2,794 2,259 
Total contract liabilities$20,217 $34,269 

Disaggregated Revenue and Concentrations
Revenue by geographic region for the years ended December 31, 2025, 2024, and 2023, which is determined based upon the geographic region in which a sale originates, was as follows:
Year Ended December 31,
(in thousands)202520242023
Americas$224,452 $253,468 $282,742 
EMEA135,825 149,734 164,673 
APAC26,625 36,919 40,654 
Total$386,902 $440,121 $488,069 
Year Ended December 31,
(in thousands)202520242023
United States (included within Americas) $221,045 $248,346 $278,268 
Germany (included within EMEA)59,347 69,101 76,995 

For the year ended December 31, 2025, two customers within our Healthcare Solutions segment represented 12.2% and 11.4% of our revenue, respectively. For the years ended December 31, 2024 and 2023, one of those customers represented 16.0% and 15.0% of our revenue, respectively. We expect to maintain our relationship with these customers.

Collaboration Arrangements

We review and update our estimate of variable consideration on a regular basis. Any adjustments to estimated revenue is recognized under the cumulative catch-up method.
For the year ended December 31, 2025, the Company recognized $8.7 million in product revenue and recognized $8.1 million, in product cost of sales, related to collaborative arrangements. We review and update our estimate of variable consideration on a regular basis. Any adjustments to estimated revenue is recognized under the cumulative catch-up method.

During the year ended December 31, 2024, the Company did not record any product revenue due to a cumulative catch-up adjustment which reduced revenue by $8.7 million. The decrease in estimated recognizable variable consideration was due to the Company's determination that incremental revenue attributable to milestone payments that are contingent upon the achievement of contractual developmental criteria are no longer probable of being earned. The Company recorded $7.1 million in product cost of sales related to collaborative arrangements during the year ended December 31, 2024.
During the year ended December 31, 2023, the Company recognized $17.0 million in product revenue which included a cumulative catch-up adjustment to record incremental services revenue of $4.5 million. The increase in estimated recognizable variable consideration was due to the execution of a modification to the related customer contract and the Company's determination that incremental revenue attributable to milestone payments that are contingent upon the achievement of contractual developmental criteria would be earned under the modified contract. The Company recorded $14.1 million in product cost of sales related to collaborative arrangements during the year ended December 31, 2023.
v3.25.4
INVENTORIES
 12 Months Ended
Dec. 31, 2025
Inventory Disclosure [Abstract]  
INVENTORIES
NOTE 5 - INVENTORIES

Components of inventories at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Raw materials$45,350 $43,138 
Work in process2,137 3,481 
Finished goods and parts80,009 71,911 
Total inventories$127,496 $118,530 

The inventory reserve was $26.5 million and $21.9 million as of December 31, 2025 and 2024, respectively.
v3.25.4
PROPERTY AND EQUIPMENT
 12 Months Ended
Dec. 31, 2025
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT
NOTE 6 - PROPERTY AND EQUIPMENT

Property and equipment at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Machinery and equipment$129,493 $134,111 
Capitalized software25,811 25,888 
Office furniture and equipment5,238 5,454 
Leasehold improvements40,765 37,794 
Construction in progress9,652 4,831 
Total property and equipment a
210,959 208,078 
Less: Accumulated depreciation and amortization a
(161,710)(157,034)
Total property and equipment, net$49,249 $51,044 
a. The impairment charges subsequently discussed resulted in the establishment of a new cost basis for certain assets reflected in the table. Gross asset carrying values and accumulated depreciation and amortization have been adjusted to reflect the new cost basis of assets for which the carrying value was reduced due to impairment.

We include all depreciation related to assets attributable to the generation of revenue in cost of sales on the consolidated statements of operations. Depreciation related to assets that are not attributable to the generation of revenue is included in Research and development and Selling, general and administrative expenses on the consolidated statements of operations. Depreciation expense on property and equipment for the years ended December 31, 2025, 2024 and 2023 was $17.4 million, $19.0 million and $21.3 million, respectively.
In 2024, the Company concluded that there were indicators that the primary asset group underlying the Company's core operations should be tested for recoverability based upon the reporting of losses and negative cash flows as well as the significant decline in the Company's stock price. As a result of this assessment, the Company recognized a $5.9 million impairment charge related to property and equipment, net within Asset impairment charges on our consolidated statement of operations for the year ended December 31, 2024. For the year ended December 31, 2023, we recognized impairment charges of $1.4 million related to property and equipment, net in Selling, general and administrative expense on the consolidated statement of operations.
v3.25.4
INTANGIBLES ASSETS
 12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLES ASSETS
NOTE 7 - INTANGIBLES ASSETS

At December 31, 2025 and 2024, the Company's intangible assets with finite lives were as follows:
20252024
(in thousands)
Gross
Accumulated Amortization
Net
Gross
Accumulated AmortizationNet
Intangible assets with finite lives:
Customer relationships$53,119 $(53,099)$20 $47,051 $(47,023)$28 
Acquired technology14,203 (7,024)7,179 13,768 (6,149)7,619 
Trade names10,413 (8,616)1,797 11,973 (9,998)1,975 
Patent costs14,716 (7,550)7,166 14,915 (6,950)7,965 
Acquired patents11,458 (11,395)63 14,596 (14,485)111 
Other6,758 (6,369)389 7,666 (7,344)322 
Total intangible assets with finite lives
$110,667 $(94,053)$16,614 $109,969 $(91,949)$18,020 

Amortization expense related to our intangible assets with finite lives was $2.3 million, $12.7 million and $12.1 million for the years ended December 31, 2025, 2024 and 2023, respectively. Amortization expense is estimated to be $1.9 million in 2026, $1.9 million in 2027, $1.8 million in 2028, $1.7 million in 2029, and $1.6 million in 2030.

Impairment of Intangible Assets During the Year Ended December 31, 2024

During the year ended December 31, 2024, the Company concluded that the carrying value of the primary asset group underlying the Company's core operations was impaired, resulting in an impairment charge to intangible assets of $31.2 million. Also during the year ended December 31, 2024, the Company concluded that the carrying value of the software asset group was fully impaired, resulting in an additional $1.2 million impairment charge to intangible assets. Both intangible asset impairment charges are recorded within Asset impairment charges on our consolidated statements of operations.

Impairment of Intangible Assets During the Year Ended December 31, 2023

Indefinite-Life Intangible Assets (Excluding Goodwill)

During the year ended December 31, 2023, the Company decided to cease the development of IPR&D related to the 2022 acquisition of dp polar. The Company recorded a charge of $5.6 million within Asset impairment charges on our consolidated statement of operations for the year ended December 31, 2023 to write off the carrying value of this asset.

Impairment of Intangible Assets with Finite Lives

dp polar

As dp polar was not capable of generating revenue or positive cash flows without the continued development of its IPR&D, the Company concluded that dp polar's long-lived assets, including the remaining carrying value of the trade name intangible asset recorded when dp polar was acquired, were fully impaired. Accordingly, the Company recorded a charge of $3.8 million within Asset impairment charges on our consolidated statement of operations for the year ended December 31, 2023 to write off dp polar's trade name.

Oqton MOS

During the year ended December 31, 2023, the Company concluded that it was more likely than not that it would sell or otherwise dispose of a portion of its software business unit, Oqton MOS, that it had previously acquired. Based on revised long-term cash flows, this asset group was tested for impairment. The Company recognized a $13.6 million impairment charge during the year ended December 31, 2023, which reduced the carrying values of the asset group's acquired technology and trade name intangible assets to $0.
v3.25.4
GOODWILL
 12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL
NOTE 8 - GOODWILL

The following table reflects the changes in the carrying amount of goodwill by reporting unit for the years ended December 31, 2025 and 2024:

HealthcareIndustrialConsolidated
(in thousands)
Gross Goodwill
Cumulative Impairments
Net GoodwillGross Goodwill
Cumulative Impairments
Net Goodwill
Gross Goodwill
Cumulative Impairments
Net Goodwill
Balance, December 31, 2023$148,137 $(32,055)$116,082 $322,137 $(322,137)$— $470,274 $(354,192)$116,082 
Impairment charge
— (101,445)(101,445)— — — — (101,445)(101,445)
Foreign currency translation adjustments242 — 242 — — — 242 — 242 
Balance, December 31, 2024$148,379 $(133,500)$14,879 $322,137 $(322,137)$— $470,516 $(455,637)$14,879 
Foreign currency translation adjustments696 — 696 — — — 696 — 696 
Balance, December 31, 2025$149,075 $(133,500)$15,575 $322,137 $(322,137)$— $471,212 $(455,637)$15,575 

Interim and Annual Impairment Test During the Year Ended December 31, 2025

During the second quarter of 2025, management identified a triggering event for the Healthcare reporting unit resulting from macroeconomic uncertainties, updates to strategic plans and restructuring initiatives, and a decline in the Company's stock price. Accordingly, an interim goodwill impairment assessment was performed. Based on the results of the quantitative test, no impairment was identified, as the estimated fair value of the reporting unit exceeded its carrying value. We also tested our goodwill for impairment as of our annual impairment testing date, November 1, 2025, and no impairment was identified.

Although no impairment was identified during the interim test and the annual test in 2025, future changes to operating results, cash flows, share price market capitalization, or discount rates could adversely affect the implied fair value of goodwill and may result in future impairment charges.

Impairment of Goodwill During the Year Ended December 31, 2024

During the year ended December 31, 2024, as a result of the significant decline in the trading price of our common stock and our market capitalization as well as reduced long term cash flow forecasts, we performed an interim period quantitative goodwill impairment test as of September 30, 2024, and we recorded a $101.4 million goodwill impairment charge reported within Asset impairment charges on our consolidated statement of operations.

Impairment of Goodwill During the Year Ended December 31, 2023
For the year ended December 31, 2023, we completed the required annual goodwill impairment test for each of our reporting units (Healthcare Solutions and Industrial Solutions) and we determined that the carrying value of our Industrial Solutions reporting unit exceeded its fair value by an amount that was in excess of the goodwill assigned to the Industrial Solutions reporting unit. We recognized a goodwill impairment charge of $279.8 million to write off the entire goodwill balance assigned to the Industrial Solutions reporting unit for the year ended December 31, 2023. This goodwill charge is reported within Asset impairment charges on our consolidated statement of operations.
v3.25.4
INVESTMENTS AND NOTE RECEIVABLE
 12 Months Ended
Dec. 31, 2025
Equity Method Investments and Joint Ventures [Abstract]  
INVESTMENTS AND NOTE RECEIVABLE
NOTE 9 - INVESTMENTS AND NOTE RECEIVABLE

The Company holds various equity investments. The following table summarizes our investment balance, which are reported in Other assets on our consolidated balance sheets:

(in thousands)December 31, 2025December 31, 2024
Equity investments under the equity method of accounting$753 $5,051 
Equity investments without readily determinable fair values21,712 20,696 
Total equity investments
$22,465 $25,747 

National Additive Manufacturing Innovation ("NAMI") Joint Venture

In February 2023, we became a shareholder in a joint venture formed with the Saudi Arabian Industrial Investments Company ("Dussur") for purposes of expanding the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. During April 2023, we deposited our initial investment commitment of approximately $6.5 million into a bank account of the joint venture for use in its operations. In May 2024, we made an incremental investment of $2.5 million. Additional future investments in the joint venture are contingent upon agreement by the parties to the joint venture to invest additional capital. As of both December 31, 2025 and December 31, 2024, the Company owned 49% of the joint venture's common stock.

The Company accounts for its investment in the joint venture under the equity method of accounting, requiring the Company to recognize its proportionate share of the joint venture's reported net income or loss, which the Company recognizes on a one quarter lag. For the years ended December 31, 2025 and December 31, 2024, the Company has reported a loss on equity method investment in its consolidated statements of operations. The carrying values of the Company's equity method investment at December 31, 2025 and 2024 are $0.4 million and $4.3 million, respectively.

The Company enters into related-party transactions with NAMI in the ordinary course of business. Reported revenue and cost of sales for the year ended December 31, 2025 attributable to NAMI were not material. The Company's reported revenue and cost of sales for the year ended December 31, 2024 attributable to NAMI of $3.8 million and $2.6 million, respectively. The Company's reported revenue and cost of sales for the year ended December 31, 2023 attributable to NAMI of $1.7 million and $1.0 million, respectively. As of December 31, 2025 and December 31, 2024, the outstanding related party receivable balances attributable to our sales to NAMI were not material.

In December 2024, the Company entered into a short-term, non-interest bearing related party note receivable agreement with NAMI whereby NAMI borrowed $2.0 million to finance its working capital and capital expenditures requirements. The note receivable originally matured on June 30, 2025. During the quarter ended September 30, 2025, the parties amended the note receivable agreement to extend the maturity date to June 30, 2026, and increase the note receivable to $4.4 million.

The note receivable is recorded at cost, which approximates fair value as of December 31, 2025. The carrying value of the note receivable was $4.4 million and $2.0 million as of December 31, 2025 and December 31, 2024, respectively. The note receivable is reported in Prepaid expenses and other current assets, on our consolidated balance sheets as of December 31, 2025 and December 31, 2024.

Theradaptive, Inc.

In June 2023, we made an $8.0 million investment in Theradaptive, Inc. ("Theradaptive"), via the purchase of Series A Preferred Stock. Theradaptive is currently developing a protein that encourages bone growth. This biotechnology could be applied to 3D printed metal splints for patients who otherwise may require amputation of a limb because the lost bone is too vast to replace with a splint. The Company has accounted for its investment in Theradaptive on a cost basis, subject to assessment for impairment, as (1) the fair value of Theradaptive's equity is not readily determinable and (2) the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The investment in Theradaptive is not expected to materially impact our future financial position, results of operations, or cash flows. No impairment charges were recognized with respect to this investment during the years ended December 31, 2025, 2024, or 2023.
Enhatch Inc.

In March 2022, the Company made a $10.0 million investment in Enhatch Inc. ("Enhatch"), the developer of the Intelligent Surgery Ecosystem, and received convertible preferred shares, a warrant to purchase additional shares of Enhatch, and the right to purchase in the future the remaining shares of Enhatch that 3D Systems does not own if certain revenue targets are achieved (the "call option").

As of December 31, 2025 and 2024, the reported carrying value of the Company's convertible preferred stock investment in Enhatch (i.e., inclusive of the call option) is $6.9 million, which is accounted for on a cost basis, subject to assessment for impairment, and is recorded in Other assets on our consolidated balance sheets. The investment in Enhatch is recorded on a cost basis, as (1) the fair value of Enhatch's equity is not readily determinable and (2) the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The investment in Enhatch is not expected to materially impact our future financial position, results of operations, or cash flows. This adjusted carrying value reflects the impact of a $2.8 million impairment charge that was recorded during the year ended December 31, 2022.

Additionally, the Company has an investment in Enhatch common shares which is accounted for under the equity method of accounting due to the Company's ability to exert significant influence over the financial and operating policies of Enhatch. During the years ended December 31, 2025 and 2024, the Company purchased $1.5 million and $0.6 million of shares, respectively. Accordingly, for purposes of its investment in Enhatch's common shares, the Company recognizes its proportionate share of Enhatch's reported net income or loss on a one quarter lag.

The carrying value of this equity method investment was $0.4 million as of December 31, 2025, and the Company owns approximately 79% of Enhatch's outstanding common stock and approximately 46% of Enhatch's outstanding voting stock.

The Company enters into related-party transactions with Enhatch in the ordinary course of business. During the years ended December 31, 2025 and 2024, the Company made purchases from Enhatch of $1.0 million and $0.7 million, respectively. As of December 31, 2025 and 2024, the outstanding related party payable balances attributable to our purchases from Enhatch were not material.

GenesisTissue Inc.

During the second quarter of 2025, the Company entered into an agreement with GenesisTissue Inc. ("GenesisTissue") to obtain shares of common stock in exchange for the sale of certain assets. As of December 31, 2025, the Company owns approximately 8% of GenesisTissue's outstanding common stock. The Company has accounted for its investment in GenesisTissue on a cost basis, subject to assessment for impairment, as (1) the fair value of GenesisTissue's equity is not readily determinable and (2) the investment is not subject to the equity method of accounting due to the Company's lack of significant influence. The carrying value of the equity investment without a readily determinable fair value is $1.0 million as of December 31, 2025.
Other Asset
In February 2025, the Company provided financing of $1.0 million to Hull Legacy Media Corporation, a production company co-owned by Charles W. Hull, EVP, Chief Technology Officer for the Company's Regenerative Medicine business and a related party of the Company. The financing is recorded in Other assets on our consolidated balance sheets as of December 31, 2025.
Variable Interest Entities ("VIEs")
The Company concluded that its investments in Theradaptive, Enhatch and NAMI are VIEs. These investments are not consolidated as we concluded that the Company is not the primary beneficiary. As of December 31, 2025, our maximum exposure to losses associated with the VIEs is limited to the $20.1 million carrying value of our investments in the VIEs, $4.4 million of which is included in Prepaid expenses and other current assets, with the remaining in Other assets on our consolidated balance sheets.
v3.25.4
LEASES
 12 Months Ended
Dec. 31, 2025
Leases [Abstract]  
LEASES
NOTE 10 - LEASES

We have various lease agreements for our facilities, equipment and vehicles with remaining lease terms ranging from one to twelve years.

For the year ending December 31, 2025 we recorded $0.6 million in impairment charges to ROU assets. The impairment charge has been recorded within Asset impairment charges on our consolidated statements of operations.
During the year ended December 31, 2024, the Company concluded that the carrying value of the primary asset group underlying the Company's core operations was impaired, resulting in a $5.2 million impairment charge to ROU assets. This impairment charge reduced the carrying values of our operating lease and finance lease ROU assets by $2.7 million and $2.5 million, respectively. This impairment charge is recorded within Asset impairment charges on our consolidated statements of operations. No impairment was recognized in the year ended December 31, 2023.

As of December 31, 2025 and 2024, short-term finance lease obligations of $1.6 million and $1.5 million, respectively, are included in Accrued and other liabilities on our consolidated balance sheets, and long-term finance lease obligations of $9.5 million and $10.5 million, respectively are included in Other long-term liabilities on our consolidated balance sheets.

Incremental Lease Commitments

Components of lease cost (income) for the years ended December 31, 2025, 2024, and 2023 were as follows:

(in thousands)202520242023
Operating lease cost$13,715 $14,331 $13,667 
Finance lease cost - amortization expense1,586 1,706 991 
Finance lease cost - interest expense955 1,017 478 
Short-term lease cost157 347 494 
Variable lease cost4,492 4,142 3,953 
Sublease income(69)(132)(186)
Total$20,836 $21,411 $19,397 

As of December 31, 2025, our future minimum lease payments under operating leases and finance leases with initial or remaining lease terms in excess of one year were as follows:

(in thousands)Finance LeasesOperating Leases
Years ending December 31:
2026$2,470 $15,094 
20272,535 11,987 
20282,499 10,880 
20292,132 9,317 
20301,539 7,095 
Thereafter3,261 18,680 
Total lease payments (undiscounted)14,436 73,053 
Less: imputed interest(3,321)(16,050)
Present value of lease liabilities$11,115 $57,003 

Supplemental cash flow information related to our leases for the years ended December 31, 2025, 2024 and 2023 was as follows:

(in thousands)202520242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflow for operating leases$14,151 $13,986 $13,177 
Operating cash outflow for finance leases$955 $1,017 $478 
Financing cash outflow for finance leases$1,593 $1,385 $644 
The weighted-average remaining lease term and discount rate for our finance and operating leases as of December 31, 2025 and 2024 were as follows:
20252024
FinanceOperatingFinanceOperating
Weighted-average remaining lease term (in years)6.16.67.07.3
Weighted-average discount rate8.47%7.23%8.44%7.17%
LEASES
NOTE 10 - LEASES

We have various lease agreements for our facilities, equipment and vehicles with remaining lease terms ranging from one to twelve years.

For the year ending December 31, 2025 we recorded $0.6 million in impairment charges to ROU assets. The impairment charge has been recorded within Asset impairment charges on our consolidated statements of operations.
During the year ended December 31, 2024, the Company concluded that the carrying value of the primary asset group underlying the Company's core operations was impaired, resulting in a $5.2 million impairment charge to ROU assets. This impairment charge reduced the carrying values of our operating lease and finance lease ROU assets by $2.7 million and $2.5 million, respectively. This impairment charge is recorded within Asset impairment charges on our consolidated statements of operations. No impairment was recognized in the year ended December 31, 2023.

As of December 31, 2025 and 2024, short-term finance lease obligations of $1.6 million and $1.5 million, respectively, are included in Accrued and other liabilities on our consolidated balance sheets, and long-term finance lease obligations of $9.5 million and $10.5 million, respectively are included in Other long-term liabilities on our consolidated balance sheets.

Incremental Lease Commitments

Components of lease cost (income) for the years ended December 31, 2025, 2024, and 2023 were as follows:

(in thousands)202520242023
Operating lease cost$13,715 $14,331 $13,667 
Finance lease cost - amortization expense1,586 1,706 991 
Finance lease cost - interest expense955 1,017 478 
Short-term lease cost157 347 494 
Variable lease cost4,492 4,142 3,953 
Sublease income(69)(132)(186)
Total$20,836 $21,411 $19,397 

As of December 31, 2025, our future minimum lease payments under operating leases and finance leases with initial or remaining lease terms in excess of one year were as follows:

(in thousands)Finance LeasesOperating Leases
Years ending December 31:
2026$2,470 $15,094 
20272,535 11,987 
20282,499 10,880 
20292,132 9,317 
20301,539 7,095 
Thereafter3,261 18,680 
Total lease payments (undiscounted)14,436 73,053 
Less: imputed interest(3,321)(16,050)
Present value of lease liabilities$11,115 $57,003 

Supplemental cash flow information related to our leases for the years ended December 31, 2025, 2024 and 2023 was as follows:

(in thousands)202520242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflow for operating leases$14,151 $13,986 $13,177 
Operating cash outflow for finance leases$955 $1,017 $478 
Financing cash outflow for finance leases$1,593 $1,385 $644 
The weighted-average remaining lease term and discount rate for our finance and operating leases as of December 31, 2025 and 2024 were as follows:
20252024
FinanceOperatingFinanceOperating
Weighted-average remaining lease term (in years)6.16.67.07.3
Weighted-average discount rate8.47%7.23%8.44%7.17%
v3.25.4
ACCRUED AND OTHER LIABILITIES
 12 Months Ended
Dec. 31, 2025
Payables and Accruals [Abstract]  
ACCRUED AND OTHER LIABILITIES
NOTE 11 - ACCRUED AND OTHER LIABILITIES

Accrued and other liabilities at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Compensation and benefits$11,293 $12,646 
Accrued taxes15,040 8,034 
Legal contingencies1,765 4,739 
Accrued product warranty liability
3,537 2,650 
Current finance lease liabilities
1,606 1,482 
Other accrued liabilities
13,415 15,937 
Total$46,656 $45,488 

Changes in our accrued product warranty liability balance for the years ended December 31, 2025, 2024 and 2023 are summarized below:

(in thousands)December 31, 2025December 31, 2024December 31, 2023
Balance at beginning of period
$2,650 $2,106 $3,677 
Settlements made
(3,451)(3,264)(4,397)
Accruals for warranties issued
4,338 3,808 2,826 
Balance at the end of period
$3,537 $2,650 $2,106 

Other liabilities at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Long-term finance lease liabilities
$9,509 $10,543 
Defined benefit pension obligation6,358 5,716 
Long-term tax liability2,624 2,277 
Long-term employee indemnity2,032 3,480 
Long-term deferred revenue2,794 2,259 
Other long-term liabilities683 726 
Total$24,000 $25,001 
v3.25.4
BORROWINGS
 12 Months Ended
Dec. 31, 2025
Debt Disclosure [Abstract]  
BORROWINGS
NOTE 12 - BORROWINGS

Convertible Senior Notes
Convertible senior secured notes due 2030
Pursuant to an indenture dated June 23, 2025 (the "2030 Indenture"), the Company issued $92.0 million aggregate principal amount of 5.875% convertible senior secured notes due 2030 (the "2030 Notes") in a private placement to a limited number of qualified institutional buyers. The net proceeds from the 2030 Notes, along with $78.0 million of cash on hand, were used to repurchase an aggregate principal amount of $179.7 million of the Company's outstanding 0% convertible senior notes due 2026 (the "2026 Notes").
The 2030 Notes are senior secured obligations, guaranteed by certain U.S. subsidiaries of the Company (the "Note Parties"), and bear interest semiannually at a rate of 5.875%, payable on June 15 and December 15 of each year, beginning December 15, 2025. The 2030 Notes are secured on a first-priority basis by substantially all assets of the Note Parties, subject to certain exceptions (including with respect to the intellectual property of the Note Parties; provided that, certain breaches by the Company or any of its subsidiaries of the limitation on liens covenant in the 2030 Indenture with respect to liens on its intellectual property will cause the 2030 Notes to automatically become secured by a prior security interest in all the intellectual property of the Note Parties). The 2030 Indenture also includes certain financial covenants, including a requirement for the Note Parties to maintain certain minimum cash, accounts receivable and inventory balances each quarter. Under the original 2030 Indenture, as of the last day of each fiscal quarter, the Note Parties were required to maintain at least $40.0 million in qualified cash and a minimum of $75.0 million in accounts receivable and inventory, and the Company was required to maintain at least $16.8 million in restricted cash until certain conditions were satisfied.
In December 2025, the Company entered into a second supplemental indenture (the "Second Supplemental Indenture") to the 2030 Indenture, where certain restrictions were amended in exchange for cash payments in an aggregate amount of $1.8 million paid to the holders of the 2030 Notes. The Second Supplemental Indenture amended the minimum cash requirement to require the Note Parties to maintain at least $20.0 million in qualified cash as of the last day of the fiscal quarter, removed the restricted cash account covenant and released the related lien on the restricted cash amount.
The initial conversion rate was 445.6328 shares per $1,000 principal amount, equivalent to a conversion price of approximately $2.24 per share, which reflected a 20% premium over the $1.87 closing price of the Company’s common stock on June 17, 2025. The 2030 Notes are set to mature on June 15, 2030, unless earlier redeemed, repurchased, or converted in accordance with their terms.
Prior to March 15, 2030, the 2030 Notes are only convertible upon the occurrence of certain events and will be convertible thereafter at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.
The 2030 Notes are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the election of the Company.
Holders of the 2030 Notes have a one-time put right on June 23, 2028, to require the Company to repurchase all or a portion of their 2030 Notes for cash at 100% of the principal amount, plus accrued and unpaid interest. Additionally, upon a fundamental change (as defined in the 2030 Indenture), holders may require repurchase on the same terms. The Company is required to increase the conversion rate for holders who convert in connection with certain fundamental changes or in connection with a redemption.
On or after June 23, 2028 and prior to the 41st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable, in whole or in part, at the Company's option, for cash, provided that the last reported sale price of the Company's common stock has been at least 130% of the conversion price then in effect for a specified period, as described in the 2030 Indenture.
The effective interest rate on the 2030 Notes is 8.6%, inclusive of original issue discounts, commissions, and offering expenses.
Convertible senior notes due 2026
The 2026 Notes were issued pursuant to an indenture dated November 16, 2021 (the "2026 Indenture") between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the "Trustee"), in an initial aggregate principal amount of $460.0 million. Although the 2026 Notes do not bear regular interest and their principal does not accrete, they have an annual effective interest rate of 0.594%, reflecting original issue discounts, commissions, and offering expenses. The 2026 Notes had an initial conversion rate of 27.8364 shares of common stock per $1 principal amount of Notes (which is subject to adjustment in certain circumstances). This is equivalent to an initial conversion price of approximately $35.92 per share. The conversion rate is subject to customary adjustments under certain circumstances in accordance with the terms of the 2026 Indenture. The 2026 Notes are scheduled to mature on November 15, 2026, unless earlier redeemed, repurchased, or converted in accordance with their terms.
Prior to August 15, 2026, the 2026 Notes are only convertible upon the occurrence of certain events and will be convertible thereafter at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, the Company will pay cash for the principal portion of the 2026 Notes being converted and may elect to settle the remainder of its conversion obligation, if any, in excess of the principal amount in cash, shares of the Company's common stock or a combination of cash and shares of common stock.
The 2026 Notes are redeemable, in whole or in part, for cash at the Company’s option at any time, and from time to time, on or after November 20, 2024 and before the 41st scheduled trading day immediately preceding the maturity date, but only if the last reported sale price per share of the Company's common stock has been at least 130% of the conversion price then in effect for a specified period of time.
The Company incurred debt issuance cost accretion related to the 2026 Notes and the 2030 Notes of $1.5 million for the year ended December 31, 2025. The Company incurred debt issuance cost accretion relating to the 2026 Notes of $1.4 million and $2.6 million for the years ended December 31, 2024 and December 31, 2023, respectively.

The following tables summarize the detail of the Company's convertible senior notes:
(in thousands)Outstanding PrincipalUnamortized Deferred Issuance CostsCarrying Value
December 31, 2025
0% Convertible senior notes due 2026
$3,944 $— $3,944 
5.875% Convertible senior notes due 2030
92,030 (5,636)86,394 
Outstanding convertible notes$95,974 $(5,636)$90,338 
(in thousands)Outstanding PrincipalUnamortized Deferred Issuance CostsCarrying Value
December 31, 2024
0% Convertible senior notes due 2026
$214,378 $(2,383)$211,995 
Outstanding convertible notes$214,378 $(2,383)$211,995 

As of December 31, 2025, the Company was in compliance with all of the covenants included in the 2026 Indenture and 2030 Indenture.
Debt Exchange and Extinguishment    

December 2025 Debt Exchange - 2026 Notes

In December 2025, the Company entered into separate, privately negotiated agreements with a limited number of existing holders (the "Transaction Participants") of the Company’s 2026 Notes. The Company agreed to exchange $30.8 million aggregate principal amount of 2026 Notes held by the Transaction Participants for an aggregate of 16.6 million shares of the Company’s common stock ("the Exchange"). Immediately following the Exchange, $3.9 million in aggregate principal amount of the 2026 Notes remained outstanding. The Exchange resulted in the recognition of a loss on debt extinguishment of $2.7 million, after transaction costs and the write off of $0.2 million in related debt issuance costs. The loss is reported in Other income, net on the Company’s consolidated statements of operations for the year ended December 31, 2025. The Company incurred $1.6 million of transaction costs in connection with the Exchange. These transaction costs included 0.7 million shares of the Company's common stock issued for services provided in connection with the Exchange.

June 2025 Debt Extinguishment - 2026 Notes
In June 2025, the Company used the proceeds of $92.0 million from the issuance of the 2030 Notes, along with $78.0 million of cash on hand, to repurchase an aggregate principal amount of $179.7 million of its outstanding 2026 Notes, which were retired upon receipt, and the retirement of the debt obligations was accounted for as an extinguishment of debt. The repurchase of the 2026 Notes at a discount resulted in the recognition of a gain of $8.2 million, after transaction expenses and the write-off of $1.5 million in related debt issuance costs. The gain is reported in Other income, net on the Company’s consolidated statements of operations for the year ended December 31, 2025.
In March 2024, the Company repurchased $110.5 million of the 2026 Notes for $87.2 million, including transaction expenses. The repurchased 2026 Notes were retired upon receipt, and the retirement of the debt obligations was accounted for as an extinguishment of debt. The repurchase of the 2026 Notes at a discount resulted in the recognition of a gain of $21.5 million, after transaction expenses and the write-off of $1.8 million in related debt issuance costs. The gain is reported in Other income, net on the Company’s consolidated statements of operations for the year ended December 31, 2024.
v3.25.4
EMPLOYEEE BENEFITS
 12 Months Ended
Dec. 31, 2025
Retirement Benefits [Abstract]  
EMPLOYEEE BENEFITS
NOTE 13 - EMPLOYEEE BENEFITS

We sponsor a Section 401(k) plan (the "Plan") covering substantially all of our eligible U.S. employees. The Plan entitles eligible employees to make contributions to the Plan after meeting certain eligibility requirements. Contributions are limited to the maximum contribution allowances permitted under the Internal Revenue Code. We match 50% of contributions on the first 6% of the participant’s eligible compensation.

For the years ended December 31, 2025, 2024 and 2023, we expensed $2.3 million, $2.5 million and $2.6 million, respectively, for matching contributions related to the Plan.

International Retirement Plan

We sponsor a non-contributory defined benefit pension plan for certain employees of a non-U.S. subsidiary. We maintain insurance contracts outside of the plan that provide an annuity that is used to fund the current obligations under this plan. The fair value of the insurance contract assets under the plan are $2.2 million as of December 31, 2025 and 2024 and are recorded in other assets on the Company’s consolidated balance sheets. The following table provides a reconciliation of the changes in the projected benefit obligation for the years ended December 31, 2025 and 2024:

(in thousands)20252024
Reconciliation of benefit obligation:
Obligation as of January 1$5,896 $6,027 
Service cost63 59 
Interest cost227 210 
Actuarial (gain) loss
(934)145 
Benefit payments(199)(187)
Effect of foreign currency exchange rate changes1,508 (358)
Benefit obligation as of December 31$6,561 $5,896 

We recognized the following amounts in the consolidated balance sheets at December 31, 2025 and 2024:

(in thousands)20252024
Accrued and other liabilities203 180 
Other liabilities6,358 5,716 
Total liability
$6,561 $5,896 

Following are the projected benefit obligation and accumulated benefit obligation at December 31, 2025 and 2024:

(in thousands)20252024
Projected benefit obligation$6,561 $5,896 
Accumulated benefit obligation$5,678 $5,672 
The following table shows the components of net periodic benefit costs and the amounts recognized in accumulated other comprehensive income (loss) for the years ended December 31, 2025, 2024 and 2023:


(in thousands)202520242023
Net periodic benefit cost:
Service cost$63 $59 $59 
Interest cost227 210 220 
Amortization of actuarial gain
(93)— (46)
Total net periodic pension cost197 269 233 
Other changes in plan assets and benefit obligations recognized in other comprehensive income (loss):
Net loss (gain)
(841)145 541 
Amortization of prior years' unrecognized gain (loss)
— — 46 
Total recognized as other comprehensive income (loss), excluding tax(841)145 587 
Total (gain) expenses recognized in net periodic benefit cost and other comprehensive (loss) income
$(644)$414 $820 

The following assumptions are used to determine the benefit obligations as of December 31, 2025 and 2024:

20252024
Discount rate4.4%3.6%
Rate of compensation3.0%3.0%

The following benefit payments, including expected future service cost, are expected to be paid:

(in thousands) 
Estimated future benefit payments for the years ending December 31: 
2026$232 
2027258 
2028287 
2029321 
2030353 
2031 through 2035
1,885 
v3.25.4
REDEEMABLE NON-CONTROLLING INTEREST
 12 Months Ended
Dec. 31, 2025
Noncontrolling Interest [Abstract]  
REDEEMABLE NON-CONTROLLING INTEREST
NOTE 14 - REDEEMABLE NON-CONTROLLING INTEREST

For each of the periods presented in our consolidated financial statements, the Company holds a 93.75% controlling interest in a consolidated foreign subsidiary that was acquired on April 1, 2022. The remaining 6.25% non-controlling interest in this foreign subsidiary is subject to redemption at a future date upon either (1) the exercise of a put option by the holder of the underlying shares or a call option by the Company, each of which is subject to the subsidiary achieving certain specified conditions, or (2) the passage of time subsequent to the date on which this subsidiary was acquired.

The put and call rights related to 50% of the common shares underlying this RNCI can be exercised upon the achievement of an initial revenue and gross profit target, while the put and call rights related to the remaining 50% of the common shares underlying the RNCI can be exercised upon the achievement of a second revenue and gross profit target. The exercise prices at which the shares underlying the RNCI can be put by their holders or called by the Company are determined based upon whether the consolidated foreign subsidiary achieves either or both of the predetermined revenue and gross profit targets. If either (1) one or both sets of revenue and gross margin targets are not achieved by the consolidated foreign subsidiary within specified time periods or (2) neither the put or call options are exercised within specified time periods despite the achievement of one or both sets of targets, the exercise price for the put and call options will be set at a floor strike price for periods thereafter. Up to 50% of the exercise price can be paid in shares of Common Stock at our election.
On December 9, 2024, the Company signed a profit and loss transfer agreement with the foreign subsidiary whereby the subsidiary transfers its entire net profit or loss to 3D Systems for the next five years. For the years ended December 31, 2025 and 2024, the Company consolidated 100% of the foreign subsidiary net loss.

In December 2025, the agreement was amended to allow for immediate exercise of the put option for $2.0 million, subject to the completion of the certain milestones, which will be paid in three installments in 2026. Upon completion of the initial payment, the remaining shares will be assigned to the Company.

Changes to the Company's RNCI balance during the years ended December 31, 2025, 2024 and 2023 are summarized below:
(in thousands)
Year Ended December 31
202520242023
Balance at beginning of period
$1,958 $2,006 $1,760 
Fair value at the date of acquisition
— — — 
Net loss
— — (265)
Redemption value (below) in excess of carrying value
— (61)479 
Translation adjustments
235 13 32 
Balance at end of period
$2,193 $1,958 $2,006 
v3.25.4
STOCK-BASED COMPENSATION
 12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION
NOTE 15 - STOCK-BASED COMPENSATION

Stock Incentive Plans

2015 Incentive Plan

The Company is authorized to grant shares of restricted stock, restricted stock units ("RSUs"), stock appreciation rights, cash incentive awards and options to purchase shares of common stock to employees and non-employees inclusive of directors pursuant to its 2015 Incentive Plan (the "2015 Plan"). The 2015 Plan also designates that shares may be used for performance-based awards and market-based awards. The vesting period for awards granted under the 2015 Plan is generally determined by the Board of Directors at the date of the grant. Generally, the awards vest one third each year, over 3 years. The total number of shares of common stock reserved and available for distribution under the 2015 Plan and the total number of shares of common stock that can be issued pursuant to stock options is 29,235,000 shares. Stock-based compensation expense is generally included in selling, general and administrative expenses in the consolidated statements of operations.

Systemic Bio Phantom Unit Plan

During the year ended December 31, 2023, we began granting phantom unit awards ("Phantom Units") under a new compensation plan designed for employees and non-employees performing services for Systemic Bio, a wholly-owned subsidiary of 3D Systems Corporation. All awards granted under the plan are subsidiary-level awards. The Phantom Units granted under the plan include both a time-based vesting condition (generally 4 years, subject to acceleration in connection with specified liquidity events) and a market condition that is met if (1) the value of Systemic Bio exceeds a specified multiple of the capital invested in this subsidiary (the "hurdle") and (2) the business achieves a specified minimum internal rate of return. The market conditions will be assessed upon (A) a trigger event (e.g., change in control, IPO or plan expiration of December 31, 2030) and/or (B) an interim liquidity event (defined as January 1, 2028) that occurs prior to a trigger event. All awards under the plan will be liability-classified due to our intention to settle these awards with cash; although, we have discretion to partially or fully settle these awards in equity upon vesting. Liability classification of the awards requires them to be remeasured at their fair value at the end of each reporting period. Due to the presence of the market-condition and the fact that Systemic Bio does not have a readily available share price, the awards are valued using a Monte Carlo simulation with the assistance of a third-party valuation firm. This valuation requires significant judgment regarding the input of various assumptions and estimates, which include the projected cash flows of (including projected capital invested in) Systemic Bio, the probability and/or timing of a trigger event or a liquidity event, the expected stock price volatility for selected public companies with comparable characteristics to Systemic Bio, the discount for the lack of marketability of Systemic Bio as a privately-held company, and the risk-free interest rate.
During the years ended December 31, 2024 and 2023, we granted 147,000 and 597,000 Phantom Units, respectively. As of December 31, 2024 and 2023, 721,000 and 596,000 Phantom Units were outstanding. During the years ended December 31, 2024 and 2023, we recognized $0.1 million and $0.5 million of compensation expense related to the Phantom Units. As of December 31, 2024 and 2023, the liability recognized in other liabilities on the consolidated balances sheets for the Phantom Units was $0.6 million and $0.5 million, respectively.

During the year ending December 31, 2025, the remaining outstanding Phantom Units were forfeited due to not achieving the required performance conditions and $0.6 million of compensation expense relating to the Phantom Units was reversed. As of December 31, 2025, there was no liability on the consolidated balances sheets for the Phantom Units. The Phantom Units are excluded from the restricted stock and RSU summary table below.

Restricted Stock and Restricted Stock Units

A summary of our restricted stock and RSU activity for the years ended December 31, 2025, 2024 and 2023 is as follows:
(in thousands, except per share amounts)Number of Shares/UnitsWeighted Average Grant Date Fair Value
Outstanding as of December 31, 2022 — unvested5,015 $18.19 
Granted4,439 $10.26 
Canceled(1,118)$15.45 
Vested(2,154)$13.09 
Outstanding as of December 31, 2023 — unvested6,182 $14.77 
Granted3,392 $1.98 
Canceled(1,845)$14.69 
Vested(2,544)$13.28 
Outstanding as of December 31, 2024 — unvested5,185 $7.16 
Granted2,958 $2.25 
Canceled(1,323)$4.37 
Vested(1,659)$7.14 
Outstanding as of December 31, 2025 — unvested5,161 $5.06 

Included in the above outstanding balance as of December 31, 2025 are 1,687,753 shares of restricted stock that vest under specified market conditions, which were awarded to certain employees in 2025, 2024, and 2023.

During the year ended December 31, 2025, the Company granted 810,000 performance-based RSUs ("PSUs") to employees with a weighted-average grant date fair value of $0.47 per share. The PSUs are subject to three-year cliff vesting. Vesting is contingent upon the continued service and market conditions that are met based on annualized stock price growth goals.

Stock Options 

During the year ended December 31, 2016, we awarded certain employees market condition stock options under the 2015 Plan that vest under specified market conditions. Each employee was generally awarded two equal tranches of market condition stock options that immediately vest when our common stock trades at either $30 or $40 per share for ninety consecutive calendar days.

We recognize compensation expense related to stock options on a straight-line basis over the derived term of the awards. The fair value of stock options with market conditions is estimated using a binomial lattice Monte Carlo simulation model. Expense for awards with a market condition is not reversed if the market condition is not met.
Year Ended December 31, 2024
(in thousands, except per share amounts)Number of SharesWeighted Average ExerciseWeighted Average Remaining Contractual Term (in years)Aggregate Intrinsic Value
Stock option activity:
Outstanding at beginning of year420 $13.26 2.7$— 
Forfeited and expired(260)13.26 — — 
Outstanding at end of year160 $13.26 1.6$— 

During the years ended December 31, 2025 and 2023, there was no stock option activity. The aggregate intrinsic value of the outstanding stock options was $0 as of December 31, 2025 and 2023, respectively. As of December 31, 2025, 2024 and 2023, none of the outstanding stock options were exercisable, and there was no unrecognized stock-based compensation expense related to stock options.

Other Compensation Arrangements that Include Share Settlement

Regenerative Medicine Earnout Payments and Performance-Based Stock Units

Volumetric Acquisition Earnout Payments

On December 1, 2021, the Company acquired Volumetric Biotechnologies, Inc. (“Volumetric”). Pursuant to the terms of the related acquisition agreement, the Company was potentially subject to aggregate earnout payments of up to $355.0 million (i.e., incremental to the previously paid acquisition purchase price). These earnout payments would be triggered by (1) the achievement of seven discrete non-financial milestones, each of which required attainment prior to either December 31, 2030 or December 31, 2035, and (2) the continued employment of certain Volumetric key employees. Each potential milestone-based payment was deemed to be compensation expense that the Company would recognize ratably from the point in time when a milestone was deemed probable of achievement through the estimated time of achievement. Each milestone payment, if earned, would be expected to be settled approximately half in cash and half in shares of Common Stock and, accordingly, expense recognized for the portion of this earnout that is expected to be settled with shares of Common Stock would be reflected in the disclosure of stock-based compensation included herein, if and when accrued.

In February 2024, the Company informed the former owners of Volumetric, to whom the acquisition-related earnout payments of up to $355.0 million could have potentially become payable, that four of the seven milestone-related earnout payments, each of which was related to kidney and liver research, were terminated. These four milestone-based earnout payments were terminated in accordance with the terms of the Volumetric acquisition agreement, based upon a determination that achievement was no longer financially viable due to the loss of the funding required from the Company's key strategic partner for the related research and development efforts. Upon termination of the four milestone-based earnout payments, the Company's maximum liability for earnout payments attributable to the acquisition of Volumetric was reduced to $175.0 million, which would be payable if (1) each of the three remaining non-financial, science-based milestones was achieved within the timeframes set forth in the Volumetric acquisition agreement and (2) the certain key individuals from Volumetric continue to be employed.

On April 29, 2024, two key employees from Volumetric ("Volumetric Key Employees"), who were required to be employed at the time of achievement of each non-financial, science-based milestone outlined in the Volumetric acquisition agreement for each related acquisition earnout payment to become payable, resigned from their positions with the Company. As a result of the resignation of the Volumetric Key Employees, all parties to which the remaining three milestone-based earnout payments totaling $175.0 million were potentially payable were notified that such amount was no longer eligible to be earned. While the Volumetric Key Employees claim that their terminations were for good reason, which would preserve the rights to milestone-based earnout payments under the Volumetric acquisition agreement, the Company vigorously denies this claim. Refer to Note 20 for further details regarding the resignation of the certain Volumetric Key Employees and all related actions occurring thereafter.
Regenerative Medicine Performance-Based Stock Units

The Company previously granted certain performance-based stock units (“PSUs” or the "RegMed Awards") to other employees with vesting terms that were based upon four individually-measured, science-based (i.e., non-financial) milestones to other employees who work on advancements in regenerative medicine related to lungs and tissue organs. The compensation expense associated with each individual milestone attributable to a RegMed Award was required to be recognized over the period commencing on the date that the respective milestone was deemed probable of being met through the anticipated date of achievement. During the fourth quarter of 2024, the Company cancelled all outstanding RegMed awards, which had an immaterial impact on the Company's consolidated financial statements.

Earnout and PSU Compensation Expense

Prior to the year ended December 31, 2023, the Company recognized compensation expense related to (1) one of the Volumetric milestones for which the potential earnout payment due to the sellers would be $65.0 million and (2) one RegMed Award milestone for which the aggregate grant date fair value of the outstanding and unvested awards was $4.5 million as of December 31, 2022, as the related milestone was deemed probable of achievement. During the year ended December 31, 2023, the Company reduced its budgeted funding for the research and development related to the respective Volumetric earnout and RegMed Award milestones, which resulted in the Company concluding that it was no longer probable that these respective milestones would be achieved by the end of the term of the Volumetric earnout arrangement or prior to the expiration of the RegMed Awards. In concluding that the Volumetric and RegMed Award milestone would no longer be achieved, the Company reversed all of the previously recognized compensation expense, one half of which was expected to be settled with Common Stock shares, which reduced selling, general and administrative expense by $18.4 million, and our reported net loss per basic and diluted share of Common Stock by $0.14 for the year ended December 31, 2023. No liability related to the Volumetric earnout was recognized on our consolidated balance sheets as of December 31, 2024 or December 31, 2023.

dp polar Earnout

On October 4, 2022 the Company acquired dp polar. The acquisition agreement included an earnout arrangement for $2.2 million incremental to the acquisition purchase price, which would be settled via the issuance of 250,000 shares of the Company's Common Stock. The issuance and vesting of these shares was contingent upon certain service conditions of a key individual from dp polar through December 31, 2024. Management concluded that this potential obligation for the issuance of 250,000 shares of Common Stock should be accounted for as compensation expense recognized over the individual's service period and, accordingly, the related expense is reflected in the disclosure of stock-based compensation included herein. During April 2024, due to a change in the key individual's employment status, all service conditions of the dp polar earnout were deemed to have been met based on the terms of the initial arrangement. Accordingly, all remaining expense related to these shares was recognized during the year ended December 31, 2024. This arrangement was settled during the year ended December 31, 2025 with the issuance of 250,000 shares of Common Stock.

Stock-Based Compensation Activity and Expense

The following table shows the stock-based compensation expense recognized during the years ended December 31, 2025, 2024, and 2023:

(in thousands)202520242023
Stock-based compensation expense$9,525 $18,457 $23,504 
Tax benefit$— $— $— 

The Company has historically paid annual incentive compensation in shares of Common Stock that vest upon grant. The Company did not accrue and pay any annual incentive compensation related to the years ended December 31, 2025, 2024 or 2023.

The year ended December 31, 2023 also includes the reversal of $8.6 million of expense related to an earnout agreement as part of the Volumetric acquisition from 2021. The years ended December 31, 2024 and 2023 include $1.0 million each of expense related to the earnout agreement from the 2022 acquisition of dp polar.

At December 31, 2025, there was $8.6 million of unrecognized stock-based compensation expense related to all unvested equity awards, which we expect to recognize over a weighted-average period of 2.1 years.
v3.25.4
INCOME TAXES
 12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE 16 - INCOME TAXES

The components of our income (loss) before income taxes for the years ended December 31, 2025, 2024 and 2023 are as follows:
(in thousands)202520242023
Income (loss) before income taxes:
Domestic$13,858 $(160,709)$(239,971)
Foreign35,734 (89,287)(122,341)
Total$49,592 $(249,996)$(362,312)

The components of income tax provision for the years ended December 31, 2025, 2024 and 2023 are as follows:

(in thousands)202520242023
Current:
U.S. federal$— $24 $135 
State99 301 (50)
Foreign14,867 2,820 1,686 
Total$14,966 $3,145 $1,771 
Deferred:
U.S. federal$838 $— $— 
State— — — 
Foreign(933)(952)(2,412)
Total(95)(952)(2,412)
Total income tax provision (benefit)
$14,871 $2,193 $(641)

Upon adoption of ASU 2023-09, Improvements to Income Tax Disclosures, as described in Note 2, Summary of Significant Accounting Policies, cash paid for income taxes (net of refunds) during the year ended December 31, 2025, consisted of the following:
(in thousands)2025
Federal
$799 
State:
Other (a)
492 
Total State
492 
Foreign:
Germany
2,431 
Korea
1,860 
Netherlands
1,723 
China
559 
Mexico
522 
Other (a)
1,247 
Total Foreign
8,342 
Cash paid for income taxes (net of refunds)
$9,633 
(a) The amount of income taxes paid during the year does not meet the 5% disaggregation threshold and is included in Other.

Cash paid for income taxes, net of refunds, during the years ended December 31, 2024 and 2023, was $5.5 million and $3.9 million respectively.
The components of our net deferred income tax assets and net deferred income tax (liabilities) at December 31, 2025 and 2024 as follows:

(in thousands)20252024
Deferred income tax assets:
Intangible assets$11,860 $15,685 
Stock options and restricted stock awards1,666 3,032 
Reserves and allowances4,511 6,879 
Net operating loss carryforwards79,161 59,641 
Tax credit carryforwards32,287 31,326 
Accrued liabilities2,235 2,681 
Deferred revenue1,055 2,176 
Lease tax assets12,248 17,498 
Research expenditures capitalization31,905 44,773 
Other5,607 3,236 
Valuation allowance(170,425)(168,299)
Total deferred income tax assets$12,110 $18,628 
Deferred income tax liabilities:
Intangible assets$1,171 $2,081 
Property and equipment710 2,352 
Lease tax liabilities10,182 14,159 
Other— 49 
Total deferred income tax liabilities$12,063 $18,641 
Net deferred income tax asset (liability)
$47 $(13)

At December 31, 2025, $79.2 million of our deferred income tax assets was attributable to $475.4 million of gross net operating loss carryforwards, which consisted of $111.0 million of loss carryforwards for U.S. federal income tax purposes, $175.1 million of loss carryforwards for U.S. state income tax purposes and $189.3 million of loss carryforwards for foreign income tax purposes.

The net operating loss carryforwards for U.S. federal income tax purposes do not expire. The net operating loss carryforwards for U.S. state income tax purposes began to expire in 2025. In addition, certain net loss carryforwards for foreign income tax purposes begin to expire in 2026 and certain other loss carryforwards for foreign purposes do not expire.

At December 31, 2025, tax credit carryforwards deferred assets of $32.3 million consisted of $22.4 million of research and experimentation credit carryforwards for U.S. federal income tax purposes, $5.9 million of research and experimentation tax credit carryforwards for U.S. state income tax purposes, and $4.0 million of foreign tax credits for U.S. federal income tax purposes. We have recorded a valuation allowance related to the U.S. federal and state tax credits.

During the year ended December 31, 2025, management reevaluated its assertion regarding the indefinite reinvestment of earnings generated by certain foreign subsidiaries. Historically, the Company had asserted that these undistributed foreign earnings would be indefinitely reinvested, and accordingly, no deferred tax liability had been recorded on the associated outside basis differences. As a result of changes in business plans and capital allocation strategies, including updated cash flow projections and anticipated funding needs in the parent jurisdiction, management determined that it can no longer assert indefinite reinvestment for a portion of these foreign earnings. Accordingly, as of December 31, 2025, we recorded the deferred tax liability related to undistributed earnings of foreign subsidiaries of $0.8 million.
Including interest and penalties, the total net decrease of our unrecognized benefits is $2.1 million for the year ended December 31, 2025. The decrease was primarily related to the lapse of statute for certain credits. The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate is $2.6 million. We include interest and penalties in the consolidated financial statements as a component of income tax expense.

Unrecognized Tax Benefits(1)
(in thousands)202520242023
Balance at January 1$(16,413)$(18,604)$(17,150)
Increases related to prior year tax positions(240)(1,170)(99)
Decreases related to prior year tax positions106 4,337 107 
Decreases related to prior year tax positions as a result of lapse of statute3,170 — 271 
Decreases related to settlement— — — 
Increases related to current year tax positions(933)(976)(1,733)
Increases related to acquired tax positions— — — 
Decreases related to acquired tax positions— — — 
Balance at December 31$(14,310)$(16,413)$(18,604)
(1) The unrecognized tax benefit balance as of December 31, 2025, 2024, and 2023 includes $0.5 million, $1.3 million, and $0.3 million of interest and penalty, respectively.

Tax years 2021 through 2024 remain subject to examination by the U.S. Internal Revenue Service. State income tax returns are generally subject to examination for a period of three to four years after filing the respective tax returns. The tax years 2020 through 2024 remain open to examination by the various foreign taxing jurisdictions to which the Company is subject.

The following presents the changes in the balance of our deferred income tax asset valuation allowance:
Year EndedItemBalance at beginning of yearAdditions (reductions) charged to expense
Other(1)
Balance at end of year
2025Deferred income tax asset valuation allowance$168,299 $(1,915)$4,041 $170,425 
2024Deferred income tax asset valuation allowance$125,533 $43,365 $(599)$168,299 
2023Deferred income tax asset valuation allowance$100,694 $23,606 $1,233 $125,533 
(1) The Other portion of changes to our valuation allowance consists primarily of the impact of acquisitions and changes in foreign currency translation rates.

In 2025, we recorded a full valuation allowance for Oqton Belgium and a partial valuation allowance for 3D Systems SA. In 2024, we recorded full valuation allowances for 3DSystems GmbH and Kumovis GmbH. In addition, we released a valuation allowance for Oqton Belgium. In 2023, we recorded full valuation allowances for Wematter and Layerwise. All of which are foreign subsidiaries of the Company. We continue to review results of operations and forecast estimates to determine if it is more likely than not that the deferred tax assets will be realized.
The overall effective tax rate differs from the statutory federal tax rate for the years ended December 31, 2025 as follows:

(in thousands)AmountPercent
Tax provision based on the federal statutory rate$10,414 21.0 %
State and local income taxes(1)
79 0.2 %
Foreign tax effects
Belgium
Foreign income tax rate differential(779)(1.6)%
Changes in valuation allowances6,738 13.6 %
Deferred adjustments(2,289)(4.6)%
Other(588)(1.2)%
Germany
Changes in valuation allowances(1,874)(3.8)%
Other145 0.3 %
Netherlands
Changes in valuation allowances1,623 3.3 %
Other(344)(0.7)%
Switzerland
Changes in valuation allowances1,708 3.4 %
Tax-deductible goodwill(1,985)(4.0)%
Other(409)(0.8)%
Other foreign jurisdictions3,924 7.9 %
Effect of cross-border tax laws
Global intangible low-taxed income inclusion5,980 12.1 %
Subpart F income inclusion725 1.5 %
Tax credits
Research and development tax credits(3,593)(7.2)%
Expired foreign tax credits3,253 6.6 %
Changes in valuation allowances(9,951)(20.1)%
Nontaxable or nondeductible items
Employee share-based payments2,483 5.0 %
Equity method investment(827)(1.7)%
Impairment of investments1,338 2.7 %
Unremitted foreign earnings838 1.7 %
Deferred adjustments559 1.1 %
Payable adjustments(637)(1.3)%
Other791 1.6 %
Changes in unrecognized tax benefits(2,451)(4.9)%
Total
$14,871 30.0 %
(1) In 2025, state taxes in California, New York, New Jersey, New York City, and Michigan made up the majority (greater than 50%) of the tax effect in this category.

The difference between our effective tax rate and the federal statutory rate for 2025 was 9.0 percentage points. The difference in the effective rate is primarily due to the global intangible low-taxed income inclusion ("GLTI").
The overall effective tax rate differs from the statutory federal tax rate for the years ended December 31, 2024, and 2023 are as follows:
% of Pretax (Loss) Income
20242023
Tax provision based on the federal statutory rate21.0 %21.0 %
Increase in valuation allowances(17.3)(6.5)
Change in carryforward attributes— — 
Global intangible low-taxed income inclusion— (0.4)
Non-deductible expenses— — 
Non-deductible earnout expense— 1.0 
Goodwill impairment charge
(8.7)(14.6)
Foreign income tax rate differential0.2 0.5 
Deemed income related to foreign operations(0.6)(0.3)
Tax rate change(0.1)— 
Employee share-based payments(0.3)(0.5)
Other(0.3)(0.7)
Deferred and payable adjustments1.3 (1.3)
Non-deductible penalties— — 
State taxes, net of federal benefit, before valuation allowance1.2 0.7 
Return-to-provision adjustments(0.5)0.2 
Other tax credits2.0 1.1 
Uncertain tax positions and audit settlements1.3 — 
Effective tax rate(0.8)%0.2 %

The difference between our effective tax rate for 2024 and 2023 and the federal statutory rate was 21.8 and 20.8 percentage points, respectively. The difference in the effective rate is primarily due to the net increase in valuation allowances and non-deductible goodwill impairment charges.
v3.25.4
NET INCOME (LOSS) PER SHARE
 12 Months Ended
Dec. 31, 2025
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER SHARE
NOTE 17 - NET INCOME (LOSS) PER SHARE

Basic net income (loss) per share is calculated by dividing net loss attributable to 3D Systems' common stock shareholders by the weighted average number of common shares outstanding during the applicable period. Diluted net income (loss) per share incorporates the additional shares issuable upon the assumed exercise of stock options, the vesting of restricted stock and restricted stock units, and the assumed conversion of debt, except in such case when (1) the inclusion of such shares or potential
shares would be anti-dilutive or (2) when the vesting of restricted stock or restricted stock units is contingent upon one or more performance conditions that have not been met as of the balance sheet date.
Year Ended December 31,
(in thousands, except per share amounts)202520242023
Numerator (basic):
Net income (loss) attributable to 3D Systems Corporation
$29,883 $(255,593)$(362,688)
Redeemable non-controlling interest redemption value in excess of carrying value— 61 (479)
Net income (loss) attributable to common stock shareholders
$29,883 $(255,532)$(363,167)
Numerator (diluted):
Net income (loss) income attributable to 3D Systems' common stock shareholders
$29,883 $(255,532)$(363,167)
Add back: Interest on 2030 Notes2,809 — — 
Net income (loss) income attributable to 3D Systems' common stock shareholders plus assumed conversions
$32,692 $(255,532)$(363,167)
Denominator:
Basic weighted average common shares outstanding(a)
129,159 131,861 129,944 
Effect of Dilutive securities:
Restricted stock and RSUs1,393 — — 
Conversion of 2030 Notes44,962 — — 
Diluted weighted average common shares outstanding175,514 131,861 129,944 
Net income (loss) per share – basic
$0.23 $(1.94)$(2.79)
Net income (loss) per share - diluted
$0.19 $(1.94)$(2.79)

The following table presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share attributable to common stockholders because their effect was considered anti-dilutive for the years ended December 31, 2025, 2024 and 2023, respectively.

Year Ended December 31,
(in thousands)202520242023
Restricted stock, restricted stock units, and PSUs
2,691 5,185 6,182 
Stock options160 160 420 
Total2,851 5,345 6,602 
On November 16, 2021, the Company issued $460.0 million in aggregate principal amount of 0% Convertible Senior Notes due November 15, 2026, as discussed in Note 12. The Notes’ impact to diluted shares is calculated using the if-converted method as prescribed in ASU 2020-06. The Notes will increase the diluted share count when the average share price over a quarterly or annual reporting period is greater than $35.92 per share, the conversion price of the Notes. For the year ended December 31, 2025, 2024 and 2023, the Notes were anti-dilutive on a stand-alone basis because the average share price during these periods did not exceed the conversion price. For the years ended December 31, 2024 and 2023, the Notes were also anti-dilutive because we reported a net loss for each of the respective periods.
The anti-dilution table above excludes shares issued in connection with the settlement of accrued incentive compensation. In the years ended December 31, 2025 and 2024 and 2023 there were no shares related to the payment of accrued incentive compensation.
For the year ended December 31, 2023, the table above excludes an estimate of 138 thousand shares that are contingently issuable under the dp polar earnout agreement, as discussed in Note 15.
Diluted income per common share was computed using the treasury stock method for restricted stock and restricted stock units and the if-converted method for convertible debt.
Share Repurchases
On June 23, 2025, 3D Systems repurchased 8.0 million shares of its outstanding common stock at a price of $1.87 per share, which was equal to the closing price of the common stock on the New York Stock Exchange on June 17, 2025. The share repurchase was executed concurrently with the issuance of the 2030 Notes (refer to Note 12).
The share repurchase was approved by the Company’s Board of Directors in connection with the broader refinancing transaction. It was structured to mitigate potential dilution associated with the issuance of the 2030 Notes and was funded as part of the same transaction that retired a significant portion of the Company’s 2026 Notes at a discount to par. The Company retired its common stock upon repurchase.
v3.25.4
ACCUMULATED OTHER COMPREHENSIVE LOSS
 12 Months Ended
Dec. 31, 2025
Stockholders' Equity Note [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE LOSS
NOTE 18 - ACCUMULATED OTHER COMPREHENSIVE LOSS

The changes in the balances of accumulated other comprehensive loss by component are as follows:

(in thousands)Foreign currency translation adjustmentDefined benefit pension planUnrealized loss on short-term investmentsTotal
Balance at December 31, 2022$(54,194)$700 $(328)$(53,822)
Other comprehensive income (loss)9,630 (354)108 9,384 
Amounts reclassified from accumulated other comprehensive (loss) income a
— (32)220 188 
Balance at December 31, 2023(44,564)314 — (44,250)
Other comprehensive loss
(10,653)(163)— (10,816)
Balance at December 31, 2024(55,217)151 — (55,066)
Other comprehensive income
7,219 20 — 7,239 
Balance at December 31, 2025$(47,998)$171 $— $(47,827)
a.Amount reclassified into Other income, net on the consolidated statements of operations.
The amounts presented in the table above are net of income taxes. Income tax effects of these items are released from accumulated other comprehensive loss contemporaneously with the related gross pretax amount.
v3.25.4
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION
NOTE 19 - SEGMENT INFORMATION

Our chief operating decision maker ("CODM"), who is our President and Chief Executive Officer, is responsible for reviewing segment performance and making decisions regarding resource allocation. Our CODM regularly reviews the results of our business through two reportable segments: Healthcare Solutions and Industrial Solutions, which are based on the industry verticals they serve. For Healthcare Solutions, those industry verticals include dental, medical devices, personalized health services and regenerative medicine. For Industrial Solutions, those industry verticals include aerospace, defense, transportation and general manufacturing.

The CODM evaluates the operating results of each segment based upon gross profit, which is used during the annual budget and forecasting process, as well as on a quarterly basis when reviewing budget-to-actual and period-over-period variances. All internal segment reporting and discussions of results with our CODM are now based on segment gross profit. Prior year segment results have been revised to conform with current year presentation in connection with the changes referenced above.

The CODM does not review disaggregated asset information on the basis of the Company's segments; therefore, such information is not presented.
Revenue, cost of sales and gross profit for each of our reportable segments were as follows:

Year Ended December 31,
(in thousands)202520242023
Revenue:
Healthcare Solutions$179,589 $189,736 $213,216 
Industrial Solutions207,313 250,385 274,853 
Total revenue
386,902 440,121 488,069 
Cost of sales:
Healthcare Solutions
107,783 116,237 128,066 
Industrial Solutions
148,074 159,706 163,582 
Total cost of sales
255,857 275,943 291,648 
Gross profit:
Healthcare Solutions
71,806 73,499 85,150 
Industrial Solutions
59,239 90,679 111,271 
Total gross profit
131,045 164,178 196,421 
Selling, general and administrative(161,331)(210,132)(210,172)
Research and development(65,037)(86,479)(89,466)
Asset impairment charges
(760)(144,967)(302,787)
Foreign exchange gain (loss), net
3,637 2,452 (4,825)
Interest income
3,956 7,302 19,511 
Interest expense
(5,162)(2,564)(3,301)
Gain on disposition139,590 — — 
Other income, net
3,654 20,214 32,307 
Income (loss) before income taxes
$49,592 $(249,996)$(362,312)

Depreciation and amortization included in the measurement of gross profit by segment were as follows:
Year Ended December 31,
(in thousands)202520242023
Depreciation and amortization:
Healthcare Solutions
$5,431 $5,389 $4,593 
Industrial Solutions
$2,378 $2,947 $2,801 

The following table summarizes long-lived assets by geographic region as of December 31, 2025 and 2024:

Year Ended December 31,
(in thousands)20252024
United States
$68,893 $76,829 
Belgium
18,893 19,598 
Other foreign entities
14,501 14,058 
Total$102,287 $110,485 
v3.25.4
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE 20 - COMMITMENTS AND CONTINGENCIES

The Company has certain purchase commitments under agreements with remaining terms in excess of one year, primarily related to printer assemblies, inventory, capital expenditures, and software licenses. As of December 31, 2025, such purchase commitments totaled $15.9 million, with $8.1 million of the purchase obligations expected to come due within the next twelve months.

Indemnification

In the normal course of business, we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant, and we are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.

To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors and officers insurance coverage that may enable us to recover future amounts paid, subject to a deductible and the policy limits. There is no assurance that the policy limits will be sufficient to cover all damages, if any.

Other Commitments

Government Settlement

As previously disclosed, beginning in October 2017, the Company undertook an internal investigation relating to possible violations of U.S. export control laws, including the International Traffic in Arms Regulations administered by the Directorate of Defense Trade Controls of the Department of State ("DTCC") and the Export Administration Regulations administered by the Bureau of Industry and Security of the Department of Commerce ("BIS"). In February 2023, the Company settled these matters with the U.S. Department of Justice ("DOJ"), DTCC and BIS. As a part of these settlement agreements, the Company agreed to pay $15.0 million in civil monetary penalties to these agencies, with an additional $10.0 million suspended penalty amount to be allocated to remedial compliance measures required by DTCC. The penalty amounts subject to payment were broken down as follows: DTCC, $10.0 million (payable in three installments over a three-year period); BIS, $2.8 million; and DOJ, $2.3 million.

During the year ended December 31, 2025, we paid the final installment penalty of $3.0 million in accordance with the DTCC settlement agreement. The original $10.0 million suspended penalty has not been recognized as a liability, as it will be recognized as incurred for remedial compliance measures during the three-year term of the settlement agreement. The application of the Company’s spend on remedial compliance measures as a reduction to the original $10.0 million suspended penalty must be approved by the DTCC, which approval will be sought on an annual basis in accordance with the terms of the settlement agreement. As of December 31, 2025, the approved suspended penalty balance remaining was $5.1 million. In February 2026, DTCC approved the Company’s spend of the remaining suspended penalty balance of $5.1 million, resulting in no further suspended penalty due.

On February 20, 2026, the DTCC notified the Company that it has closed the settlement agreement based upon the Company’s completion of all required terms.

Letter of Credit

On June 2, 2023, we issued $1.2 million of guarantees in the form of a standby letter of credit as security for a long-term real estate lease. The letter of credit has a maturity date of June 2026 and includes automatic one-year extensions, which are not to continue beyond July 1, 2033. As of December 31, 2025, the letter of credit has been reduced to $0.4 million. We have not recorded any liability for this guarantee, as we believe the likelihood of having to perform under the letter of credit is remote. In connection with this transaction, we pledged an equal amount of cash to the issuing bank of this letter of credit. The cash pledged is recorded as restricted cash and included in other assets on our consolidated balance sheets.
Litigation
SEC Investigation
On April 15, 2022, the Company was informed the SEC is conducting a formal investigation of the Company related to, among other things, allegations brought in a securities class action lawsuit against the Company in 2021 that settled in 2024, and the Company received subpoenas from the SEC for the production of documents and information related to its investigation as a follow on to a previous voluntary request for documents. The Company received its most recent subpoena from the SEC on August 20, 2024. The Company substantially completed its production in response to the subpoena on or about the deadline of October 4, 2024. The SEC took testimony from the Company’s former Chief Accounting Officer in January 2025, and from the Company’s Chief Financial Officer in late March 2025. The Company intends to continue to cooperate with the SEC.
Termination of Volumetric Milestones Related to Potential Earnout Payments
Following the acquisition of Volumetric in 2021, the Company could have been required to pay up to $355.0 million of acquisition-related earnout payments to the former owners of Volumetric if the Company was to achieve seven non-financial, science-based milestones prior to either December 31, 2030 or December 31, 2035. Due to the loss of funding from the Company's key strategic partner for kidney and liver research and development efforts, the Company notified the former owners of Volumetric on February 24, 2024 that it was terminating the four milestones that related to those kidney and liver research and development efforts, as achievement was no longer financially viable. As a result of the termination of the four milestones, the Company's maximum liability for acquisition-related earnout payments was reduced to $175.0 million, which would have been payable if each of the three remaining non-financial, science-based milestones was achieved within the timeframes set forth in the Volumetric acquisition agreement.
On March 29, 2024, the former owners of Volumetric notified the Company that they were initiating dispute resolution under the provisions of the acquisition agreement in an effort to recover the $355.0 million. The parties did not reach a resolution during the 30-day negotiation period following this notice and entered into non-binding mediation in accordance with the terms of the acquisition agreement.
On April 29, 2024, two key employees from Volumetric ("Volumetric Key Employees"), who were required to be employed at the time of achievement of each non-financial, science-based milestone outlined in the Volumetric acquisition agreement for each related acquisition earnout payment to become payable, resigned from their positions with the Company. As a result of the resignation of the Volumetric Key Employees, all parties to which the remaining three milestone-based earnout payments totaling $175.0 million were potentially payable were notified that such amount was no longer eligible to be earned. While the Volumetric Key Employees claim that their terminations were for good reason, which would preserve the rights to milestone-based earnout payments under the Volumetric acquisition agreement, the Company vigorously denies this claim. On August 21, 2024, the Company proposed a settlement of $1.8 million with the former Volumetric shareholders and Volumetric Key Employees during mediation and this amount is recorded within Accrued and other liabilities on our consolidated balance sheets as of December 31, 2025 and 2024. The former Volumetric shareholders have not responded to the settlement offer. On December 13, 2024, the Company received a Notice of Claim for Indemnification from VBI Stockholders’ Representative, LLC, which claims to be the successor Stockholders’ Representative under the acquisition agreement. The Notice repeated the former Volumetric shareholders’ and Volumetric Key Employees' claims of breach. On January 10, 2025, the Company served a Notice of Objection which denied all liability. The delivery of this Notice of Objection triggered a 45-day negotiation period under the terms of the acquisition agreement. As of the date of this filing, there have been no further developments regarding this matter.
Intrepid Automation

On May 19, 2021, 3D Systems, Inc. initiated a lawsuit in the Superior Court of the State of California for the County of San Diego against five former employees and Intrepid Automation, Inc. (collectively, the "Intrepid Parties") alleging theft of trade secrets, unfair competition, breach of contract, and related claims ("2021 Lawsuit"). In June 2021, this lawsuit was removed to the United States District Court for the Southern District of California. In September 2022, the Intrepid Parties filed counterclaims against 3D Systems, Inc. In September 2022, the Company filed a motion to dismiss these counterclaims; this motion was granted in part in May 2023. The Intrepid Parties filed amended counterclaims in May 2023 alleging theft of trade secrets, fraudulent inducement, breach of contract, unfair competition, and related claims; this amended complaint sought damages in excess of $20 million as well as injunctive relief. These counterclaims were partially dismissed in March 2024 in response to a second motion to dismiss filed by the Company. The parties filed motions for summary judgment in April and May 2024. In March 2025, the Court granted the Intrepid Parties’ motion, dismissing the Company’s claims against the Intrepid Parties, but denied the Company’s motion for summary judgment with respect to the counterclaims brought by the Intrepid Parties in the 2021 Lawsuit. On April 17, 2025, the Company filed motions asking the Court to reconsider its dismissal of the Company's claims or granting a partial final judgment so that the Company may appeal the dismissal. To date, the Court has not ruled on those motions.
On December 4, 2024, Intrepid Automation, Inc. ("Intrepid") filed a lawsuit in the United States District Court for the Southern District of California against 3D Systems Corporation and 3D Systems, Inc. alleging infringement of U.S. patents 11,014,301 and 11,338,511 ("2024 Lawsuit"); this complaint seeks unspecified damages and injunctive relief. In July 2025, the Company filed inter partes review ("IPR") petitions against the asserted patents, and on December 11, 2025, the U.S. Patent and Trademark Office granted review of the IPR petitions. On December 18, 2025, the Court granted a stay of the 2024 lawsuit pending a final decision on the IPR petitions.
The Company intends to defend itself vigorously against the 2024 Lawsuit and the counterclaims in the 2021 Lawsuit.

Securities Class Action

The Company and certain of its executive offers were named as defendants in a putative securities class action filed on June 13, 2025 in the U.S. District Court for the District of Delaware. The action is styled Marcel F.M. Herbermann v. 3D Systems Corporation, et al., No. 1:25-cv-00734-GBW (D. Del.) (the "Securities Class Action"). The complaint in the Securities Class Action alleges defendants violated the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions, and that the executive officers named as defendants are control persons under Section 20(a) of the Exchange Act. It was filed on behalf of stockholders who purchased the Company’s common stock from August 13, 2024 and May 12, 2025, and seeks monetary damages on behalf of the purported class. Within fourteen days of the entry of an Order appointing Lead Plaintiff and Lead Counsel, the Parties will submit a proposed scheduling Order for the filing of an amended complaint and Defendants’ responses thereto. The Company intends to defend itself and its executive officers vigorously.

Derivative Actions

The Company was named as a nominal defendant and certain of its officers and directors were named as defendants in derivative lawsuits pending in the U.S. District Court for the District of South Carolina. The action styled Scanlon v. Graves, et al., No. 0:25-cv-07627-MGL (D.S.C.) (the "Scanlon Action") was filed July 17, 2025, and asserts claims for violations of Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder, breach of fiduciary duties, and unjust enrichment. The action styled Milligan v. Graves, et al., No. 0:25-cv-11177-MGL (D.S.C.) (the "Milligan Action"), was filed August 18, 2025, and asserts claims for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, breach of fiduciary duties, aiding and abetting breach of fiduciary duty, unjust enrichment, waste of corporate assets, and for contribution under Section 10(b) and 21D of the Securities Exchange Act of 1934. The action styled Stoopler v. Graves, et al., No. 0:25-cv-12637-MGL (D.S.C.) (the "Stoopler Action"), was filed on September 20, 2025, and asserts claims for breach of fiduciary duties, unjust enrichment, and contribution and indemnification under Sections 10(b) and 21D of the Exchange Act. The Milligan Action, Scanlon Action, and Stoopler Action were consolidated on October 23, 2025 (the "Consolidated District of South Carolina Derivative Action"). On November 17, 2025, the Consolidated District of South Carolina Derivative Action was stayed through the earlier of the dismissal of the Securities Class Action, with prejudice, and the exhaustion of all appeals related thereto, or the close of discovery in the Securities Class Action.

The Company was also named as a nominal defendant and certain of its officers and directors were named as defendants in derivative lawsuits pending in the South Carolina Court of Common Pleas for the 16th Circuit, York County. The action styled Fernicola v. Graves, et al., No. 2025CP4602544 (S.C.), Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the "Fernicola Action") was filed June 27, 2025, and asserts claims for breach of fiduciary duties, gross mismanagement, waste of corporate assets, and unjust enrichment. The action styled Geza Bohus v. Graves, et al., No. 2025CP4603762 (S.C.), Ct. of Common Pleas for the 16th Judicial Cir., Cty. of York) (the "Bohus Action") was filed on September 26, 2025, and asserts claims for breach of fiduciary duty and unjust enrichment. On November 25, 2025, the Fernicola Action and the Bohus Action were consolidated (the "Consolidated York County Derivative Action"). On December 15, 2025, the Consolidated York County Derivative Action was stayed unless and until either (1) the Securities Class Action is dismissed, with prejudice, and all appeals related thereto have been exhausted; or (2) the motion to dismiss the Securities Class Action is denied in full or in part.
The Company was also named as a nominal defendant and certain of its officers and directors were named as defendants in derivative lawsuits pending in the U.S. District Court for the District of Delaware. The action styled Ataii v. Graves, et al., No. 1:25-cv-01087-GBW (D. Del.) (the "Ataii Action") was filed on August 29, 2025 and asserts claims for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder, breach of fiduciary duties, unjust enrichment. The action styled Carter v. Graves, et al., No. 1:25-cv-01103-GBW (D. Del.) (the "Carter Action"), was filed on September 3, 2025, and asserts claims for breach of fiduciary duty, gross mismanagement, waste of corporate assets, unjust enrichment, and violation of Section 14(a) of the Exchange Act. The action styled Michaels v. Graves, et al., No. 1:25-cv-01176-GBW (D. Del.) (the "Michaels Action") was filed on September 22, 2025, and asserts claims for violations of Section 14(a) of the Exchange Act, violations of Section 20(a) of the Exchange Act, breach of fiduciary duties, and unjust enrichment. On October 30, 2025, the Ataii Action, the Carter Action, and the Michaels Action were consolidated (the "Consolidated District of Delaware Derivative Action.") On November 21, 2025, the Consolidated District of Delaware Derivative Action was stayed through the earlier of the dismissal of the Securities Class Action with prejudice, and the exhaustion of all appeals related thereto, or the close of discovery in the Securities Class Action. The Company intends to defend itself as well as its executive officers and directors vigorously against the derivative actions.
Other
We are involved in various other legal matters incidental to our business. Although we cannot predict the results of the litigation with certainty, we believe that the disposition of all of these various other legal matters will not have a material adverse effect, individually or in the aggregate, on our consolidated results of operations, consolidated cash flows or consolidated financial position.
v3.25.4
FAIR VALUE MEASUREMENTS
 12 Months Ended
Dec. 31, 2025
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE 21 - FAIR VALUE MEASUREMENTS

Fair value is the exchange price to sell an asset or transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. Fair value measurements use market data or assumptions market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs may be readily observable, corroborated by market data, or generally unobservable. Valuation techniques maximize the use of observable inputs and minimize use of unobservable inputs. The accounting guidance for fair value measurements and disclosures establishes a three-level fair value hierarchy:

•Level 1 - Inputs are based on quoted prices in active markets for identical assets and liabilities.
•Level 2 - Inputs are based on observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
•Level 3 - One or more inputs are unobservable and significant.

Financial and nonfinancial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Recurring Fair Value Measurements
The following table summarizes financial assets and financial liabilities that are measured and recorded in the consolidated financial statements at fair value on a recurring basis:
(in thousands)
Fair Value Measurement Using (a)
December 31, 2025Total Fair ValueLevel 1Level 2Level 3
Money market funds$32,760 $32,760 $— $— 
December 31, 2024
Money market funds$98,212 $98,212 $— $— 
(a) There were no transfers among the levels within the fair value hierarchy during the year ended December 31, 2025 or the year ended December 31, 2024.
Cash equivalents, including money market funds, are valued utilizing the market approach for measuring the fair value of financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value as of December 31, 2025 and December 31, 2024 because of the relatively short duration of these instruments.
The following table summarizes the carrying amount and fair value of our financial instruments:
December 31, 2025December 31, 2024
(in thousands)Carrying AmountFair ValueCarrying AmountFair Value
0% Convertible senior notes due 2026
$3,944 $3,593 $211,995 $189,409 
5.875% Convertible senior secured notes due 2030
$86,394 $117,982 $— $— 
The estimated fair value of the 2026 Notes and the 2030 Notes was determined using quoted market price in a market with limited activity, and is therefore classified as Level 2 in the fair value hierarchy.

Assets Measured at Fair Value on a Nonrecurring Basis
As discussed in Note 8, during the second quarter of 2025, management identified a triggering event for the Healthcare reporting unit and performed an interim goodwill impairment assessment. Based on the results of the quantitative test, no impairment was identified, as the estimated fair value of the reporting unit exceeded its carrying value. The fair value of the reporting unit was determined using a combination of income and market approaches. The income approach was based on discounted cash flow projections, while the market approach utilized information from comparable companies. Significant assumptions included projected revenue growth rates and a discount rate of 26.2%, derived from the Company’s weighted average cost of capital, reflecting market, industry, and risk factors. We also tested our goodwill for impairment as of our annual impairment testing date, November 1, 2025, and no impairment was identified. There were no material changes to the significant assumption between the interim goodwill impairment assessment and the annual impairment test. These assessments represent a Level 3 measurement due to the use of unobservable inputs and significant management judgment.
During the year ended December 31, 2024, the Company recorded asset impairment charges related to property and equipment, ROU assets, intangible assets and goodwill. For the impairment test related to property and equipment, right of use lease assets and intangible assets, the Company estimated the asset group’s fair value using projected discounted cash flows as well as a market approach based on revenue multiples. To allocate the impairment charge, the Company estimated the fair values of the intangible assets and right-of-use assets included in the asset group using the income approach and estimated the fair value of the property and equipment included in the asset group using the cost approach. The estimation of the fair values of all classes of long-lived assets to which the impairment charge has been allocated required the application of Level 3 valuation inputs. The related goodwill impairment test estimated the fair value of the reporting unit using Level 3 valuation inputs consistent with the 2025 interim test described above.
During the year ended December 31, 2023, the Company recorded asset impairment charges related to goodwill. The impairment test estimated the fair value of the reporting unit using Level 3 valuation inputs consistent with the 2025 interim test and 2024 annual impairment tests described above. Refer to Notes 6, 7, 8 and 10 for additional details regarding the impairment tests and charges recognized during the years ended December 31, 2025, 2024 and 2023.

These fair value estimates are based on information available to management as of the valuation date. Although we are not aware of any factors that would significantly affect these fair value estimates, such amounts have not been comprehensively revalued for purposes of these financial statements since those dates, and current estimates of fair value may differ significantly from the amounts presented.
v3.25.4
RESTRUCTURING AND EXIT ACTIVITIES COSTS
 12 Months Ended
Dec. 31, 2025
Restructuring and Related Activities [Abstract]  
RESTRUCTURING AND EXIT ACTIVITIES COSTS
NOTE 22 - RESTRUCTURING AND EXIT ACTIVITIES COSTS

2025 Restructuring Plan

In 2025, in response to continuing macroeconomic challenges impacting the Company’s financial performance, the Company implemented a series of cost savings and restructuring initiatives (the "2025 Restructuring Plan") as part of its ongoing multi-faceted transformation strategy. In March 2025, the Company authorized and began executing the next phase of its cost savings and restructuring initiative which includes initiatives to deliver sustainable growth and profitability, enabled by a streamlining of both infrastructure and business processes, while consistently investing in core research and development activities to support long-term growth opportunities. In May 2025, the Company announced and began executing an incremental cost reduction initiative focused on labor force reductions in response to continued uncertainty in the economy and our industry and the related potential negative impact on our financial performance.

We incurred $8.5 million in severance and termination benefit costs related to headcount reductions during the year ended December 31, 2025. These costs were primarily cash charges and were generally recognized when probable and estimable
consistent with the Company’s past practices or statutory law. The Company does not expect to incur significant additional restructuring charges in 2026 related to the 2025 Restructuring Plan.

2023 Restructuring Plan
In 2023, the Company initiated a restructuring plan aimed at improving operational efficiency and driving long-term value creation (the "2023 Restructuring Plan"). Key initiatives included in-sourcing certain European metal printer platforms to the Company’s Riom, France facility, co-locating engineering and manufacturing functions to accelerate the development-to-production cycle, reducing headcount across all areas of the organization, and exiting select leased facilities to streamline the Company’s geographic footprint. Substantially all restructuring activities related to the 2023 Restructuring Plan were completed as of the year ended December 31, 2024.
During the last quarter of our fiscal year ended December 31, 2023, as part of its efforts to rationalize its geographic footprint, the Company began identifying and evaluating opportunities to exit leased facilities, whether by early termination of a lease, non-renewal of a lease, or ceasing use with an intent to sublease a facility. Throughout the year ended December 31, 2024, the Company (1) partially or fully exited 18 leased facilities that were identified as part of the Company's plan and (2) commenced active marketing efforts to sublease the available space in facilities that were either partially or fully exited, but have a continuing lease. The Company exited one additional lease in the first quarter of 2025, and has now exited all facilities identified as part of its facilities rationalization plan under the 2023 Restructuring Plan.
2023 Restructuring Plan Costs, Cash Settlements and Recognized Liabilities

We incurred $8.2 million in severance and termination benefit costs related to headcount reductions between inception of our 2023 Restructuring Plan and the completion of headcount reductions under the plan during the year ended December 31, 2024. These costs were generally recognized when they became probable and estimable consistent with the Company’s past practices or statutory law. During the three months ended June 30, 2024, we recorded a reduction of approximately $1.0 million from our severance accrual included in cost of sales as a result of the decision to continue to operate certain facilities. This reduction in severance costs was partially offset by incremental severance charges recorded in cost of sales during the year ended December 31, 2024.

We may incur non-cash impairment charges as a result of exiting leased facilities for which we are unable to terminate the existing lease, if the carrying values of the related ROU asset balances and other related asset balances (e.g., leasehold improvements) will not be fully recoverable through our efforts to sublease an exited facility. However, since inception of our 2023 Restructuring Plan, with the exception of certain amounts paid to terminate certain leases early, our consolidated financial statements have not reflected material transactions or charges resulting from the decisions to cease the use of facilities for our own operations because the facilities for which we have continuing leases (and any related assets, as applicable) generally have not yet qualified to be measured for impairment separate from the asset group to which they have historically belonged, which typically occurs when we have entered into a sublease. During the year ended December 31, 2024, we paid $0.6 million to terminate certain leases related to facilities identified as part of our facilities exit plan. In addition, during 2023, the Company recognized $0.6 million of impairment charges related to certain fixed assets that were retired in connection with the Company’s restructuring activities. There were no impairment charges recorded related to fixed assets during the year ended December 31, 2024 that relate specifically to decisions to exit facilities.
The restructuring and other related charges were primarily cash charges related to severance. These charges are reflected in the following captions in the accompanying Condensed Consolidated Statements of Operations as follows:

Year Ended
(in thousands)December 31, 2025December 31, 2024December 31, 2023
Total cost of sales (a)
$1,034 $(785)$1,401 
Selling, general and administrative
5,855 370 5,598 
Research and development
1,561 385 1,243 
Total
$8,450 $(30)$8,242 
(a) Only restructuring costs recorded to cost of sales have been included in our reported segment results, as gross profit is our measure of segment profitability. For 2025, $0.5 million of severance and termination costs recorded to cost of sales are included in Healthcare and $0.5 million are included in Industrial. All severance and termination costs recorded to costs of sales for 2024 and 2023 are included in our Healthcare segment and, accordingly, are reflected in the Healthcare segment's reported gross profit. There were no facility termination costs or impairment costs included in the amounts reported for consolidated or segment cost of sales. See Note 19 for the reported gross profit for each of our reportable segments.
The activity in the restructuring accrual related to the 2025 and 2023 Restructuring Plans was as follows:
(in thousands)December 31, 2025December 31, 2024
Balance at beginning of period
$487 $3,933 
Costs incurred and other adjustments to accrued liability during the period
8,450 (30)
Amounts settled with cash
(7,707)(3,416)
Balance at the end of period
$1,230 $487 
v3.25.4
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.4
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
v3.25.4
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Internal Cybersecurity Team

Our internal Cybersecurity Team, led by the CISO, is responsible for the implementation, monitoring, and maintenance of our cybersecurity program, including the Company’s data protection practices. Reporting to our CISO are a number of experienced and trained information security professionals who have previous work experience and educational backgrounds in information technology and security, and who also have industry recognized cybersecurity certifications. In addition to our internal cybersecurity capabilities, we also utilize a number of third-party experts to assist with assessing, identifying, and managing our cybersecurity risks.

Risk Management and Strategy

Assessing, identifying and managing cybersecurity risks are integral to our risk management activities. Our cybersecurity program leverages people, processes, and technology to identify and respond to cybersecurity threats in a timely manner. We maintain continuous monitoring of our network and also assess, identify, and manage risks from cybersecurity threats through various mechanisms, which may include incident response planning, risk assessments, control gap analyses, threat modeling, penetration tests, and vulnerability scanning.
Our cybersecurity assessment analyses have identified and prioritized steps to further enhance our cybersecurity practices. We maintain cyber insurance, regularly conduct company-wide cybersecurity awareness training, and have a dedicated team of Company personnel to address cybersecurity threats. We intend to implement additional security measures and processes to enhance our detection and response to cybersecurity incidents as appropriate.

We have adopted a Cybersecurity Incident Response Plan (the "IRP") to provide a standardized framework for responding to and escalating security incidents. The IRP sets out a coordinated approach to investigating, containing, documenting, and mitigating incidents, including reporting findings and keeping senior management and other key stakeholders informed and involved as needed.

Material Cybersecurity Risks, Threats & Incidents

To date, risks from cybersecurity threats, including as a result of previous cybersecurity incidents, have not materially affected us, including our business strategy, results of operations, or financial condition, but we face certain ongoing risks from cybersecurity threats that, if realized, are reasonably likely to have such an affect. Additional information on cybersecurity risks we face can be found in Part I, Item 1A "Risk Factors" of this Report under the heading "Our business could be adversely impacted in the event of a failure of our information technology infrastructure or a successful cybersecurity incident," which should be read in conjunction with the foregoing information.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block] Assessing, identifying and managing cybersecurity risks are integral to our risk management activities. Our cybersecurity program leverages people, processes, and technology to identify and respond to cybersecurity threats in a timely manner. We maintain continuous monitoring of our network and also assess, identify, and manage risks from cybersecurity threats through various mechanisms, which may include incident response planning, risk assessments, control gap analyses, threat modeling, penetration tests, and vulnerability scanning.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block]
Governance

As part of the Company’s risk management activities, we prioritize the identification and management of risks which includes risks related to cybersecurity.

Board of Directors

Our Board has delegated to the Audit Committee the oversight of cybersecurity risks, including overseeing the actions management has taken to monitor or mitigate such exposure. The Audit Committee reviews the measures implemented by the Company to identify and mitigate data protection and cybersecurity risks on a periodic basis. As part of such reviews, the Audit Committee receives reports and presentations from members of the team responsible for overseeing the Company’s cybersecurity program, including the Chief Information Officer (CIO), which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, and technological trends. The Audit Committee and such members of our management team also report to the Board at least annually on cybersecurity matters. We have defined guidelines by which certain cybersecurity incidents are escalated within the Company and, where appropriate, reported promptly to the Audit Committee and the Board, as well as ongoing updates regarding any such incident.

Management
At the management level, our CIO and Chief Information Security Officer (CISO), have extensive cybersecurity knowledge and skills gained from work experience at the Company and other publicly traded companies. Our CIO has worked in the IT industry for numerous private and publicly traded companies for more than 35 years. During this time, he has led both the IT and Cybersecurity efforts. He holds both a bachelor’s degree and an MBA, and has obtained numerous certifications throughout his career, including a Project Management Professional (PMP) and Cisco certified Network Professional (CCNP). Our Head of Cybersecurity has worked in the Cybersecurity industry for more than 22 years. He has also worked in leadership roles at numerous private and public companies, and holds a bachelor’s degree and a Master’s Degree in Cybersecurity. He has obtained numerous certifications, including a Certified Ethical Hacker (CEH), Computer Hacking Forensic Investigator (CHFI), and is a Certified Chief Information Security Officer (C|CISO). He is a founding member of the Carolina CISO leadership network. Together, they have also had extensive training and hands-on experience with quality management, process efficiency, auditing, and security incident management and response. They lead the team responsible for implementing, monitoring, and maintaining cybersecurity, including data protection practices across our business. The CISO receives reports on cybersecurity threats from both our internal and external partners on a regular basis. The Chief Administrative Officer and Chief Executive Officer receive regular reports from the CISO and the CIO on the cyber program and measures implemented by the Company to identify and mitigate cybersecurity risks. Our CIO and CISO work closely with our Company’s Legal and Compliance teams to oversee compliance with legal, regulatory, and contractual security requirements, and also attend meetings with the Audit Committee and the Board that include cybersecurity updates.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Our Board has delegated to the Audit Committee the oversight of cybersecurity risks, including overseeing the actions management has taken to monitor or mitigate such exposure.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] The Audit Committee and such members of our management team also report to the Board at least annually on cybersecurity matters. We have defined guidelines by which certain cybersecurity incidents are escalated within the Company and, where appropriate, reported promptly to the Audit Committee and the Board, as well as ongoing updates regarding any such incident.
Cybersecurity Risk Role of Management [Text Block] At the management level, our CIO and Chief Information Security Officer (CISO), have extensive cybersecurity knowledge and skills gained from work experience at the Company and other publicly traded companies. Our CIO has worked in the IT industry for numerous private and publicly traded companies for more than 35 years. During this time, he has led both the IT and Cybersecurity efforts. He holds both a bachelor’s degree and an MBA, and has obtained numerous certifications throughout his career, including a Project Management Professional (PMP) and Cisco certified Network Professional (CCNP). Our Head of Cybersecurity has worked in the Cybersecurity industry for more than 22 years. He has also worked in leadership roles at numerous private and public companies, and holds a bachelor’s degree and a Master’s Degree in Cybersecurity. He has obtained numerous certifications, including a Certified Ethical Hacker (CEH), Computer Hacking Forensic Investigator (CHFI), and is a Certified Chief Information Security Officer (C|CISO). He is a founding member of the Carolina CISO leadership network. Together, they have also had extensive training and hands-on experience with quality management, process efficiency, auditing, and security incident management and response. They lead the team responsible for implementing, monitoring, and maintaining cybersecurity, including data protection practices across our business. The CISO receives reports on cybersecurity threats from both our internal and external partners on a regular basis. The Chief Administrative Officer and Chief Executive Officer receive regular reports from the CISO and the CIO on the cyber program and measures implemented by the Company to identify and mitigate cybersecurity risks. Our CIO and CISO work closely with our Company’s Legal and Compliance teams to oversee compliance with legal, regulatory, and contractual security requirements, and also attend meetings with the Audit Committee and the Board that include cybersecurity updates.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] At the management level, our CIO and Chief Information Security Officer (CISO), have extensive cybersecurity knowledge and skills gained from work experience at the Company and other publicly traded companies. Our CIO has worked in the IT industry for numerous private and publicly traded companies for more than 35 years. During this time, he has led both the IT and Cybersecurity efforts. He holds both a bachelor’s degree and an MBA, and has obtained numerous certifications throughout his career, including a Project Management Professional (PMP) and Cisco certified Network Professional (CCNP). Our Head of Cybersecurity has worked in the Cybersecurity industry for more than 22 years. He has also worked in leadership roles at numerous private and public companies, and holds a bachelor’s degree and a Master’s Degree in Cybersecurity. He has obtained numerous certifications, including a Certified Ethical Hacker (CEH), Computer Hacking Forensic Investigator (CHFI), and is a Certified Chief Information Security Officer (C|CISO). He is a founding member of the Carolina CISO leadership network. Together, they have also had extensive training and hands-on experience with quality management, process efficiency, auditing, and security incident management and response. They lead the team responsible for implementing, monitoring, and maintaining cybersecurity, including data protection practices across our business. The CISO receives reports on cybersecurity threats from both our internal and external partners on a regular basis. The Chief Administrative Officer and Chief Executive Officer receive regular reports from the CISO and the CIO on the cyber program and measures implemented by the Company to identify and mitigate cybersecurity risks. Our CIO and CISO work closely with our Company’s Legal and Compliance teams to oversee compliance with legal, regulatory, and contractual security requirements, and also attend meetings with the Audit Committee and the Board that include cybersecurity updates.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our CIO has worked in the IT industry for numerous private and publicly traded companies for more than 35 years. During this time, he has led both the IT and Cybersecurity efforts. He holds both a bachelor’s degree and an MBA, and has obtained numerous certifications throughout his career, including a Project Management Professional (PMP) and Cisco certified Network Professional (CCNP). Our Head of Cybersecurity has worked in the Cybersecurity industry for more than 22 years. He has also worked in leadership roles at numerous private and public companies, and holds a bachelor’s degree and a Master’s Degree in Cybersecurity. He has obtained numerous certifications, including a Certified Ethical Hacker (CEH), Computer Hacking Forensic Investigator (CHFI), and is a Certified Chief Information Security Officer (C|CISO). He is a founding member of the Carolina CISO leadership network. Together, they have also had extensive training and hands-on experience with quality management, process efficiency, auditing, and security incident management and response.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Our CIO and CISO work closely with our Company’s Legal and Compliance teams to oversee compliance with legal, regulatory, and contractual security requirements, and also attend meetings with the Audit Committee and the Board that include cybersecurity updates.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.4
SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The consolidated financial statements include the accounts of the Company, including all majority and wholly-owned subsidiaries and entities in which a controlling interest is maintained. Intercompany accounts and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current year presentation.
A non-controlling interest in a subsidiary reflects an ownership interest in a majority-owned subsidiary that is not attributable to the Company. For the periods presented, the Company's financial statements include a redeemable non-controlling interest ("RNCI"), which has been reported in temporary equity in the consolidated balance sheets. The net loss attributable to the RNCI is presented as an adjustment to the Company's consolidated net income (loss) to arrive at net income (loss) attributable to 3D Systems Corporation in the consolidated statements of operations and consolidated statements of comprehensive loss. Furthermore, adjustments to record the RNCI at its redemption value are recorded to additional paid-in capital, and the excess redemption value is recognized as an increase or decrease to net income (loss) attributable to 3D Systems’ shareholders for purposes of reporting income (loss) per share. See Note 14 for a summary of the activity related to the reported RNCI balance during the periods presented.
Our annual reporting period is the calendar year.
Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect (1) the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the balance sheet dates and (2) the reported amounts of revenues and expenses during the reporting periods. We base our estimates on historical experience, currently available information and various other assumptions that we believe are reasonable under the circumstances. Actual results could differ from these estimates.
Revenue Recognition
Revenue Recognition
We account for revenue in accordance with Accounting Standards Codification ("ASC") Topic 606, "Revenue from Contracts with Customers," ("ASC 606"). Collaborative arrangement contracts, for which the collaboration partner meets the definition of a customer, are recorded in accordance with ASC 606; otherwise, the collaborative arrangements are recorded in accordance with ASC Topic 808, "Collaborative Arrangements." See Note 4 for further discussion.
Revenue recognition for arrangements within the scope of ASC 606 includes the following five steps: (i) identifying the contract(s) with a customer; (ii) identifying the performance obligations in the contract; (iii) determining the transaction price; (iv) allocating the transaction price to the performance obligations in the contract; and (v) recognizing revenue when (or as) a performance obligation is satisfied.
Revenue is recognized when control of the promised products or services is transferred to customers and in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and, accordingly, are accounted for as separate performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based upon its relative stand-alone selling price ("SSP"). Revenue is recognized net of allowances for returns and any taxes collected from customers that are subsequently remitted to governmental authorities.

A majority of our revenue is recognized at the point in time when products are shipped to or services are performed for customers. However, the Company also enters into service contracts and collaboration agreements with customers, for which the Company is typically required to recognize revenue over time.

Hardware and Materials

Revenue from hardware and material sales is recognized when control has been transferred to the customer, which generally occurs when the goods have been shipped or delivered to the customer, risk of loss has transferred to the customer, and the Company has a present right to payment. In limited circumstances, when printer or other hardware sales include substantive customer acceptance provisions, revenue is recognized either when customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the customer acceptance provisions have been satisfied.

Printers and certain other products include an assurance warranty for periods up to one year to ensure the product works as expected. These assurance warranties are not a separate performance obligation. For these initial product warranties, estimated costs are accrued at the time of the sale of the product. These cost estimates are established using historical information regarding the nature, frequency and average cost of claims for each type of printer or other product, as well as assumptions about future activity and events. Revisions to expense accruals are made as necessary based on changes in these historical and future factors.

Software

The Company also markets and sells software tools that enable our customers to capture and customize content using our printers, design optimization and simulation software, and reverse engineering and inspection software. Our software does not require significant modification or customization, and the license provides the customer with a right to use the software as it exists when made available. Revenue from these software licenses is recognized either upon delivery of the product or of a key code which allows the customer to download the software. Customers may purchase post-sale support. Generally, the first year of support is included, but subsequent years are optional. Post-sale support, including the first year of support and the optional, subsequent years, are considered a separate obligation from the software and revenue is deferred at the time of sale and subsequently recognized ratably over future periods.

Services

The Company offers training, installation and non-contract maintenance services for our products. Additionally, the Company offers maintenance contracts customers can purchase at their option. For maintenance contracts, revenue is deferred at the time of sale based on the stand-alone selling prices of these services. Deferred revenue is recognized ratably over the term of the maintenance period on a straight-line basis and costs are expensed as incurred. Revenue from training, installation and non-contract maintenance services is recognized at the time of performance of the service. The Company also sells software as a service, whereby the customer has the right to access the software. Revenue is recognized ratably over the related subscription period, as our performance obligation to provide access to the software is progressively fulfilled over the stated term of the contract. Healthcare Solutions service sales are included within services revenue, and revenue is recognized upon shipment or delivery of the parts or performance of the service, based on the terms of the arrangement.
Collaboration Agreements

The nature of the activities to be performed and the consideration exchanged under collaboration arrangements varies on a contract-by-contract basis. We evaluate collaboration arrangements to determine whether they meet the definition of a customer relationship for which revenue should be recorded and recognized. These contracts may contain multiple performance obligations and may contain fees for licensing, research and development services, contingent milestone payments upon the achievement of contractual developmental criteria and/or royalty fees based on the licensees’ product revenue. We determine the revenue to be recognized under these arrangements based upon an evaluation of the distinct performance obligations; the identification and evaluation of material rights; the estimation of the amount of variable consideration to be included in transaction price, as well as the timing for inclusion of such variable consideration; and the amount of transaction price assigned to and the pattern of transfer of control for each distinct performance obligation. This typically results in the recognition of revenue over time using a cost-to-cost percentage of completion model to measure the progress of the transfer of control.
We review and update our estimate of variable consideration on a regular basis. Any adjustments to estimated revenue are recognized under the cumulative catch-up method.
Currently, all of our collaboration arrangement revenue and related costs relate to R&D being performed under a single regenerative medicine contract.
Terms of Sale

Shipping and handling activities are treated as fulfillment costs rather than as an additional promised service. The Company accrues the costs of shipping and handling when the related revenue is recognized. The Company’s incurred costs associated with shipping and handling are included in product cost of sales. Creditworthiness is determined, and credit is extended, based upon an evaluation of each customer’s financial condition. New customers are generally required to complete a credit application and provide references and bank information to facilitate an analysis of creditworthiness. The Company’s terms of sale generally provide payment terms that are customary in the countries where the Company transacts business. To reduce credit risk in connection with certain sales, the Company may, depending upon the circumstances, require significant deposits or payment in full prior to shipment. For maintenance services, the Company either bills customers on a time-and-materials basis or sell maintenance contracts that provide for payment in advance on either an annual or other periodic basis.

Significant Judgments

Allocation of Transaction Price

The Company’s contracts with customers often include promises to transfer multiple products and services to a customer. For such arrangements, the Company allocates revenue to each performance obligation based on its relative SSP. Judgment is required to determine the SSP for each distinct performance obligation in a contract. The Company estimates SSP using historical transaction data of observable prices. The Company uses a range of amounts to estimate SSP when the Company sells each of the products and services separately and needs to determine whether there is a discount to be allocated based on the relative SSP of the various products and services. In other instances where SSP is not directly observable, such as when the product or service is not sold separately, the Company determines the SSP using information that may include market conditions, expected cost plus margin, and other observable inputs.

In some circumstances, the Company has more than one SSP for individual products and services due to the stratification of those products and services by customers, geographic region or other factors. In these instances, the Company may use information such as the size of the customer and geographic region in determining the SSP.

Variable Consideration

The Company must assess if and when it is appropriate to include variable consideration when determining transaction price. This assessment, which impacts the timing and the amount of revenue recognized under contracts accounted for in accordance with ASC 606, requires management to conclude that it is probable that a significant reversal of the amount of cumulative revenue recognized with respect to a contract will not occur when the uncertainty associated with the variable consideration is subsequently resolved.
The Company’s collaboration agreements include the Company’s most significant variable consideration and require judgment in the estimation of the amount of variable consideration to be included in the transaction price, as well as the timing for inclusion of such variable consideration. In addition, the nature of the Company’s sales may lead to consideration that is variable in the form of discounts based on volumes purchased, trade in allowances, rebates or other discounts; however, these have historically not been material. The Company estimates variable consideration based on the expected value approach, which requires judgment in the identification of possible outcomes and in assessing the probability of those outcomes, or the most likely amount approach, which requires judgment to identify the most likely amount in a range of amounts. After estimating the amount of variable consideration, the Company includes the estimated variable consideration in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company assesses both the likelihood of a future reversal of revenue and how significant the reversal is relative to the total consideration. The Company’s estimates are based on historical experience, contract terms and other factors. Ongoing assessments are performed to determine if updates are needed to the original estimates.

Contracts Recognized Over Time

The Company recognizes the revenue attributable to certain contracts over time using a cost-to-cost percentage of completion model to measure progress of the transfer of control to the customer as services are performed, for which management believes the use of costs incurred reliably depicts the measurement of progress achieved by the Company in satisfying the performance obligation because it best depicts the transfer of control to the customer as we incur costs on our contracts. The application of this accounting requires the Company to estimate total costs that will be required to satisfy the related performance obligations. These estimates could change over the term of a contract.

Contract Balances

The timing of revenue recognition, billings and cash collections results in the recognition of billed accounts receivable and contract assets (including unbilled receivables) and customer deposits and deferred revenue (contract liabilities) on our consolidated balance sheets. Timing of revenue recognition may differ from the timing of invoicing to customers. We record accounts receivable when we have an unconditional right to recognize revenue at the time of invoicing, and unbilled receivables when revenue is recognized prior to invoicing. For most of our contracts, customers are invoiced when products are shipped or when services are performed resulting in billed accounts receivables for the remainder of the owed contract price. Unbilled receivables generally result from circumstances in which items have been shipped, revenue has been recognized, but the customer has not been charged. We also recognize a contract asset upon the recognition of revenue related to certain performance milestones that are deemed probable of achievement, but for which billing has not occurred and receipt of payment is conditioned upon factors other than the passage of time. Some contracts require the customer to remit a large payment at or near contract inception as a deposit prior to production, which is recorded as a customer deposit liability, however, revenue is not recorded until the performance obligation is satisfied. We also typically bill in advance for installation, training and maintenance contracts, as well as for extended warranties, resulting in deferred revenue.

Practical Expedients and Exemptions
We generally expense sales commissions when incurred because the amortization period would be one year or less. These costs are recorded within selling, general and administrative expenses. Additionally, the Company has excluded performance obligations with an original expected duration of one year or less from our disclosure of remaining performance obligations.
Held for Sale
Held for Sale
The Company classifies assets and liabilities to be sold ("disposal group") as held for sale in the period when all of the applicable criteria are met, including: (i) management, having the authority to approve the action, commits to a plan to sell, (ii) the disposal group is available to sell in its present condition, (iii) there is an active program to locate a buyer, (iv) the disposal group is being actively marketed at a reasonable price in relation to its fair value, (v) significant changes to the plan to sell are unlikely, and (vi) the sale of the disposal group is generally probable of being completed within one year. Management performs an assessment at least quarterly, or when events or changes in business circumstances indicate that a change in classification may be necessary. Assets and liabilities identified as held for sale are presented separately within the consolidated balance sheets, with adjustments made, if necessary, to measure the disposal group at the lower of its carrying value or fair value less costs to sell. Any loss resulting from this measurement is recognized in the period in which the held for sale criteria are met. Gains on the sale of a disposal group are not recognized until the date of sale. Depreciation of property, plant and equipment and amortization of intangible and right-of-use assets are not recorded while these assets are classified as held for sale. For each period that a disposal group remains classified as held for sale, its recoverability is reassessed and any necessary adjustments are made to its carrying value. Gains or losses recognized upon the sale of a disposal group that does not qualify as a discontinued operation are included in loss from operations in the consolidated statements of operations.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less when acquired. At times, cash and cash equivalents balances may be in excess of FDIC insurance limits.
Variable Interest Entities
Variable Interest Entities
Upon making an investment in an entity, we assess whether the entity is a variable interest entity ("VIE"). The determination of whether an entity in which we hold a direct or indirect variable interest is a VIE is based on several factors, including whether the entity’s total equity investment at risk at the time of our investment is sufficient to finance the entity’s activities without additional subordinated financial support. We make judgments regarding the sufficiency of the equity at risk based first on a qualitative analysis, and then a quantitative analysis, if necessary.
We analyze any investments in VIEs to determine whether we are the primary beneficiary. We perform this assessment at the time that we become involved with a VIE and continuously reassess whether circumstances indicate that there might be a change in our conclusion regarding whether we are the primary beneficiary. In evaluating whether we are the primary beneficiary, we consider both our direct and indirect economic interests in the entity. Determining which reporting entity, if any, is the primary beneficiary of a VIE is primarily a qualitative approach focused on identifying which reporting entity has both (1) the power to direct the activities of a VIE that most significantly impact such entity’s economic performance and (2) the obligation to absorb losses or the right to receive benefits from such entity that could potentially be significant to such entity. This analysis requires the exercise of judgment. We consider a variety of factors in identifying the entity that holds the power to direct matters that most significantly impact a VIE’s economic performance including, but not limited to, the ability to direct a VIE’s operating decisions and activities. In addition, we consider the rights of other investors to participate in those decisions.
Investments and Note Receivable
Investments and Note Receivable

Investments in Equity Securities with a Readily Determinable Fair Value

We recognize investments in equity securities without a readily determinable fair value at cost, minus impairment. In addition, we are required to remeasure the carrying value of an investment in equity securities without a readily determinable fair value if we identify observable price changes that relate to orderly transactions for an identical or similar investment in the same issuer. The remeasurement of the carrying value of an investment due to an identified observable price change shall be based upon the investment's fair value as of the date that the observable transaction occurred. Remeasurements, whether the result of impairment or observable price changes attributable to orderly transactions, are recorded as an adjustment to our reported net income or net loss.
We assess our investments in equity securities without a readily determinable fair value for potential impairment upon the occurrence of an event or a change in circumstances that would indicate the carrying amount of an investment may be impaired. On a quarterly basis, we first perform a qualitative assessment for potential impairment to determine whether measurement of the fair value of an investment to further assess for impairment is required. Impairments of equity securities without a readily determinable fair value are recorded to other income (loss), net in our consolidated statements of operations in the period in which they become impaired.

Refer to Note 9 for additional details regarding the carrying value of the Company's investments in equity securities without a readily determinable fair value as of each balance sheet date.

Equity Method of Accounting

The Company accounts for its investments in the common stock of NAMI and Enhatch using the equity method of accounting because it does not have a controlling interest and is not the primary beneficiary of these VIEs; however, the Company has the ability to exert significant influence. The Company's investments in NAMI's common stock were initially recorded at cost; whereas, the Company's investment in Enhatch's common stock, which reflects the partial exercise of a warrant, was recorded at the fair value of the common stock that was received upon exercise of the warrant. Each of these investments is subsequently adjusted for the Company’s proportionate share of the net earnings or losses and the other comprehensive income or loss of the investee. Intra-entity profits or losses associated with each equity method investment are eliminated until realized by the investee or the Company in transactions with third parties. Income or loss from these equity method investments is recorded as a separate line item in the consolidated statements of operations on a three-month lag. We evaluate material events occurring during the three-month lag period to determine whether the effects of such events should be disclosed in our financial statements. The Company evaluates each investment for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. Refer to Note 9 for additional details regarding the Company's investments accounted for in accordance with the equity method of accounting.

Notes Receivable

Refer to Note 9 for additional details regarding the carrying value of the Company’s outstanding note receivable balance as of each balance sheet date.
Accounts Receivable and Allowances for Credit Losses
Accounts Receivable and Allowance for Credit Losses
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. In evaluating the collectability of accounts receivable, we assess a number of factors, including specific customers’ ability to meet their financial obligations to us, the length of time receivables are past due, historical collection experience, current economic conditions, and reasonable and supportable forecasts. Based on these assessments, we record and adjust reserves for accounts receivable balances due from specific customers, as well as establish an allowance for expected credit losses related to our accounts receivable as a whole. If circumstances related to specific customers change or economic conditions deteriorate such that our past collection experience is no longer relevant, our estimate of the recoverability of accounts receivable could be further reduced from the levels provided for in the consolidated financial statements. As of December 31, 2025 and December 31, 2024, no single customer represented more than 10% of our consolidated accounts receivable balance.
Inventories
Inventories
Inventories are stated at the lower of cost or net realizable value, with cost reflecting standard cost, which approximates the first-in, first-out method. Capitalized inventory costs include materials, labor, and manufacturing overhead that relate to the acquisition of raw materials and production into finished goods. The Company regularly reviews inventory for excess and obsolescence and records a provision to write down inventory to its net realizable value when carrying value is in excess of such value.
Property and Equipment
Property and Equipment
Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the determination of net income or loss. Repairs and maintenance costs are expensed as incurred.
Intangible Assets (Excluding Goodwill)
Intangible Assets (Excluding Goodwill)
Intangible assets include patents, trade names, customer relationships, acquired technology, and in process research and development ("IPR&D"). Intangible assets with a finite life are (1) amortized on a straight-line basis, with estimated useful lives typically ranging from 2 to 20 years, and (2) assessed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable, consistent with the Company's accounting policy for other long-lived assets with a finite life. Amortization expense is generally recognized within selling, general and administrative expense on the consolidated statements of operations.
Acquired IPR&D represents the fair value assigned to those research and development ("R&D") projects that were acquired in a business combination for which the related products have not received regulatory approval or commercial viability and have no alternative future use. If the project is not completed or is terminated or abandoned, the Company may have to recognize an impairment related to the IPR&D, which is charged to expense.
Goodwill
Goodwill

Goodwill is the excess of the cost of an acquired entity over the amounts assigned to the assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. Goodwill is tested for impairment annually on November 1st, and is tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level, with all goodwill assigned to a reporting unit.
The testing of goodwill for impairment requires the Company to make several estimates related to projected future cash flows to determine the fair value of the reporting units to which goodwill has been assigned. The Company determines whether each reporting unit's fair value exceeds its carrying amount, including goodwill, based upon projections of future revenues, expenses, and cash flows discounted to their present value, as well as the application of a market approach. Internal operational budgets and long-range strategic plans are used as a basis for the cash flow analysis. The Company also utilizes assumptions related to working capital, capital expenditures, and terminal growth rates. The discount rate applied to the cash flow analysis is based on the weighted average cost of capital ("WACC") for each reporting unit. These valuation approaches require the application of Level 3 valuation inputs (as defined in Note 23). An impairment is recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit.
Long Lived Assets Impairment
Long Lived Assets Impairment
We review long-lived assets, including property and equipment, right of use assets and intangible assets, ("asset groups") that are held and used for impairment whenever events or changes in circumstances indicate that the carrying value of an asset group may not be recoverable. The carrying value of an asset group that is held and used is not recoverable if it exceeds the sum of the undiscounted cash flows that are expected to result from the asset group's use and eventual disposition. If we determine that an asset group's carrying value is not recoverable, we must then compare the asset group's carrying value to its estimated fair value and record any excess carrying value over fair value as an impairment loss. Any impairment loss that is recognized is required to be allocated to the long-lived assets of an asset group on a pro rata basis, using the relative carrying amounts of the long-lived assets comprising the asset group, except that the loss allocated to an individual long-lived asset shall not reduce its carrying amount below its fair value whenever that fair value is determinable without undue cost and effort.
Common Stock
Common Stock

The holders of the common stock are entitled to one vote for each share held at all meetings of stockholders (and for written actions in lieu of meetings).
We do not currently pay, and have not paid, any dividends on our common stock, and we currently intend to retain any future earnings for use in our business. Any future determination as to the declaration of dividends on our common stock will be made at the discretion of the Board of Directors and will depend on our earnings, operating and financial condition, capital requirements, and other factors deemed relevant by the Board of Directors, including the applicable requirements of the Delaware General Corporation Law, which provides that dividends are payable only out of surplus or current net profits.
The payment of dividends on our common stock may be restricted by the provisions of credit agreements or other financing documents that we may enter into or the terms of securities that we may issue from time to time. Under the 2030 Notes indenture agreement, the Company may not declare and pay a cash dividend.
Contingencies
Contingencies

We follow the provisions of ASC 450, "Contingencies," which requires that an estimated loss from a loss contingency be accrued by a charge to income if (1) it is probable that an asset has been impaired or that a liability has been incurred and (2) the amount of the loss can be reasonably estimated. Legal costs related to the defense or settlement of a loss contingency are expensed when such costs are incurred and, accordingly, future legal costs expected to be incurred are not accrued as part of the liability recorded when a loss contingency has been deemed probable and estimable.
Foreign Currency Translation and Transactions
Foreign Currency Translation and Transactions

The local currency in which a subsidiary operates is generally considered its functional currency for those subsidiaries domiciled outside the United States ("foreign subsidiaries"). The functional currency financial statements of foreign subsidiaries are translated to U.S. dollars ("USD") in connection with the preparation of the Company's consolidated financial statements. Assets and liabilities of foreign subsidiaries are translated to USD at month-end exchange rates applicable to the reporting period. Income and expense items are translated to USD monthly using monthly average exchange rates. The effects of translating a foreign subsidiary's financial statements are recorded as currency translation adjustments and reported as a component of accumulated other comprehensive income (loss) in shareholders’ equity.
Foreign currency transactions are those transactions whose terms are denominated in a currency other than an entity's functional currency. Foreign currency transactions that remain unsettled as of the end of a reporting period must be remeasured into the entity's functional currency, resulting in the recognition of a gain or loss when a change in exchange rate has occurred subsequent to the date on which the transaction was originally recognized or was most recently remeasured. The Company recognizes foreign currency transaction gains and losses within foreign exchange gain (loss), net on its consolidated statements of operations.
Research and Development Costs
Research and Development Costs
Research and development costs relate to the development of new products and services and consist primarily of employee compensation, operating supplies, facility costs and depreciation. These costs are expensed as incurred.
Earnings Per Share and Net Loss Per Share
Earnings Per Share and Net Loss Per Share
Basic net income (loss) per share is calculated using the weighted-average number of common shares outstanding during each period. Diluted net income (loss) per share is calculated based upon the inclusion of additional dilutive and potentially dilutive shares, which include shares issuable upon exercise of outstanding stock options, upon vesting of employee restricted stock-based awards, upon the accrual of incentive compensation to be paid in shares (if any performance-based conditions have been satisfied as of the end of the reporting period), and to settle the portion of the convertible notes that may be settled in shares (where the conversion of such instruments would be dilutive).
Advertising Costs
Advertising Costs
Advertising costs are expensed as incurred and recorded in selling, general and administrative expense.
Pension Costs
Pension Costs
We sponsor a retirement benefit for one of our non-U.S. subsidiaries in the form of a defined benefit pension plan. Accounting standards require the cost of providing this pension benefit be measured on an actuarial basis. Actuarial gains and losses resulting from both normal year-to-year changes in valuation assumptions and differences between assumptions and actual experience are deferred and amortized. The application of these accounting standards require us to make assumptions and judgments that can significantly affect these measurements. Our critical assumptions in performing these actuarial valuations include the selection of the discount rate to determine the present value of the pension obligations, which affects the amount of pension expense recorded in any given period. Changes in the discount rate could have a material effect on our reported pension obligations and related pension expense.
Equity Compensation Plans
Equity Compensation Plans

We recognize compensation expense for our stock-based compensation programs, which provide for the issuance of stock options, restricted stock, and restricted stock units ("RSU") that can have service-based conditions and market-based conditions.

The fair value of service-based awards is estimated at the grant date and recognized as expense ratably over the requisite service period of the award.

The fair value of awards with market conditions ("market-based awards") is determined using a Monte Carlo valuation model and is expensed over an implicit or explicit service period regardless of whether the market condition is probable of achievement or not. Market-based awards that cliff vest are expensed ratably using the straight-line method; whereas, market-based awards with graded vesting features are expensed using the graded vesting method. Stock compensation expense is not reversed if the market condition is not met.
For all share-based payment awards, we recognize forfeitures when they occur.
Income Taxes
Income Taxes

We and the majority of our domestic subsidiaries file a consolidated U.S. federal income tax return. Our non-U.S. subsidiaries file income tax returns in their respective jurisdictions.
Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax benefit carryforwards. Our deferred income tax assets and liabilities at the end of each period are determined using enacted tax rates.
We establish a valuation allowance for those jurisdictions in which the expiration date of tax benefit carryforwards or projected taxable earnings leads us to conclude that it is "more likely than not" that a deferred tax asset will not be realized. This evaluation process includes the consideration of all available evidence regarding historical results and future projections, including the estimated timing of reversals of existing taxable temporary differences and potential tax planning strategies. Once a valuation allowance is established, it is maintained until a change in factual circumstances gives rise to sufficient income of the appropriate character and timing that will allow a partial or full utilization of the deferred tax asset.
In accordance with ASC 740, "Income Taxes," the impact of an uncertain tax position on our income tax returns is recognized at the largest amount that is more likely than not to be required to be recognized upon audit by the relevant taxing authority.
We include interest and penalties accrued in the consolidated financial statements as a component of income tax expense.
Operating and Finance Leases
Operating and Finance Leases

We determine if an arrangement contains a lease at inception. We record both operating leases and finance leases on our balance sheet and do not separate non-lease components from our real estate leases. We exclude leases with a term of one year or less from our consolidated balance sheets.
Some leases include the option to purchase the leased asset, terminate the lease or extend the lease for one or more years. These options are considered in the determination of the estimated lease term when it is reasonably certain that an option will be exercised. Our leases do not contain any material residual value guarantees or material restrictive covenants.
Most of our leases do not provide an implicit rate; therefore, we use our incremental borrowing rate based on information available at the lease commencement date to determine the present value of the future lease payments.
Certain of our leases include variable costs. Variable costs include non-lease components that are incurred based upon actual terms, rather than contractually fixed amounts. In addition, variable costs are incurred for lease payments that are indexed to a change in rate or index. Because the right-of-use ("ROU") assets recorded on the balance sheet are determined based upon factors considered at the lease commencement date, subsequent changes in the rate or index that were not contemplated in the ROU asset balances at lease commencement result in variable expenses being recorded when these expenses are incurred during the lease term.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted
In September 2025, the FASB issued ASU No. 2025-06, "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software." The ASU revises the accounting and disclosure requirements for internally developed software, including moving website development guidance from ASC 350-50 to ASC 350-40, eliminating the use of development stages, and introducing new capitalization criteria based on (1) management’s authorization and funding commitment, and (2) the probability of project completion and intended functionality. It also includes guidance for assessing significant development uncertainty. This update is effective for annual periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effects of this ASU on our consolidated financial statements.

In July 2025, the FASB issued ASU No. 2025-05, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets." The ASU introduces a practical expedient that allows entities to assume that current conditions as of the balance sheet date will remain unchanged over the remaining life of eligible accounts receivable and contract assets. Under this expedient, entities are not required to forecast future changes in conditions for these assets; however, they must continue to consider customer-specific information and any known or expected deviations from current conditions. This update is effective for annual reporting periods beginning after December 15, 2025, including interim periods within those annual periods. Early adoption is permitted. The Company does not expect that the adoption of this standard will have a material impact on our Consolidated Financial Statements.

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The amendments in this ASU require public entities to provide disaggregated disclosure of expenses included within relevant income statement expense captions, as well as additional disclosures about selling expenses. This update is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effects of this ASU on our consolidated financial statements.
Recently Adopted Accounting Standards
In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740) - Improvements to Income Tax Disclosures." The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. We adopted this ASU prospectively for the year ended December 31, 2025, and we have included the required disclosures in Note 16.
In November 2024, the FASB issued ASU No. 2024-04, "Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments," related to induced conversions of convertible debt instruments. The amendments in this ASU clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions rather than as debt extinguishments. The Company early adopted this ASU as of April 1, 2025 and applied the guidance on a prospective basis. Adoption did not have a material impact on our consolidated financial statements.
v3.25.4
SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedule of Allowance for Credit Losses
The following presents the changes in the balance of our allowance for credit losses:
YearItemBalance at beginning of yearAdditions charged to expense
Other (a)
Balance at end of year
2025
Allowance for credit losses
$2,433 $1,810 $(635)3,608 
2024
Allowance for credit losses
3,389 506 (1,462)2,433 
2023
Allowance for credit losses
3,114 595 (320)3,389 
(a)Other includes the impact of write-offs, recoveries and foreign currency translation adjustments.
Schedule of Property and Equipment
Depreciation expense has been computed principally by the straight-line method based on the estimated useful lives of the depreciable assets which are generally as follows:
Category
Useful Life (in years)
Machinery and equipment
2-5
Capitalized software
3-5
Office furniture and equipment
1-5
Leasehold improvements
Life of lease a
Construction in progressN/A
a. Leasehold improvements are amortized on a straight-line basis over the shorter of (i) their estimated useful life or (ii) the estimated or contractual life of the related lease.
Property and equipment at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Machinery and equipment$129,493 $134,111 
Capitalized software25,811 25,888 
Office furniture and equipment5,238 5,454 
Leasehold improvements40,765 37,794 
Construction in progress9,652 4,831 
Total property and equipment a
210,959 208,078 
Less: Accumulated depreciation and amortization a
(161,710)(157,034)
Total property and equipment, net$49,249 $51,044 
a. The impairment charges subsequently discussed resulted in the establishment of a new cost basis for certain assets reflected in the table. Gross asset carrying values and accumulated depreciation and amortization have been adjusted to reflect the new cost basis of assets for which the carrying value was reduced due to impairment.
v3.25.4
DIVESTITURES (Tables)
 12 Months Ended
Dec. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Components of Assets and Liabilities Held for Sale The gross and net carrying values of the revenue-based royalty receivable are summarized below.
(in thousands)December 31, 2025
Revenue-based royalty receivable, gross
$9,900 
Discount on revenue-based royalty receivable
(2,850)
Revenue-based royalty receivable, net
$7,050 
The Company determined that the associated assets and liabilities met the held for sale criteria in December 2024. The following table summarizes the assets and liabilities of Geomagic:

(in thousands)December 31, 2024
Assets
Accounts receivable, net$765 
Prepaid expenses and other current assets47 
Total current assets held for sale812 
Intangible assets, net917 
Other assets1,447 
Total assets held for sale$3,176 
Liabilities
Current operating lease liabilities
Accounts payable$491 
Accrued and other liabilities303 
Deferred revenue7,197 
Total current liabilities held for sale7,991 
Other liabilities2,260 
Total liabilities held for sale$10,251 
v3.25.4
REVENUES (Tables)
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Receivables, Contract Assets and Contract Liabilities
Our contract liabilities consisted of the following:

December 31,
(in thousands)20252024
Deferred revenue, current and customer deposits17,423 32,010 
Deferred revenue, noncurrent2,794 2,259 
Total contract liabilities$20,217 $34,269 
Schedule of Revenue by Geographic Region
Revenue by geographic region for the years ended December 31, 2025, 2024, and 2023, which is determined based upon the geographic region in which a sale originates, was as follows:
Year Ended December 31,
(in thousands)202520242023
Americas$224,452 $253,468 $282,742 
EMEA135,825 149,734 164,673 
APAC26,625 36,919 40,654 
Total$386,902 $440,121 $488,069 
Year Ended December 31,
(in thousands)202520242023
United States (included within Americas) $221,045 $248,346 $278,268 
Germany (included within EMEA)59,347 69,101 76,995 
v3.25.4
INVENTORIES (Tables)
 12 Months Ended
Dec. 31, 2025
Inventory Disclosure [Abstract]  
Schedule of Components of Inventories
Components of inventories at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Raw materials$45,350 $43,138 
Work in process2,137 3,481 
Finished goods and parts80,009 71,911 
Total inventories$127,496 $118,530 
v3.25.4
PROPERTY AND EQUIPMENT (Tables)
 12 Months Ended
Dec. 31, 2025
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Depreciation expense has been computed principally by the straight-line method based on the estimated useful lives of the depreciable assets which are generally as follows:
Category
Useful Life (in years)
Machinery and equipment
2-5
Capitalized software
3-5
Office furniture and equipment
1-5
Leasehold improvements
Life of lease a
Construction in progressN/A
a. Leasehold improvements are amortized on a straight-line basis over the shorter of (i) their estimated useful life or (ii) the estimated or contractual life of the related lease.
Property and equipment at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Machinery and equipment$129,493 $134,111 
Capitalized software25,811 25,888 
Office furniture and equipment5,238 5,454 
Leasehold improvements40,765 37,794 
Construction in progress9,652 4,831 
Total property and equipment a
210,959 208,078 
Less: Accumulated depreciation and amortization a
(161,710)(157,034)
Total property and equipment, net$49,249 $51,044 
a. The impairment charges subsequently discussed resulted in the establishment of a new cost basis for certain assets reflected in the table. Gross asset carrying values and accumulated depreciation and amortization have been adjusted to reflect the new cost basis of assets for which the carrying value was reduced due to impairment.
v3.25.4
INTANGIBLES ASSETS (Tables)
 12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets Other Than Goodwill
At December 31, 2025 and 2024, the Company's intangible assets with finite lives were as follows:
20252024
(in thousands)
Gross
Accumulated Amortization
Net
Gross
Accumulated AmortizationNet
Intangible assets with finite lives:
Customer relationships$53,119 $(53,099)$20 $47,051 $(47,023)$28 
Acquired technology14,203 (7,024)7,179 13,768 (6,149)7,619 
Trade names10,413 (8,616)1,797 11,973 (9,998)1,975 
Patent costs14,716 (7,550)7,166 14,915 (6,950)7,965 
Acquired patents11,458 (11,395)63 14,596 (14,485)111 
Other6,758 (6,369)389 7,666 (7,344)322 
Total intangible assets with finite lives
$110,667 $(94,053)$16,614 $109,969 $(91,949)$18,020 
v3.25.4
GOODWILL (Tables)
 12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table reflects the changes in the carrying amount of goodwill by reporting unit for the years ended December 31, 2025 and 2024:

HealthcareIndustrialConsolidated
(in thousands)
Gross Goodwill
Cumulative Impairments
Net GoodwillGross Goodwill
Cumulative Impairments
Net Goodwill
Gross Goodwill
Cumulative Impairments
Net Goodwill
Balance, December 31, 2023$148,137 $(32,055)$116,082 $322,137 $(322,137)$— $470,274 $(354,192)$116,082 
Impairment charge
— (101,445)(101,445)— — — — (101,445)(101,445)
Foreign currency translation adjustments242 — 242 — — — 242 — 242 
Balance, December 31, 2024$148,379 $(133,500)$14,879 $322,137 $(322,137)$— $470,516 $(455,637)$14,879 
Foreign currency translation adjustments696 — 696 — — — 696 — 696 
Balance, December 31, 2025$149,075 $(133,500)$15,575 $322,137 $(322,137)$— $471,212 $(455,637)$15,575 
v3.25.4
INVESTMENTS AND NOTE RECEIVABLE (Tables)
 12 Months Ended
Dec. 31, 2025
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Equity Investments
The Company holds various equity investments. The following table summarizes our investment balance, which are reported in Other assets on our consolidated balance sheets:

(in thousands)December 31, 2025December 31, 2024
Equity investments under the equity method of accounting$753 $5,051 
Equity investments without readily determinable fair values21,712 20,696 
Total equity investments
$22,465 $25,747 
v3.25.4
LEASES (Tables)
 12 Months Ended
Dec. 31, 2025
Leases [Abstract]  
Schedule of Components of Lease Cost
Components of lease cost (income) for the years ended December 31, 2025, 2024, and 2023 were as follows:

(in thousands)202520242023
Operating lease cost$13,715 $14,331 $13,667 
Finance lease cost - amortization expense1,586 1,706 991 
Finance lease cost - interest expense955 1,017 478 
Short-term lease cost157 347 494 
Variable lease cost4,492 4,142 3,953 
Sublease income(69)(132)(186)
Total$20,836 $21,411 $19,397 
Supplemental cash flow information related to our leases for the years ended December 31, 2025, 2024 and 2023 was as follows:

(in thousands)202520242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflow for operating leases$14,151 $13,986 $13,177 
Operating cash outflow for finance leases$955 $1,017 $478 
Financing cash outflow for finance leases$1,593 $1,385 $644 
The weighted-average remaining lease term and discount rate for our finance and operating leases as of December 31, 2025 and 2024 were as follows:
20252024
FinanceOperatingFinanceOperating
Weighted-average remaining lease term (in years)6.16.67.07.3
Weighted-average discount rate8.47%7.23%8.44%7.17%
Schedule of Future Minimum Lease Payments - Finance Leases
As of December 31, 2025, our future minimum lease payments under operating leases and finance leases with initial or remaining lease terms in excess of one year were as follows:

(in thousands)Finance LeasesOperating Leases
Years ending December 31:
2026$2,470 $15,094 
20272,535 11,987 
20282,499 10,880 
20292,132 9,317 
20301,539 7,095 
Thereafter3,261 18,680 
Total lease payments (undiscounted)14,436 73,053 
Less: imputed interest(3,321)(16,050)
Present value of lease liabilities$11,115 $57,003 
Schedule of Future Minimum Lease Payments - Operating Leases
As of December 31, 2025, our future minimum lease payments under operating leases and finance leases with initial or remaining lease terms in excess of one year were as follows:

(in thousands)Finance LeasesOperating Leases
Years ending December 31:
2026$2,470 $15,094 
20272,535 11,987 
20282,499 10,880 
20292,132 9,317 
20301,539 7,095 
Thereafter3,261 18,680 
Total lease payments (undiscounted)14,436 73,053 
Less: imputed interest(3,321)(16,050)
Present value of lease liabilities$11,115 $57,003 
v3.25.4
ACCRUED AND OTHER LIABILITIES (Tables)
 12 Months Ended
Dec. 31, 2025
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accrued and other liabilities at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Compensation and benefits$11,293 $12,646 
Accrued taxes15,040 8,034 
Legal contingencies1,765 4,739 
Accrued product warranty liability
3,537 2,650 
Current finance lease liabilities
1,606 1,482 
Other accrued liabilities
13,415 15,937 
Total$46,656 $45,488 
Schedule of Recognized Warranty Revenue and Incurred Warranty Costs
Changes in our accrued product warranty liability balance for the years ended December 31, 2025, 2024 and 2023 are summarized below:

(in thousands)December 31, 2025December 31, 2024December 31, 2023
Balance at beginning of period
$2,650 $2,106 $3,677 
Settlements made
(3,451)(3,264)(4,397)
Accruals for warranties issued
4,338 3,808 2,826 
Balance at the end of period
$3,537 $2,650 $2,106 
Schedule of Other Liabilities
Other liabilities at December 31, 2025 and 2024 are summarized as follows:

(in thousands)20252024
Long-term finance lease liabilities
$9,509 $10,543 
Defined benefit pension obligation6,358 5,716 
Long-term tax liability2,624 2,277 
Long-term employee indemnity2,032 3,480 
Long-term deferred revenue2,794 2,259 
Other long-term liabilities683 726 
Total$24,000 $25,001 
v3.25.4
BORROWINGS (Tables)
 12 Months Ended
Dec. 31, 2025
Debt Disclosure [Abstract]  
Schedule of Convertible Notes
The following tables summarize the detail of the Company's convertible senior notes:
(in thousands)Outstanding PrincipalUnamortized Deferred Issuance CostsCarrying Value
December 31, 2025
0% Convertible senior notes due 2026
$3,944 $— $3,944 
5.875% Convertible senior notes due 2030
92,030 (5,636)86,394 
Outstanding convertible notes$95,974 $(5,636)$90,338 
(in thousands)Outstanding PrincipalUnamortized Deferred Issuance CostsCarrying Value
December 31, 2024
0% Convertible senior notes due 2026
$214,378 $(2,383)$211,995 
Outstanding convertible notes$214,378 $(2,383)$211,995 
v3.25.4
EMPLOYEEE BENEFITS (Tables)
 12 Months Ended
Dec. 31, 2025
Retirement Benefits [Abstract]  
Schedule of Reconciliation of Changes in Projected Benefit Obligation The following table provides a reconciliation of the changes in the projected benefit obligation for the years ended December 31, 2025 and 2024:
(in thousands)20252024
Reconciliation of benefit obligation:
Obligation as of January 1$5,896 $6,027 
Service cost63 59 
Interest cost227 210 
Actuarial (gain) loss
(934)145 
Benefit payments(199)(187)
Effect of foreign currency exchange rate changes1,508 (358)
Benefit obligation as of December 31$6,561 $5,896 
Schedule of Amounts Recognized in Consolidated Balance Sheets
We recognized the following amounts in the consolidated balance sheets at December 31, 2025 and 2024:

(in thousands)20252024
Accrued and other liabilities203 180 
Other liabilities6,358 5,716 
Total liability
$6,561 $5,896 
Schedule of Accumulated and Projected Benefit Obligations
Following are the projected benefit obligation and accumulated benefit obligation at December 31, 2025 and 2024:

(in thousands)20252024
Projected benefit obligation$6,561 $5,896 
Accumulated benefit obligation$5,678 $5,672 
The following table shows the components of net periodic benefit costs and the amounts recognized in accumulated other comprehensive income (loss) for the years ended December 31, 2025, 2024 and 2023:


(in thousands)202520242023
Net periodic benefit cost:
Service cost$63 $59 $59 
Interest cost227 210 220 
Amortization of actuarial gain
(93)— (46)
Total net periodic pension cost197 269 233 
Other changes in plan assets and benefit obligations recognized in other comprehensive income (loss):
Net loss (gain)
(841)145 541 
Amortization of prior years' unrecognized gain (loss)
— — 46 
Total recognized as other comprehensive income (loss), excluding tax(841)145 587 
Total (gain) expenses recognized in net periodic benefit cost and other comprehensive (loss) income
$(644)$414 $820 
Schedule of Assumptions Used to Determine Benefit Obligations
The following assumptions are used to determine the benefit obligations as of December 31, 2025 and 2024:

20252024
Discount rate4.4%3.6%
Rate of compensation3.0%3.0%
Schedule of Estimated Future Benefit Payments
The following benefit payments, including expected future service cost, are expected to be paid:

(in thousands) 
Estimated future benefit payments for the years ending December 31: 
2026$232 
2027258 
2028287 
2029321 
2030353 
2031 through 2035
1,885 
v3.25.4
REDEEMABLE NON-CONTROLLING INTEREST (Tables)
 12 Months Ended
Dec. 31, 2025
Noncontrolling Interest [Abstract]  
Schedule of Redeemable Noncontrolling Interest
Changes to the Company's RNCI balance during the years ended December 31, 2025, 2024 and 2023 are summarized below:
(in thousands)
Year Ended December 31
202520242023
Balance at beginning of period
$1,958 $2,006 $1,760 
Fair value at the date of acquisition
— — — 
Net loss
— — (265)
Redemption value (below) in excess of carrying value
— (61)479 
Translation adjustments
235 13 32 
Balance at end of period
$2,193 $1,958 $2,006 
v3.25.4
STOCK-BASED COMPENSATION (Tables)
 12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Shares and Units of Restricted Common Stock
A summary of our restricted stock and RSU activity for the years ended December 31, 2025, 2024 and 2023 is as follows:
(in thousands, except per share amounts)Number of Shares/UnitsWeighted Average Grant Date Fair Value
Outstanding as of December 31, 2022 — unvested5,015 $18.19 
Granted4,439 $10.26 
Canceled(1,118)$15.45 
Vested(2,154)$13.09 
Outstanding as of December 31, 2023 — unvested6,182 $14.77 
Granted3,392 $1.98 
Canceled(1,845)$14.69 
Vested(2,544)$13.28 
Outstanding as of December 31, 2024 — unvested5,185 $7.16 
Granted2,958 $2.25 
Canceled(1,323)$4.37 
Vested(1,659)$7.14 
Outstanding as of December 31, 2025 — unvested5,161 $5.06 
Schedule of Stock Option Activity The fair value of stock options with market conditions is estimated using a binomial lattice Monte Carlo simulation model. Expense for awards with a market condition is not reversed if the market condition is not met.
Year Ended December 31, 2024
(in thousands, except per share amounts)Number of SharesWeighted Average ExerciseWeighted Average Remaining Contractual Term (in years)Aggregate Intrinsic Value
Stock option activity:
Outstanding at beginning of year420 $13.26 2.7$— 
Forfeited and expired(260)13.26 — — 
Outstanding at end of year160 $13.26 1.6$— 
Schedule of Stock-based Compensation Expense
The following table shows the stock-based compensation expense recognized during the years ended December 31, 2025, 2024, and 2023:

(in thousands)202520242023
Stock-based compensation expense$9,525 $18,457 $23,504 
Tax benefit$— $— $— 
v3.25.4
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Before Income Taxes
The components of our income (loss) before income taxes for the years ended December 31, 2025, 2024 and 2023 are as follows:
(in thousands)202520242023
Income (loss) before income taxes:
Domestic$13,858 $(160,709)$(239,971)
Foreign35,734 (89,287)(122,341)
Total$49,592 $(249,996)$(362,312)
Schedule of Components of Income Tax Provision
The components of income tax provision for the years ended December 31, 2025, 2024 and 2023 are as follows:

(in thousands)202520242023
Current:
U.S. federal$— $24 $135 
State99 301 (50)
Foreign14,867 2,820 1,686 
Total$14,966 $3,145 $1,771 
Deferred:
U.S. federal$838 $— $— 
State— — — 
Foreign(933)(952)(2,412)
Total(95)(952)(2,412)
Total income tax provision (benefit)
$14,871 $2,193 $(641)
Schedule of Cash Paid For Income Taxes (Net Of Refunds) Summary of Significant Accounting Policies, cash paid for income taxes (net of refunds) during the year ended December 31, 2025, consisted of the following:
(in thousands)2025
Federal
$799 
State:
Other (a)
492 
Total State
492 
Foreign:
Germany
2,431 
Korea
1,860 
Netherlands
1,723 
China
559 
Mexico
522 
Other (a)
1,247 
Total Foreign
8,342 
Cash paid for income taxes (net of refunds)
$9,633 
(a) The amount of income taxes paid during the year does not meet the 5% disaggregation threshold and is included in Other.
Schedule of Deferred Tax Assets and Liabilities
The components of our net deferred income tax assets and net deferred income tax (liabilities) at December 31, 2025 and 2024 as follows:

(in thousands)20252024
Deferred income tax assets:
Intangible assets$11,860 $15,685 
Stock options and restricted stock awards1,666 3,032 
Reserves and allowances4,511 6,879 
Net operating loss carryforwards79,161 59,641 
Tax credit carryforwards32,287 31,326 
Accrued liabilities2,235 2,681 
Deferred revenue1,055 2,176 
Lease tax assets12,248 17,498 
Research expenditures capitalization31,905 44,773 
Other5,607 3,236 
Valuation allowance(170,425)(168,299)
Total deferred income tax assets$12,110 $18,628 
Deferred income tax liabilities:
Intangible assets$1,171 $2,081 
Property and equipment710 2,352 
Lease tax liabilities10,182 14,159 
Other— 49 
Total deferred income tax liabilities$12,063 $18,641 
Net deferred income tax asset (liability)
$47 $(13)
Schedule of Unrecognized Tax Benefits Roll Forward We include interest and penalties in the consolidated financial statements as a component of income tax expense.
Unrecognized Tax Benefits(1)
(in thousands)202520242023
Balance at January 1$(16,413)$(18,604)$(17,150)
Increases related to prior year tax positions(240)(1,170)(99)
Decreases related to prior year tax positions106 4,337 107 
Decreases related to prior year tax positions as a result of lapse of statute3,170 — 271 
Decreases related to settlement— — — 
Increases related to current year tax positions(933)(976)(1,733)
Increases related to acquired tax positions— — — 
Decreases related to acquired tax positions— — — 
Balance at December 31$(14,310)$(16,413)$(18,604)
(1) The unrecognized tax benefit balance as of December 31, 2025, 2024, and 2023 includes $0.5 million, $1.3 million, and $0.3 million of interest and penalty, respectively.
Schedule of Deferred Income Tax Asset Valuation Allowance
The following presents the changes in the balance of our deferred income tax asset valuation allowance:
Year EndedItemBalance at beginning of yearAdditions (reductions) charged to expense
Other(1)
Balance at end of year
2025Deferred income tax asset valuation allowance$168,299 $(1,915)$4,041 $170,425 
2024Deferred income tax asset valuation allowance$125,533 $43,365 $(599)$168,299 
2023Deferred income tax asset valuation allowance$100,694 $23,606 $1,233 $125,533 
(1) The Other portion of changes to our valuation allowance consists primarily of the impact of acquisitions and changes in foreign currency translation rates.
Schedule of Effective Tax Rate Reconciliation
The overall effective tax rate differs from the statutory federal tax rate for the years ended December 31, 2025 as follows:

(in thousands)AmountPercent
Tax provision based on the federal statutory rate$10,414 21.0 %
State and local income taxes(1)
79 0.2 %
Foreign tax effects
Belgium
Foreign income tax rate differential(779)(1.6)%
Changes in valuation allowances6,738 13.6 %
Deferred adjustments(2,289)(4.6)%
Other(588)(1.2)%
Germany
Changes in valuation allowances(1,874)(3.8)%
Other145 0.3 %
Netherlands
Changes in valuation allowances1,623 3.3 %
Other(344)(0.7)%
Switzerland
Changes in valuation allowances1,708 3.4 %
Tax-deductible goodwill(1,985)(4.0)%
Other(409)(0.8)%
Other foreign jurisdictions3,924 7.9 %
Effect of cross-border tax laws
Global intangible low-taxed income inclusion5,980 12.1 %
Subpart F income inclusion725 1.5 %
Tax credits
Research and development tax credits(3,593)(7.2)%
Expired foreign tax credits3,253 6.6 %
Changes in valuation allowances(9,951)(20.1)%
Nontaxable or nondeductible items
Employee share-based payments2,483 5.0 %
Equity method investment(827)(1.7)%
Impairment of investments1,338 2.7 %
Unremitted foreign earnings838 1.7 %
Deferred adjustments559 1.1 %
Payable adjustments(637)(1.3)%
Other791 1.6 %
Changes in unrecognized tax benefits(2,451)(4.9)%
Total
$14,871 30.0 %
(1) In 2025, state taxes in California, New York, New Jersey, New York City, and Michigan made up the majority (greater than 50%) of the tax effect in this category.
The overall effective tax rate differs from the statutory federal tax rate for the years ended December 31, 2024, and 2023 are as follows:
% of Pretax (Loss) Income
20242023
Tax provision based on the federal statutory rate21.0 %21.0 %
Increase in valuation allowances(17.3)(6.5)
Change in carryforward attributes— — 
Global intangible low-taxed income inclusion— (0.4)
Non-deductible expenses— — 
Non-deductible earnout expense— 1.0 
Goodwill impairment charge
(8.7)(14.6)
Foreign income tax rate differential0.2 0.5 
Deemed income related to foreign operations(0.6)(0.3)
Tax rate change(0.1)— 
Employee share-based payments(0.3)(0.5)
Other(0.3)(0.7)
Deferred and payable adjustments1.3 (1.3)
Non-deductible penalties— — 
State taxes, net of federal benefit, before valuation allowance1.2 0.7 
Return-to-provision adjustments(0.5)0.2 
Other tax credits2.0 1.1 
Uncertain tax positions and audit settlements1.3 — 
Effective tax rate(0.8)%0.2 %
v3.25.4
NET INCOME (LOSS) PER SHARE (Tables)
 12 Months Ended
Dec. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Net Loss Per Share Reconciliation
Year Ended December 31,
(in thousands, except per share amounts)202520242023
Numerator (basic):
Net income (loss) attributable to 3D Systems Corporation
$29,883 $(255,593)$(362,688)
Redeemable non-controlling interest redemption value in excess of carrying value— 61 (479)
Net income (loss) attributable to common stock shareholders
$29,883 $(255,532)$(363,167)
Numerator (diluted):
Net income (loss) income attributable to 3D Systems' common stock shareholders
$29,883 $(255,532)$(363,167)
Add back: Interest on 2030 Notes2,809 — — 
Net income (loss) income attributable to 3D Systems' common stock shareholders plus assumed conversions
$32,692 $(255,532)$(363,167)
Denominator:
Basic weighted average common shares outstanding(a)
129,159 131,861 129,944 
Effect of Dilutive securities:
Restricted stock and RSUs1,393 — — 
Conversion of 2030 Notes44,962 — — 
Diluted weighted average common shares outstanding175,514 131,861 129,944 
Net income (loss) per share – basic
$0.23 $(1.94)$(2.79)
Net income (loss) per share - diluted
$0.19 $(1.94)$(2.79)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share attributable to common stockholders because their effect was considered anti-dilutive for the years ended December 31, 2025, 2024 and 2023, respectively.

Year Ended December 31,
(in thousands)202520242023
Restricted stock, restricted stock units, and PSUs
2,691 5,185 6,182 
Stock options160 160 420 
Total2,851 5,345 6,602 
v3.25.4
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
 12 Months Ended
Dec. 31, 2025
Stockholders' Equity Note [Abstract]  
Schedule of Accumulated Other Comprehensive Loss
The changes in the balances of accumulated other comprehensive loss by component are as follows:

(in thousands)Foreign currency translation adjustmentDefined benefit pension planUnrealized loss on short-term investmentsTotal
Balance at December 31, 2022$(54,194)$700 $(328)$(53,822)
Other comprehensive income (loss)9,630 (354)108 9,384 
Amounts reclassified from accumulated other comprehensive (loss) income a
— (32)220 188 
Balance at December 31, 2023(44,564)314 — (44,250)
Other comprehensive loss
(10,653)(163)— (10,816)
Balance at December 31, 2024(55,217)151 — (55,066)
Other comprehensive income
7,219 20 — 7,239 
Balance at December 31, 2025$(47,998)$171 $— $(47,827)
a.Amount reclassified into Other income, net on the consolidated statements of operations.
v3.25.4
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Segment
Revenue, cost of sales and gross profit for each of our reportable segments were as follows:

Year Ended December 31,
(in thousands)202520242023
Revenue:
Healthcare Solutions$179,589 $189,736 $213,216 
Industrial Solutions207,313 250,385 274,853 
Total revenue
386,902 440,121 488,069 
Cost of sales:
Healthcare Solutions
107,783 116,237 128,066 
Industrial Solutions
148,074 159,706 163,582 
Total cost of sales
255,857 275,943 291,648 
Gross profit:
Healthcare Solutions
71,806 73,499 85,150 
Industrial Solutions
59,239 90,679 111,271 
Total gross profit
131,045 164,178 196,421 
Selling, general and administrative(161,331)(210,132)(210,172)
Research and development(65,037)(86,479)(89,466)
Asset impairment charges
(760)(144,967)(302,787)
Foreign exchange gain (loss), net
3,637 2,452 (4,825)
Interest income
3,956 7,302 19,511 
Interest expense
(5,162)(2,564)(3,301)
Gain on disposition139,590 — — 
Other income, net
3,654 20,214 32,307 
Income (loss) before income taxes
$49,592 $(249,996)$(362,312)
Schedule of Segment Reporting Information Depreciation and Amortization
Depreciation and amortization included in the measurement of gross profit by segment were as follows:
Year Ended December 31,
(in thousands)202520242023
Depreciation and amortization:
Healthcare Solutions
$5,431 $5,389 $4,593 
Industrial Solutions
$2,378 $2,947 $2,801 
Schedule of Long-Lived Assets by Geographical Region
The following table summarizes long-lived assets by geographic region as of December 31, 2025 and 2024:

Year Ended December 31,
(in thousands)20252024
United States
$68,893 $76,829 
Belgium
18,893 19,598 
Other foreign entities
14,501 14,058 
Total$102,287 $110,485 
v3.25.4
FAIR VALUE MEASUREMENTS (Tables)
 12 Months Ended
Dec. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis
The following table summarizes financial assets and financial liabilities that are measured and recorded in the consolidated financial statements at fair value on a recurring basis:
(in thousands)
Fair Value Measurement Using (a)
December 31, 2025Total Fair ValueLevel 1Level 2Level 3
Money market funds$32,760 $32,760 $— $— 
December 31, 2024
Money market funds$98,212 $98,212 $— $— 
(a) There were no transfers among the levels within the fair value hierarchy during the year ended December 31, 2025 or the year ended December 31, 2024.
Schedule of Fair Value of Financial Instruments
The following table summarizes the carrying amount and fair value of our financial instruments:
December 31, 2025December 31, 2024
(in thousands)Carrying AmountFair ValueCarrying AmountFair Value
0% Convertible senior notes due 2026
$3,944 $3,593 $211,995 $189,409 
5.875% Convertible senior secured notes due 2030
$86,394 $117,982 $— $— 
v3.25.4
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Tables)
 12 Months Ended
Dec. 31, 2025
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Related Costs These charges are reflected in the following captions in the accompanying Condensed Consolidated Statements of Operations as follows:
Year Ended
(in thousands)December 31, 2025December 31, 2024December 31, 2023
Total cost of sales (a)
$1,034 $(785)$1,401 
Selling, general and administrative
5,855 370 5,598 
Research and development
1,561 385 1,243 
Total
$8,450 $(30)$8,242 
(a) Only restructuring costs recorded to cost of sales have been included in our reported segment results, as gross profit is our measure of segment profitability. For 2025, $0.5 million of severance and termination costs recorded to cost of sales are included in Healthcare and $0.5 million are included in Industrial. All severance and termination costs recorded to costs of sales for 2024 and 2023 are included in our Healthcare segment and, accordingly, are reflected in the Healthcare segment's reported gross profit. There were no facility termination costs or impairment costs included in the amounts reported for consolidated or segment cost of sales. See Note 19 for the reported gross profit for each of our reportable segments.
The activity in the restructuring accrual related to the 2025 and 2023 Restructuring Plans was as follows:
(in thousands)December 31, 2025December 31, 2024
Balance at beginning of period
$487 $3,933 
Costs incurred and other adjustments to accrued liability during the period
8,450 (30)
Amounts settled with cash
(7,707)(3,416)
Balance at the end of period
$1,230 $487 
v3.25.4
OVERVIEW AND BASIS OF PRESENTATION (Details)
 12 Months Ended
Dec. 31, 2025
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of reportable segments 2
v3.25.4
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2025
USD ($)
vote
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Common stock, number of votes per share | vote 1    
Advertising costs $ 4.0 $ 5.1 $ 7.1
Unrecognized tax benefits, income tax penalties and interest accrued $ 0.0 $ 1.0 $ 0.0
Lease renewal term 1 year    
Minimum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Useful life 2 years    
Maximum      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Useful life 20 years    
v3.25.4
SIGNIFICANT ACCOUNTING POLICIES (Schedule of Allowance for Credit Losses) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Balance at beginning of year $ 2,433 $ 3,389 $ 3,114
Additions charged to expense 1,810 506 595
Other (635) (1,462) (320)
Balance at end of year $ 3,608 $ 2,433 $ 3,389
v3.25.4
SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment) (Details)
Dec. 31, 2025
Minimum | Machinery and equipment  
Property, Plant and Equipment [Line Items]  
Useful Life (in years) 2 years
Minimum | Capitalized software  
Property, Plant and Equipment [Line Items]  
Useful Life (in years) 3 years
Minimum | Office furniture and equipment  
Property, Plant and Equipment [Line Items]  
Useful Life (in years) 1 year
Maximum | Machinery and equipment  
Property, Plant and Equipment [Line Items]  
Useful Life (in years) 5 years
Maximum | Capitalized software  
Property, Plant and Equipment [Line Items]  
Useful Life (in years) 5 years
Maximum | Office furniture and equipment  
Property, Plant and Equipment [Line Items]  
Useful Life (in years) 5 years
v3.25.4
DIVESTITURES (Narrative) (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2025
Dec. 31, 2025
Oct. 31, 2025
Apr. 01, 2025
3DXpert And Oqton        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Sale of business     $ 3,300  
Royalty receivable   $ 7,050 $ 7,100  
Royalty receivable, effective interest rate   6.00%    
Pre-tax gain   $ 13,900    
Loss on disposal   0    
Geomagic software        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Sale of business       $ 119,400
Pre-tax gain $ 125,700      
Loss on disposal   $ 0    
v3.25.4
DIVESTITURES (Schedule of Carrying Value of Revenue) (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - 3DXpert And Oqton - USD ($)
$ in Thousands
Dec. 31, 2025
Oct. 31, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Revenue-based royalty receivable, gross $ 9,900  
Discount on revenue-based royalty receivable (2,850)  
Revenue-based royalty receivable, net $ 7,050 $ 7,100
v3.25.4
DIVESTITURES (Schedule of Components of Assets and Liabilities Held for Sale) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Assets    
Total current assets held for sale $ 0 $ 3,176
Liabilities    
Total current liabilities held for sale $ 0 10,251
Geomagic software | Disposal Group, Held-for-Sale, Not Discontinued Operations    
Assets    
Accounts receivable, net   765
Prepaid expenses and other current assets   47
Total current assets held for sale   812
Intangible assets, net   917
Other assets   1,447
Total assets held for sale   3,176
Liabilities    
Accounts payable   491
Accrued and other liabilities   303
Deferred revenue   7,197
Total current liabilities held for sale   7,991
Other liabilities   2,260
Total liabilities held for sale   $ 10,251
v3.25.4
REVENUES (Narrative) (Details)
 12 Months Ended
Dec. 31, 2025
USD ($)
numberOfCustomers
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Remaining performance obligation $ 6,500,000    
Contract with customer, asset 1,600,000 $ 300,000  
Amounts included in contract liability at the beginning of period 32,600,000 32,000,000.0  
Total revenue 386,902,000 440,121,000 $ 488,069,000
Total cost of sales 255,857,000 275,943,000 291,648,000
Services      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Total revenue 163,497,000 160,943,000 159,338,000
Total cost of sales 104,712,000 100,084,000 88,390,000
Recognized revenue   8,700,000 4,500,000
Collaborative Arrangement      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Total revenue 8,700,000 0 17,000,000.0
Total cost of sales $ 8,100,000 $ 7,100,000 $ 14,100,000
Revenue Benchmark | Customer Concentration Risk | Healthcare Solutions      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Number of customers | numberOfCustomers 2    
Customer A | Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Concentration risk (as a percentage) 12.20% 16.00% 15.00%
Customer B | Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Concentration risk (as a percentage) 11.40%    
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Axis]: 2026-01-01      
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]      
Remaining performance obligation (as a percentage) 90.00%    
Performance obligations expected to be satisfied, expected timing 2 years    
v3.25.4
REVENUES (Schedule of Contract with Customer, Contract Asset, Contract Liability, and Receivable) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]    
Deferred revenue, current and customer deposits $ 17,423 $ 32,010
Deferred revenue, noncurrent 2,794 2,259
Total contract liabilities $ 20,217 $ 34,269
v3.25.4
REVENUES (Schedule of Revenue by Geographic Region) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]      
Total revenue $ 386,902 $ 440,121 $ 488,069
Americas      
Disaggregation of Revenue [Line Items]      
Total revenue 224,452 253,468 282,742
United States      
Disaggregation of Revenue [Line Items]      
Total revenue 221,045 248,346 278,268
EMEA      
Disaggregation of Revenue [Line Items]      
Total revenue 135,825 149,734 164,673
Germany      
Disaggregation of Revenue [Line Items]      
Total revenue 59,347 69,101 76,995
APAC      
Disaggregation of Revenue [Line Items]      
Total revenue $ 26,625 $ 36,919 $ 40,654
v3.25.4
INVENTORIES (Schedule of Components Of Inventories) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Inventory Disclosure [Abstract]    
Raw materials $ 45,350 $ 43,138
Work in process 2,137 3,481
Finished goods and parts 80,009 71,911
Total inventories $ 127,496 $ 118,530
v3.25.4
INVENTORIES (Narrative) (Details) - USD ($)
$ in Millions
Dec. 31, 2025
Dec. 31, 2024
Inventory Disclosure [Abstract]    
Inventory reserve $ 26.5 $ 21.9
v3.25.4
PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 210,959 $ 208,078
Less: Accumulated depreciation and amortization (161,710) (157,034)
Total property and equipment, net 49,249 51,044
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 129,493 134,111
Capitalized software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 25,811 25,888
Office furniture and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 5,238 5,454
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 40,765 37,794
Construction in progress    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 9,652 $ 4,831
v3.25.4
PROPERTY AND EQUIPMENT (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]      
Depreciation $ 17,400 $ 19,000 $ 21,300
Asset impairment charges $ 760 144,967 302,787
Property, Plant and Equipment      
Property, Plant and Equipment [Line Items]      
Asset impairment charges   $ 5,900 $ 1,400
v3.25.4
INTANGIBLES ASSETS (Schedule of Intangible Assets Other Than Goodwill) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]    
Gross $ 110,667 $ 109,969
Accumulated Amortization (94,053) (91,949)
Net 16,614 18,020
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross 53,119 47,051
Accumulated Amortization (53,099) (47,023)
Net 20 28
Acquired technology    
Finite-Lived Intangible Assets [Line Items]    
Gross 14,203 13,768
Accumulated Amortization (7,024) (6,149)
Net 7,179 7,619
Trade names    
Finite-Lived Intangible Assets [Line Items]    
Gross 10,413 11,973
Accumulated Amortization (8,616) (9,998)
Net 1,797 1,975
Patent costs    
Finite-Lived Intangible Assets [Line Items]    
Gross 14,716 14,915
Accumulated Amortization (7,550) (6,950)
Net 7,166 7,965
Acquired patents    
Finite-Lived Intangible Assets [Line Items]    
Gross 11,458 14,596
Accumulated Amortization (11,395) (14,485)
Net 63 111
Other    
Finite-Lived Intangible Assets [Line Items]    
Gross 6,758 7,666
Accumulated Amortization (6,369) (7,344)
Net $ 389 $ 322
v3.25.4
INTANGIBLES ASSETS (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]      
Amortization expense $ 2.3 $ 12.7 $ 12.1
Amortization expense for intangible assets, 2026 1.9    
Amortization expense for intangible assets, 2027 1.9    
Amortization expense for intangible assets, 2028 1.8    
Amortization expense for intangible assets, 2029 1.7    
Amortization expense for intangible assets, 2030 $ 1.6    
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]   Asset impairment charges  
Impairment of assets   $ 31.2  
Impairment, intangible asset, indefinite-lived (excluding goodwill), statement of income or comprehensive income     Asset impairment charges
Impairment of indefinite-lived intangible assets     $ 5.6
Acquired technology      
Finite-Lived Intangible Assets [Line Items]      
Impairment of assets   $ 1.2  
Finite lives impairment charge     $ 13.6
Impairment, intangible asset, finite-lived (excluding goodwill), statement of income or comprehensive income     Asset impairment charges
Acquired intangible assets     $ 0.0
Trade names      
Finite-Lived Intangible Assets [Line Items]      
Finite lives impairment charge     $ 3.8
v3.25.4
GOODWILL (Schedule of Roll Forward) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Goodwill [Roll Forward]    
Balance at beginning of year, gross $ 470,516 $ 470,274
Balance at beginning of year, impairments (455,637) (354,192)
Balance at beginning of period 14,879 116,082
Impairment charge   (101,445)
Foreign currency translation adjustments 696 242
Balance at ending of year, gross 471,212 470,516
Balance at ending of year, impairments (455,637) (455,637)
Balance at end of period 15,575 14,879
Healthcare    
Goodwill [Roll Forward]    
Balance at beginning of year, gross 148,379 148,137
Balance at beginning of year, impairments (133,500) (32,055)
Balance at beginning of period 14,879 116,082
Impairment charge   (101,445)
Foreign currency translation adjustments 696 242
Balance at ending of year, gross 149,075 148,379
Balance at ending of year, impairments (133,500) (133,500)
Balance at end of period 15,575 14,879
Industrial    
Goodwill [Roll Forward]    
Balance at beginning of year, gross 322,137 322,137
Balance at beginning of year, impairments (322,137) (322,137)
Balance at beginning of period 0 0
Balance at ending of year, gross 322,137 322,137
Balance at ending of year, impairments (322,137) (322,137)
Balance at end of period $ 0 $ 0
v3.25.4
GOODWILL (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Goodwill [Line Items]    
Impairment charge $ 101,445  
Industrial    
Goodwill [Line Items]    
Impairment charge   $ 279,800
Goodwill impairment loss, statement of income or comprehensive income   Asset impairment charges
v3.25.4
INVESTMENTS AND NOTE RECEIVABLE (Schedule of Equity Investments) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]    
Equity investments under the equity method of accounting $ 753 $ 5,051
Equity investments without readily determinable fair values 21,712 20,696
Total equity investments $ 22,465 $ 25,747
v3.25.4
INVESTMENTS AND NOTE RECEIVABLE (Narrative) (Details) - USD ($)
 1 Months Ended 12 Months Ended
Feb. 28, 2025
May 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2025
Jun. 30, 2023
Apr. 30, 2023
Mar. 31, 2022
Schedule of Equity Method Investments [Line Items]                    
Investment     $ 753,000 $ 5,051,000            
Total revenue     386,902,000 440,121,000 $ 488,069,000          
Total cost of sales     255,857,000 275,943,000 291,648,000          
Receivable balance     83,806,000 101,471,000            
Total carrying value of the VIEs     21,712,000 20,696,000            
Related party payable     41,017,000 41,833,000            
Maximum exposure to losses     20,100,000              
Related Party                    
Schedule of Equity Method Investments [Line Items]                    
Receivable balance     0 0            
Saudi Arabian Industrial Investments Company                    
Schedule of Equity Method Investments [Line Items]                    
Investment     $ 400,000 $ 4,300,000         $ 6,500,000  
Payments to investment   $ 2,500,000                
Ownership percentage     49.00% 49.00%            
Loan amount     $ 4,400,000 $ 2,000,000.0     $ 4,400,000      
Saudi Arabian Industrial Investments Company | Related Party                    
Schedule of Equity Method Investments [Line Items]                    
Total revenue     0 3,800,000 1,700,000          
Total cost of sales     0 2,600,000 1,000,000.0          
Theradaptive, Inc                    
Schedule of Equity Method Investments [Line Items]                    
Total carrying value of the VIEs               $ 8,000,000.0    
Investment impairment charge     0 0 $ 0          
Entach Inc                    
Schedule of Equity Method Investments [Line Items]                    
Investment     400,000              
Payments to investment     $ 1,000,000.0 700,000            
Ownership percentage     79.00%              
Total carrying value of the VIEs     $ 6,900,000 6,900,000           $ 10,000,000.0
Investment impairment charge           $ 2,800,000        
Ownership percentage     46.00%              
Entach Inc | Related Party                    
Schedule of Equity Method Investments [Line Items]                    
Related party payable     $ 0 0            
GenesisTissue Inc.                    
Schedule of Equity Method Investments [Line Items]                    
Ownership percentage     8.00%              
Total carrying value of the VIEs     $ 1,000,000.0              
Hull Legacy Media Corporation                    
Schedule of Equity Method Investments [Line Items]                    
Provided financing $ 1,000,000.0                  
Enhatch                    
Schedule of Equity Method Investments [Line Items]                    
Payments to acquire investments     $ 1,500,000 $ 600,000            
v3.25.4
LEASES (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Lessee, Lease, Description [Line Items]      
Impairment loss $ 600 $ 5,200 $ 0
Operating lease, impairment loss   2,700  
Finance lease, impairment loss   2,500  
Finance lease, liability, current 1,606 1,482  
Long-term finance lease liabilities $ 9,509 $ 10,543  
Minimum      
Lessee, Lease, Description [Line Items]      
Remaining lease term 1 year    
Maximum      
Lessee, Lease, Description [Line Items]      
Remaining lease term 12 years    
v3.25.4
LEASES (Schedule of Components of Lease Cost) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Leases [Abstract]      
Operating lease cost $ 13,715 $ 14,331 $ 13,667
Finance lease cost - amortization expense 1,586 1,706 991
Finance lease cost - interest expense 955 1,017 478
Short-term lease cost 157 347 494
Variable lease cost 4,492 4,142 3,953
Sublease income (69) (132) (186)
Total $ 20,836 $ 21,411 $ 19,397
v3.25.4
LEASES (Schedule of Future Minimum Lease Payments) (Details)
$ in Thousands
Dec. 31, 2025
USD ($)
Finance Leases  
2026 $ 2,470
2027 2,535
2028 2,499
2029 2,132
2030 1,539
Thereafter 3,261
Total lease payments (undiscounted) 14,436
Less: imputed interest (3,321)
Present value of lease liabilities 11,115
Operating Leases  
2026 15,094
2027 11,987
2028 10,880
2029 9,317
2030 7,095
Thereafter 18,680
Total lease payments (undiscounted) 73,053
Less: imputed interest (16,050)
Present value of lease liabilities $ 57,003
v3.25.4
LEASES (Schedule of Supplemental Cash Flows) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash outflow for operating leases $ 14,151 $ 13,986 $ 13,177
Operating cash outflow for finance leases 955 1,017 478
Financing cash outflow for finance leases $ 1,593 $ 1,385 $ 644
v3.25.4
LEASES (Schedule of Lease Weighted Average) (Details)
Dec. 31, 2025
Dec. 31, 2024
Weighted-average remaining lease term (in years)    
Finance 6 years 1 month 6 days 7 years
Operating 6 years 7 months 6 days 7 years 3 months 18 days
Weighted-average discount rate    
Finance 8.47% 8.44%
Operating 7.23% 7.17%
v3.25.4
ACCRUED AND OTHER LIABILITIES (Schedule of Accrued Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Payables and Accruals [Abstract]    
Compensation and benefits $ 11,293 $ 12,646
Accrued taxes 15,040 8,034
Legal contingencies 1,765 4,739
Accrued product warranty liability 3,537 2,650
Current finance lease liabilities 1,606 1,482
Other accrued liabilities 13,415 15,937
Total $ 46,656 $ 45,488
Finance lease, liability, current, statement of financial position, extensible list Total Total
v3.25.4
ACCRUED AND OTHER LIABILITIES (Schedule of Recognized Warranty Revenue and Incurred Warranty Costs) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Warrant Obligation [Roll Forward]        
Balance at beginning of period $ 3,537 $ 2,650 $ 2,106 $ 3,677
Settlements made (3,451) (3,264) (4,397)  
Accruals for warranties issued 4,338 3,808 2,826  
Balance at the end of period $ 3,537 $ 2,650 $ 2,106 $ 3,677
v3.25.4
ACCRUED AND OTHER LIABILITIES (Schedule Of Other Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Payables and Accruals [Abstract]    
Long-term finance lease liabilities $ 9,509 $ 10,543
Defined benefit pension obligation 6,358 5,716
Long-term tax liability 2,624 2,277
Long-term employee indemnity 2,032 3,480
Long-term deferred revenue 2,794 2,259
Other long-term liabilities 683 726
Total $ 24,000 $ 25,001
Finance lease, liability, noncurrent, statement of financial position, extensible list Total Total
v3.25.4
BORROWINGS (Narrative) (Details)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 12 Months Ended
Jun. 23, 2025
USD ($)
$ / shares
Nov. 16, 2021
USD ($)
$ / shares
Dec. 31, 2025
USD ($)
shares
Jun. 30, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jun. 17, 2025
$ / shares
Jun. 30, 2024
USD ($)
Line of Credit Facility [Line Items]                    
Amortization of debt issuance costs           $ 1,500 $ 1,400 $ 2,600    
Gain (loss) on debt extinguishment           5,484 21,518 $ 32,181    
Convertible Debt                    
Line of Credit Facility [Line Items]                    
Long-term debt, gross     $ 95,974     $ 95,974 $ 214,378      
Convertible Senior Notes Due 2030 | Convertible Debt                    
Line of Credit Facility [Line Items]                    
Aggregate principal amount $ 92,000                  
Interest rate (as a percentage) 5.875%   5.875%     5.875%        
Cash on hand to repurchase $ 78,000                  
Debt instrument, repurchased face amount 179,700                  
Debt instrument, covenant, cash 40,000         $ 20,000        
Debt instrument, covenant, accounts receivable and inventory 75,000                  
Debt instrument, covenant, restricted cash $ 16,800                  
Debt instrument, covenant, cash payments     $ 1,800     $ 1,800        
Debt instrument, conversion price (in dollars per share) | $ / shares $ 2.24                  
Premium over closing price (as a percentage) 20.00%                  
Share price (in dollars per share) | $ / shares                 $ 1.87  
Debt instrument, principal (as a percentage) 100.00%                  
Conversion price (as a percentage) 130.00%                  
Effective interest rate (as a percentage)     8.60%     8.60%        
Long-term debt, gross     $ 92,030     $ 92,030        
Gain (loss) on debt extinguishment       $ 8,200            
Deferred debt issuance cost, write-off       1,500            
Net proceeds       $ 92,000            
Convertible Senior Notes Due 2026 | Convertible Debt                    
Line of Credit Facility [Line Items]                    
Aggregate principal amount   $ 460,000                
Interest rate (as a percentage) 0.00%   0.00%     0.00% 0.00%      
Debt instrument, repurchased face amount                   $ 110,500
Conversion ratio   0.0278364                
Conversion price (as a percentage)   130.00%                
Effective interest rate (as a percentage)   0.594%                
Conversion price (in dollars per share) | $ / shares   $ 35.92                
Debt exchanged     $ 30,800              
Shares exchanged (in shares) | shares     16.6              
Long-term debt, gross     $ 3,944     $ 3,944 $ 214,378      
Gain (loss) on debt extinguishment           (2,700) 21,500      
Deferred debt issuance cost, write-off           200 $ 1,800      
Debt transaction costs           $ 1,600        
Shares issued for services (in shares) | shares           0.7        
Repayments of convertible debt         $ 87,200          
v3.25.4
BORROWINGS (Schedule of Convertible Notes Payable) (Details) - Convertible Debt - USD ($)
$ in Thousands
Dec. 31, 2025
Jun. 23, 2025
Dec. 31, 2024
Line of Credit Facility [Line Items]      
Outstanding Principal $ 95,974   $ 214,378
Unamortized Deferred Issuance Costs (5,636)   (2,383)
Carrying Value $ 90,338   $ 211,995
Convertible Senior Notes Due 2026      
Line of Credit Facility [Line Items]      
Interest rate (as a percentage) 0.00% 0.00% 0.00%
Outstanding Principal $ 3,944   $ 214,378
Unamortized Deferred Issuance Costs 0   (2,383)
Carrying Value $ 3,944   211,995
Convertible Senior Notes Due 2030      
Line of Credit Facility [Line Items]      
Interest rate (as a percentage) 5.875% 5.875%  
Outstanding Principal $ 92,030    
Unamortized Deferred Issuance Costs (5,636)    
Carrying Value $ 86,394   $ 0
v3.25.4
EMPLOYEEE BENEFITS (Narrative) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Retirement Benefits [Abstract]      
Employer matching contribution percentage 50.00%    
Employee percentage of match 6.00%    
Employee benefit expenses $ 2.3 $ 2.5 $ 2.6
Employee benefit, plan assets $ 2.2 $ 2.2  
v3.25.4
EMPLOYEEE BENEFITS (Schedule of Reconciliation of Changes In Projected Benefit Obligation) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Reconciliation of benefit obligation:      
Obligation as of January 1 $ 5,896 $ 6,027  
Service cost 63 59 $ 59
Interest cost 227 210 220
Actuarial (gain) loss (934) 145  
Benefit payments (199) (187)  
Effect of foreign currency exchange rate changes 1,508 (358)  
Benefit obligation as of December 31 $ 6,561 $ 5,896 $ 6,027
v3.25.4
EMPLOYEEE BENEFITS (Schedule of Amounts Recognized in Consolidated Balance Sheets) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Retirement Benefits [Abstract]    
Accrued and other liabilities $ 203 $ 180
Other liabilities 6,358 5,716
Total liability $ 6,561 $ 5,896
v3.25.4
EMPLOYEEE BENEFITS (Schedule of Accumulated And Projected Benefit Obligations) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Retirement Benefits [Abstract]      
Projected benefit obligation $ 6,561 $ 5,896 $ 6,027
Accumulated benefit obligation $ 5,678 $ 5,672  
v3.25.4
EMPLOYEEE BENEFITS (Schedule of Components of Net Periodic Benefit Costs and Other Amounts Recognized in Other Comprehensive Income) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Retirement Benefits [Abstract]      
Service cost $ 63 $ 59 $ 59
Interest cost 227 210 220
Amortization of actuarial gain (93) 0 (46)
Total net periodic pension cost 197 269 233
Other changes in plan assets and benefit obligations recognized in other comprehensive income (loss):      
Net loss (gain) (841) 145 541
Amortization of prior years' unrecognized gain (loss) 0 0 46
Total recognized as other comprehensive income (loss), excluding tax (841) 145 587
Total (gain) expenses recognized in net periodic benefit cost and other comprehensive (loss) income $ (644) $ 414 $ 820
Defined benefit plan, net periodic benefit cost (credit) excluding service cost, statement of income or comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
v3.25.4
EMPLOYEEE BENEFITS (Schedule of Assumptions Used to Determine Benefit Obligations) (Details)
Dec. 31, 2025
Dec. 31, 2024
Retirement Benefits [Abstract]    
Discount rate 4.40% 3.60%
Rate of compensation 3.00% 3.00%
v3.25.4
EMPLOYEEE BENEFITS (Schedule of Estimated Future Benefit Payments) (Details)
$ in Thousands
Dec. 31, 2025
USD ($)
Estimated future benefit payments for the years ending December 31:  
2026 $ 232
2027 258
2028 287
2029 321
2030 353
2031 through 2035 $ 1,885
v3.25.4
REDEEMABLE NON-CONTROLLING INTEREST (Narrative) (Details)
$ in Millions
 12 Months Ended
Dec. 09, 2024
Dec. 31, 2025
USD ($)
installment
Dec. 31, 2024
Apr. 01, 2022
Construction Contractor, Receivable, after Year One, Interest Rate [Line Items]        
Redeemable noncontrolling interest, equity, percent of common shares, exercisable upon target one (as percent)   50.00%    
Redeemable noncontrolling interest, equity, percent of common shares, exercisable upon target two (as percent)   50.00%    
Redeemable noncontrolling interest, equity, common stock, percent of exercise price to be paid (as percent)   50.00%    
Agreement option fee amount | $   $ 2.0    
Number of installment payments | installment   3    
Kumovis GmbH        
Construction Contractor, Receivable, after Year One, Interest Rate [Line Items]        
Ownership percentage   100.00% 100.00% 93.75%
Ownership percentage by existing shareholders   6.25%    
Profit or loss transfer agreement, term 5 years      
v3.25.4
REDEEMABLE NON-CONTROLLING INTEREST (Schedule of Redeemable Noncontrolling Interest) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Redeemable Noncontrolling Interest Equity [Roll Forward]      
Balance at beginning of period $ 1,958 $ 2,006 $ 1,760
Fair value at the date of acquisition 0 0 0
Net loss 0 0 (265)
Redemption value (below) in excess of carrying value 0 (61) 479
Translation adjustments 235 13 32
Balance at ending of period $ 2,193 $ 1,958 $ 2,006
v3.25.4
STOCK-BASED COMPENSATION (Narrative) (Details)
 1 Months Ended 12 Months Ended
Apr. 29, 2024
USD ($)
employee
milestone
Feb. 24, 2024
USD ($)
milestone
Oct. 04, 2022
USD ($)
shares
Dec. 01, 2021
USD ($)
milestone
Feb. 29, 2024
USD ($)
milestone
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
milestone
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2016
tranche
$ / shares
Dec. 31, 2022
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Vesting period           3 years        
Granted (in shares) | shares           29,235,000        
Stock-based compensation expense           $ 9,525,000 $ 18,457,000 $ 23,504,000    
Other liabilities, noncurrent           24,000,000 25,001,000      
Aggregate intrinsic value           $ 0 $ 0 $ 0    
Stock options exercisable (in shares) | shares           0 0 0    
Unrecognized stock-based compensation expense           $ 0 $ 0 $ 0    
Stock based compensation expense reversal               $ 18,400,000    
Basic (in dollars per share) | $ / shares               $ 0.14    
Diluted (in dollars per share) | $ / shares               $ 0.14    
Volumetric Biotechnologies, Inc.                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Stock-based compensation expense               $ (8,600,000)    
Additional payments $ 175,000,000.0     $ 355,000,000.0 $ 355,000,000.0          
Number of milestones | milestone       7            
Milestones terminated | milestone   4     4          
Reduced liability   $ 175,000,000.0     $ 175,000,000.0          
Remaining milestones | milestone 3 3     3          
Number of employees | employee 2                  
Earnout payment milestone               65,000,000.0    
Aggregate grant date fair value of outstanding and unvested               4,500,000    
Volumetric Biotechnologies, Inc. | Minimum                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of milestones | milestone         4          
Volumetric Biotechnologies, Inc. | Maximum                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of milestones | milestone         7          
Dp polar GmbH                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Stock-based compensation expense             $ 1,000,000.0 $ 1,000,000.0    
Additional payments     $ 2,200,000              
Issuance of shares (in shares) | shares     250,000              
Issuance of shares to settle (in shares) | shares           250,000        
Systemic Bio Phantom Unit Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares) | shares             721,000 596,000    
Phantom Share Units (PSUs)                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Vesting period           2 years 1 month 6 days        
Unrecognized stock-based compensation expense           $ 8,600,000        
Phantom Share Units (PSUs) | Systemic Bio Phantom Unit Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Vesting period               4 years    
Granted (in shares) | shares             147,000 597,000    
Stock-based compensation expense             $ 100,000 $ 500,000    
Other liabilities, noncurrent             $ 600,000 $ 500,000    
Unrecognized stock-based compensation expense           $ 600,000        
Restricted Stock - Market Conditions                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Shares awarded (in shares) | shares           1,687,753        
Restricted Stock Units (RSUs)                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Granted (in shares) | shares           2,958,000 3,392,000 4,439,000    
Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number (in shares) | shares           5,161,000 5,185,000 6,182,000   5,015,000
Granted (in dollars per share) | $ / shares           $ 2.25 $ 1.98 $ 10.26    
Stock Options and Restricted Stock Awards | 2015 Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of tranches | tranche                 2  
Trading price for stock award, tranche one (in dollars per share) | $ / shares                 $ 30  
Trading price for stock award, tranche two (in dollars per share) | $ / shares                 $ 40  
Stock award tranche granting period                 90 days  
Performance Shares                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Vesting period           3 years        
Granted (in shares) | shares           810,000        
Granted (in dollars per share) | $ / shares           $ 0.47        
Number of non-financial milestones | milestone             4      
Incentive Awards                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Stock-based compensation expense           $ 0 $ 0 $ 0    
v3.25.4
STOCK-BASED COMPENSATION (Schedule of Shares and Units of Restricted Common Stock) (Details) - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Systemic Bio Phantom Unit Plan      
Number of Shares/Units      
Outstanding at beginning of year — unvested (in shares) 721 596  
Outstanding at end of year — unvested (in shares)   721 596
Restricted Stock Units (RSUs)      
Number of Shares/Units      
Outstanding at beginning of year — unvested (in shares) 5,185 6,182 5,015
Granted (in shares) 2,958 3,392 4,439
Cancelled (in shares) (1,323) (1,845) (1,118)
Vested (in shares) (1,659) (2,544) (2,154)
Outstanding at end of year — unvested (in shares) 5,161 5,185 6,182
Weighted Average Grant Date Fair Value      
Outstanding at beginning of year — unvested (in dollars per share) $ 7.16 $ 14.77 $ 18.19
Granted (in dollars per share) 2.25 1.98 10.26
Cancelled (in dollars per share) 4.37 14.69 15.45
Vested (in dollars per share) 7.14 13.28 13.09
Outstanding at end of year — unvested (in dollars per share) $ 5.06 $ 7.16 $ 14.77
Phantom Share Units (PSUs) | Systemic Bio Phantom Unit Plan      
Number of Shares/Units      
Granted (in shares)   147 597
v3.25.4
STOCK-BASED COMPENSATION (Schedule of Stock Option Activity) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2025
Number of Shares      
Outstanding at beginning of year (in shares) 420    
Forfeited and expired (in shares) (260)    
Outstanding at end of year (in shares) 160 420  
Weighted Average Exercise      
Outstanding at beginning of year (in dollars per share) $ 13.26    
Forfeited and expired (in dollars per share) 13.26    
Outstanding at end of year (in dollars per share) $ 13.26 $ 13.26  
Weighted Average Remaining Contractual Term (in years) 1 year 7 months 6 days 2 years 8 months 12 days  
Aggregate Intrinsic Value $ 0 $ 0 $ 0
v3.25.4
STOCK-BASED COMPENSATION (Schedule of Stock-based Compensation Expense) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]      
Stock-based compensation expense $ 9,525 $ 18,457 $ 23,504
Tax benefit $ 0 $ 0 $ 0
v3.25.4
INCOME TAXES (Schedule of Components of Income Before Income Taxes) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]      
Domestic $ 13,858 $ (160,709) $ (239,971)
Foreign 35,734 (89,287) (122,341)
Net income (loss) before income taxes $ 49,592 $ (249,996) $ (362,312)
v3.25.4
INCOME TAXES (Schedule of Components of Income Tax Provision) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Current:      
U.S. federal $ 0 $ 24 $ 135
State 99 301 (50)
Foreign 14,867 2,820 1,686
Total 14,966 3,145 1,771
Deferred:      
U.S. federal 838 0 0
State 0 0 0
Foreign (933) (952) (2,412)
Total (95) (952) (2,412)
Total income tax provision (benefit) $ 14,871 $ 2,193 $ (641)
v3.25.4
INCOME TAXES (Schedule of Cash Paid For Income Taxes (Net Of Refunds)) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Tax Paid, by Individual Jurisdiction [Line Items]      
Federal $ 799    
Total State 492    
Foreign:      
Total Foreign 8,342    
Cash paid for income taxes (net of refunds) 9,633 $ 5,540 $ 3,898
Other      
Income Tax Paid, by Individual Jurisdiction [Line Items]      
Total State 492    
Germany      
Foreign:      
Total Foreign 2,431    
Korea      
Foreign:      
Total Foreign 1,860    
Netherlands      
Foreign:      
Total Foreign 1,723    
China      
Foreign:      
Total Foreign 559    
Mexico      
Foreign:      
Total Foreign 522    
Other      
Foreign:      
Total Foreign $ 1,247    
v3.25.4
INCOME TAXES (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Operating Loss Carryforwards [Line Items]      
Cash income tax payments, net $ 9,633 $ 5,540 $ 3,898
Deferred income tax assets 79,200    
Net operating loss carryforwards 475,400    
Loss carryforwards for U.S. federal income tax purposes 111,000    
Loss carryforwards for U.S. state income tax purposes 175,100    
Loss carryforwards for foreign income tax purposes 189,300    
Tax credit carryforwards 32,287 $ 31,326  
Unrecognized deferred tax liability 800    
Unrecognized tax benefits decrease 2,100    
Unrecognized tax benefits that would impact effective tax rate $ 2,600    
Difference in effective rate (as a percentage) 9.00% 21.80% 20.80%
Domestic Tax Jurisdiction      
Operating Loss Carryforwards [Line Items]      
Research and experimentation tax credit carryforwards $ 22,400    
Foreign tax credits 4,000    
State:      
Operating Loss Carryforwards [Line Items]      
Research and experimentation tax credit carryforwards $ 5,900    
v3.25.4
INCOME TAXES (Schedule of Components of Net Deferred Income Tax Assets and Net Deferred Income Tax Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Deferred income tax assets:    
Intangible assets $ 11,860 $ 15,685
Stock options and restricted stock awards 1,666 3,032
Reserves and allowances 4,511 6,879
Net operating loss carryforwards 79,161 59,641
Tax credit carryforwards 32,287 31,326
Accrued liabilities 2,235 2,681
Deferred revenue 1,055 2,176
Lease tax assets 12,248 17,498
Research expenditures capitalization 31,905 44,773
Other 5,607 3,236
Valuation allowance (170,425) (168,299)
Total deferred income tax assets 12,110 18,628
Deferred income tax liabilities:    
Intangible assets 1,171 2,081
Property and equipment 710 2,352
Lease tax liabilities 10,182 14,159
Other 0 49
Total deferred income tax liabilities 12,063 18,641
Net deferred income tax asset $ 47  
Net deferred income tax asset (liability)   $ (13)
v3.25.4
INCOME TAXES (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Unrecognized Tax Benefits      
Balance at January 1 $ (16,413) $ (18,604) $ (17,150)
Increases related to prior year tax positions (240) (1,170) (99)
Decreases related to prior year tax positions 106 4,337 107
Decreases related to prior year tax positions as a result of lapse of statute 3,170 0 271
Decreases related to settlement 0 0 0
Increases related to current year tax positions (933) (976) (1,733)
Increases related to acquired tax positions 0 0 0
Decreases related to acquired tax positions 0 0 0
Balance at December 31 (14,310) (16,413) (18,604)
Unrecognized tax benefits, income tax penalties and interest expense $ 500 $ 1,300 $ 300
v3.25.4
INCOME TAXES (Schedule of Deferred Income Tax Asset Valuation Allowance) (Details) - Deferred income tax asset valuation allowance - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of year $ 168,299 $ 125,533 $ 100,694
Additions (reductions) charged to expense (1,915) 43,365 23,606
Other 4,041 (599) 1,233
Balance at end of year $ 170,425 $ 168,299 $ 125,533
v3.25.4
INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Amount      
Tax provision based on the federal statutory rate $ 10,414    
State and Local Income Taxes 79    
Tax-deductible goodwill (1,985)    
Global intangible low-taxed income inclusion 5,980    
Subpart F income inclusion 725    
Research and development tax credits (3,593)    
Expired foreign tax credits 3,253    
Employee share-based payments 2,483    
Equity method investment (827)    
Impairment of investments 1,338    
Unremitted foreign earnings 838    
Payable adjustments (637)    
Other 791    
Changes in unrecognized tax benefits (2,451)    
Total income tax provision (benefit) $ 14,871 $ 2,193 $ (641)
Percent      
Tax provision based on the federal statutory rate 21.00% 21.00% 21.00%
State and Local Income Taxes 0.20%    
Foreign income tax rate differential   0.20% 0.50%
Changes in valuation allowances   (17.30%) (6.50%)
Other   (0.30%) (0.70%)
Tax-deductible goodwill (4.00%)    
Global intangible low-taxed income inclusion 12.10% 0.00% (0.40%)
Subpart F income inclusion 1.50%    
Research and development tax credits (7.20%)    
Expired foreign tax credits 6.60%    
Employee share-based payments 5.00% (0.30%) (0.50%)
Equity method investment (1.70%)    
Impairment of investments 2.70%    
Unremitted foreign earnings 1.70% (0.60%) (0.30%)
Payable adjustments (1.30%)    
Other 1.60%    
Changes in unrecognized tax benefits (4.90%)    
Total 30.00% (0.80%) 0.20%
United States      
Amount      
Changes in valuation allowances $ (9,951)    
Deferred adjustments $ 559    
Percent      
Changes in valuation allowances (20.10%)    
Deferred adjustments 1.10%    
Belgium      
Amount      
Foreign income tax rate differential $ (779)    
Changes in valuation allowances 6,738    
Deferred adjustments (2,289)    
Other $ (588)    
Percent      
Foreign income tax rate differential (1.60%)    
Changes in valuation allowances 13.60%    
Deferred adjustments (4.60%)    
Other (1.20%)    
Germany      
Amount      
Changes in valuation allowances $ (1,874)    
Other $ 145    
Percent      
Changes in valuation allowances (3.80%)    
Other 0.30%    
Netherlands      
Amount      
Changes in valuation allowances $ 1,623    
Other $ (344)    
Percent      
Changes in valuation allowances 3.30%    
Other (0.70%)    
Switzerland      
Amount      
Changes in valuation allowances $ 1,708    
Other $ (409)    
Percent      
Changes in valuation allowances 3.40%    
Other (0.80%)    
Other      
Amount      
Foreign income tax rate differential $ 3,924    
Percent      
Foreign income tax rate differential 7.90%    
v3.25.4
INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Percent      
Tax provision based on the federal statutory rate 21.00% 21.00% 21.00%
Increase in valuation allowances   (17.30%) (6.50%)
Change in carryforward attributes   0.00% 0.00%
Global intangible low-taxed income inclusion 12.10% 0.00% (0.40%)
Non-deductible expenses   0.00% 0.00%
Non-deductible earnout expense   0.00% 1.00%
Goodwill impairment charge   (8.70%) (14.60%)
Foreign income tax rate differential   0.20% 0.50%
Deemed income related to foreign operations 1.70% (0.60%) (0.30%)
Tax rate change   (0.10%) 0.00%
Employee share-based payments 5.00% (0.30%) (0.50%)
Other   (0.30%) (0.70%)
Deferred and payable adjustments   1.30% (1.30%)
Non-deductible penalties   0.00% 0.00%
State taxes, net of federal benefit, before valuation allowance   1.20% 0.70%
Return-to-provision adjustments   (0.50%) 0.20%
Other tax credits   2.00% 1.10%
Uncertain tax positions and audit settlements   1.30% 0.00%
Total 30.00% (0.80%) 0.20%
v3.25.4
NET INCOME (LOSS) PER SHARE (Schedule of Net Loss Per Share Reconciliation) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Oct. 04, 2022
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Numerator (basic):        
Net income (loss) attributable to 3D Systems Corporation   $ 29,883 $ (255,593) $ (362,688)
Redeemable non-controlling interest redemption value in excess of carrying value   0 61 (479)
Net income (loss) attributable to common stock shareholders   29,883 (255,532) (363,167)
Numerator (diluted):        
Net (loss) income attributable to 3D Systems' common stock shareholders   29,883 (255,532) (363,167)
Add back: Interest on 2030 Notes   2,809 0 0
Net income (loss) income attributable to 3D Systems' common stock shareholders plus assumed conversions   $ 32,692 $ (255,532) $ (363,167)
Denominator:        
Basic weighted average common shares outstanding (in shares)   129,159,000 131,861,000 129,944,000
Effect of Dilutive securities:        
Restricted stock and RSUs (in shares)   1,393,000 0 0
Conversion of 2030 Notes (in shares)   44,962,000 0 0
Diluted weighted average common shares outstanding (in shares)   175,514,000 131,861,000 129,944,000
Net (loss) income per common share:        
Basic (in dollars per share)   $ 0.23 $ (1.94) $ (2.79)
Diluted (in dollars per share)   $ 0.19 $ (1.94) $ (2.79)
Anti-dilutive shares (in shares)   2,851,000 5,345,000 6,602,000
Dp polar GmbH        
Net (loss) income per common share:        
Issuance of shares (in shares) 250,000      
v3.25.4
NET INCOME (LOSS) PER SHARE (Schedule of Equity Awards) (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]      
Anti-dilutive shares (in shares) 2,851 5,345 6,602
Restricted stock, restricted stock units, and PSUs      
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]      
Anti-dilutive shares (in shares) 2,691 5,185 6,182
Stock options      
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]      
Anti-dilutive shares (in shares) 160 160 420
v3.25.4
NET INCOME (LOSS) PER SHARE (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Thousands
 12 Months Ended
Jun. 23, 2025
Nov. 16, 2021
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]          
Shares excluded from diluted loss per share calculation (in shares)     2,851 5,345 6,602
Repurchased common, shares 8,000        
Shares acquired, average cost per share $ 1.87        
Dp polar GmbH          
Subsidiary, Sale of Stock [Line Items]          
Shares excluded from diluted loss per share calculation (in shares)         138
Convertible Senior Notes Due 2026 | Senior Notes          
Subsidiary, Sale of Stock [Line Items]          
Aggregate principal amount   $ 460,000,000.0      
Interest rate (as a percentage)   0.00%      
Conversion price (in dollars per share)   $ 35.92      
v3.25.4
ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance $ 176,193 $ 426,753 $ 749,944
Other comprehensive income (loss) 7,239 (10,816) 9,384
Amounts reclassified from accumulated other comprehensive (loss) income     188
Ending balance 240,358 176,193 426,753
Total      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (55,066) (44,250) (53,822)
Ending balance (47,827) (55,066) (44,250)
Foreign currency translation adjustment      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance (55,217) (44,564) (54,194)
Other comprehensive income (loss) 7,219 (10,653) 9,630
Amounts reclassified from accumulated other comprehensive (loss) income     0
Ending balance (47,998) (55,217) (44,564)
Defined benefit pension plan      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 151 314 700
Other comprehensive income (loss) 20 (163) (354)
Amounts reclassified from accumulated other comprehensive (loss) income     (32)
Ending balance 171 151 314
Unrealized loss on short-term investments      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Beginning balance 0 0 (328)
Other comprehensive income (loss) 0 0 108
Amounts reclassified from accumulated other comprehensive (loss) income     220
Ending balance $ 0 $ 0 $ 0
v3.25.4
SEGMENT INFORMATION (Narrative) (Details)
 12 Months Ended
Dec. 31, 2025
segment
Segment Reporting [Abstract]  
Number of reportable segments 2
v3.25.4
SEGMENT INFORMATION (Schedule of Operating Results by Segment) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Total revenue $ 386,902 $ 440,121 $ 488,069
Total cost of sales 255,857 275,943 291,648
Gross profit 131,045 164,178 196,421
Selling, general and administrative (161,331) (210,132) (210,172)
Research and development (65,037) (86,479) (89,466)
Asset impairment charges 760 144,967 302,787
Foreign exchange gain (loss), net 3,637 2,452 (4,825)
Interest income 3,956 7,302 19,511
Interest expense (5,162) (2,564) (3,301)
Gain on disposition 139,590 0 0
Other income, net 3,654 20,214 32,307
Net income (loss) before income taxes 49,592 (249,996) (362,312)
Operating Segments | Healthcare Solutions      
Segment Reporting Information [Line Items]      
Total revenue 179,589 189,736 213,216
Total cost of sales 107,783 116,237 128,066
Gross profit 71,806 73,499 85,150
Operating Segments | Industrial Solutions      
Segment Reporting Information [Line Items]      
Total revenue 207,313 250,385 274,853
Total cost of sales 148,074 159,706 163,582
Gross profit 59,239 90,679 111,271
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment      
Segment Reporting Information [Line Items]      
Selling, general and administrative (161,331) (210,132) (210,172)
Research and development (65,037) (86,479) (89,466)
Asset impairment charges (760) (144,967) (302,787)
Foreign exchange gain (loss), net 3,637 2,452 (4,825)
Interest income 3,956 7,302 19,511
Interest expense (5,162) (2,564) (3,301)
Gain on disposition 139,590 0 0
Other income, net $ 3,654 $ 20,214 $ 32,307
v3.25.4
SEGMENT INFORMATION (Schedule of Depreciation and Amortization) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Healthcare Solutions      
Segment Reporting Information [Line Items]      
Depreciation and amortization: $ 5,431 $ 5,389 $ 4,593
Industrial Solutions      
Segment Reporting Information [Line Items]      
Depreciation and amortization: $ 2,378 $ 2,947 $ 2,801
v3.25.4
SEGMENT INFORMATION (Schedule of Long-Lived Assets by Geographic Region) (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets $ 102,287 $ 110,485
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 68,893 76,829
Belgium    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 18,893 19,598
Other foreign entities    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets $ 14,501 $ 14,058
v3.25.4
COMMITMENTS AND CONTINGENCIES (Details)
$ in Millions
 1 Months Ended 12 Months Ended
May 12, 2025
Jan. 10, 2025
day
Aug. 21, 2024
USD ($)
Apr. 29, 2024
USD ($)
employee
milestone
Mar. 29, 2024
USD ($)
Feb. 24, 2024
USD ($)
milestone
Jun. 02, 2023
USD ($)
Dec. 01, 2021
USD ($)
milestone
May 19, 2021
defendant
Feb. 28, 2026
USD ($)
Feb. 29, 2024
USD ($)
milestone
May 31, 2023
USD ($)
Feb. 28, 2023
USD ($)
installment
Dec. 31, 2025
USD ($)
Loss Contingencies [Line Items]                            
Obligation to purchase inventory                           $ 15.9
Purchase obligation, to be purchase within next year                           8.1
Volumetric Biotechnologies, Inc.                            
Loss Contingencies [Line Items]                            
Payments for legal settlements     $ 1.8                      
Additional payments       $ 175.0       $ 355.0     $ 355.0      
Number of milestones | milestone               7            
Milestones terminated | milestone           4         4      
Reduced liability           $ 175.0         $ 175.0      
Remaining milestones | milestone       3   3         3      
Acquisition related earnout amount to be recovered         $ 355.0                  
Negotiation period         30 days                  
Number of employees | employee       2                    
Negotiation days | day   45                        
Financial Standby Letter of Credit                            
Loss Contingencies [Line Items]                            
Guarantor obligations             $ 1.2              
Guarantor obligations, extension term, (in years)             1 year              
Letter of credit                           0.4
Export Controls and Government Contracts Compliance                            
Loss Contingencies [Line Items]                            
Amount awarded                         $ 15.0  
Payments for legal settlements                           3.0
Export Controls and Government Contracts Compliance | Directorate of Defense Trade Controls                            
Loss Contingencies [Line Items]                            
Amount awarded                         $ 10.0 $ 10.0
Number of installment payments | installment                         3  
Payment period                         3 years 3 years
Suspended penalty amount                           $ 5.1
Export Controls and Government Contracts Compliance | Directorate of Defense Trade Controls | Subsequent Event                            
Loss Contingencies [Line Items]                            
Suspended penalty amount                   $ 5.1        
Export Controls and Government Contracts Compliance | Bureau of Industry and Security oThe Department of Commerce                            
Loss Contingencies [Line Items]                            
Amount awarded                         $ 2.8  
Export Controls and Government Contracts Compliance | U.S. Department Of Justice                            
Loss Contingencies [Line Items]                            
Amount awarded                         $ 2.3  
Intrepid Automation                            
Loss Contingencies [Line Items]                            
Number of employees brought against in lawsuit | defendant                 5          
Litigation amount                       $ 20.0    
Securities Class Action                            
Loss Contingencies [Line Items]                            
Period to submit complaint and responses 14 days                          
v3.25.4
FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) - Money market funds - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 32,760 $ 98,212
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 32,760 98,212
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 0 $ 0
v3.25.4
FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Financial Instruments) (Details) - Convertible Debt - USD ($)
$ in Thousands
Dec. 31, 2025
Jun. 23, 2025
Dec. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Carrying Amount $ 90,338   $ 211,995
Convertible Senior Notes Due 2026      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Interest rate (as a percentage) 0.00% 0.00% 0.00%
Carrying Amount $ 3,944   $ 211,995
Fair Value $ 3,593   189,409
Convertible Senior Notes Due 2030      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Interest rate (as a percentage) 5.875% 5.875%  
Carrying Amount $ 86,394   0
Fair Value $ 117,982   $ 0
v3.25.4
FAIR VALUE MEASUREMENTS (Narrative) (Details)
Dec. 31, 2025
Fair Value Disclosures [Abstract]  
Goodwill impairment, weighted average discount rate 26.20%
v3.25.4
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Narrative) (Details)
 3 Months Ended 12 Months Ended
Jun. 30, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
lease
Dec. 31, 2023
USD ($)
Restructuring Cost and Reserve [Line Items]        
Total   $ 8,450,000 $ (30,000) $ 8,242,000
Number of leases exited | lease     18  
Costs incurred     $ 8,200,000  
Severance costs $ 1,000,000.0      
Payments to terminate lease     600,000  
Asset impairment charges   760,000 144,967,000 302,787,000
Severance, Termination Benefits and Other Employee Costs        
Restructuring Cost and Reserve [Line Items]        
Total   $ 8,450,000 (30,000)  
Asset impairment charges     $ 0 $ 600,000
v3.25.4
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Costs Incurred) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]      
Total $ 8,450 $ (30) $ 8,242
Healthcare      
Restructuring Cost and Reserve [Line Items]      
Total 500    
Industrial      
Restructuring Cost and Reserve [Line Items]      
Total 500    
Cost of sales      
Restructuring Cost and Reserve [Line Items]      
Total $ 1,034 $ (785) $ 1,401
Restructuring, incurred cost, statement of income or comprehensive income Total cost of sales Total cost of sales Total cost of sales
Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total $ 5,855 $ 370 $ 5,598
Restructuring, incurred cost, statement of income or comprehensive income Selling, General and Administrative Expense Selling, General and Administrative Expense Selling, General and Administrative Expense
Research and development      
Restructuring Cost and Reserve [Line Items]      
Total $ 1,561 $ 385 $ 1,243
Restructuring, incurred cost, statement of income or comprehensive income Research and Development Expense Research and Development Expense Research and Development Expense
v3.25.4
RESTRUCTURING AND EXIT ACTIVITIES COSTS (Restructuring Charges) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Restructuring Reserve [Roll Forward]      
Costs incurred and other adjustments to accrued liability during the period $ 8,450 $ (30) $ 8,242
Employee Severance, Termination Benefits, and Other Restructuring      
Restructuring Reserve [Roll Forward]      
Balance at beginning of period 487 3,933  
Costs incurred and other adjustments to accrued liability during the period 8,450 (30)  
Amounts settled with cash (7,707) (3,416)  
Balance at the end of period $ 1,230 $ 487 $ 3,933